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ABSTRACT
Overexpression of HOXB4 in hematopoietic stem cells (HSCs) leads to increased
self-renewal without causing hematopoietic malignancies in transplanted mice. The
molecular basis of HOXB4-mediated benign HSC expansion in vivo is not well
understood. To gain further insight into the molecular events underlying HOXB4mediated HSC expansion, we analyzed gene expression changes at multiple time points
in Lin-Sca1+c-kit+ (LSK) cells from mice transplanted with bone marrow (BM) cells
transduced with a MSCV-HOXB4-ires-YFP vector. A distinct HOXB4 transcriptional
program was reproducibly induced and stabilized by 12 weeks after transplant. Dynamic
expression changes were observed in genes critical for HSC self-renewal as well as genes
involved in myeloid and B cell differentiation. Prdm16, a transcription factor associated
with human acute myeloid leukemia (AML), was markedly repressed by HOXB4 but
upregulated by HOXA9 and HOXA10, suggesting that Prdm16 downregulation was
involved in preventing leukemia in HOXB4 transplanted mice. Functional evidence to
support this mechanism was obtained by enforcing co-expression of sPrdm16 and
HOXB4, which led to myeloid expansion, and leukemia. Before the onset of leukemia
decreased HSC frequency was observed in HOXB4and sPrdm16 co-expressing cells,
suggesting sustained expression of Prdm16 abolished HOXB4-mediated HSC expansion.
Altogether, these studies define the transcriptional pathways involved in HOXB4 HSC
expansion in vivo and identify repression of Prdm16 transcription as a mechanism by
which HOXB4 mediates a benign HSC expansion.
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CHAPTER 1.

INTRODUCTION

Hematopoiesis
All the blood cells are continuously generated by hematopoietic stem cells
(HSCs) throughout life. Maintenance of hematopoietic system homeostasis and
replenishment of mature blood cells rely on the self-renewal capacity and multipotency of
HSCs. Hematopoiesis includes adult and embryonic hematopoiesis, which arises from
different hematopoietic organs and undergoes distinct biology process. So far the murine
hematopoietic system is the best understood of all species.
Adult hematopoietic hierarchy
Hematopoiesis is the process of production, multiplication and specification of
blood cells in the bone marrow. With a combination of cell surface marker expression
and functional assays, the hierarchical structure of the hematopoietic system was
achieved (Figure 1-1). HSCs are the first well-characterized tissue-specific stem cells
with self-renewal and multipotency and reside at the top of the hierarchy. HSCs give rise
to the multipotent progenitor (MPP)1,2 which further differentiated into two oligopotent
progenitors: the common lymphoid progenitor (CLP)3 and the common myeloid
progenitor (CMP).4 CMPs then give rise to megakaryocyte-erythrocyte progenitors
(MEPs) and granulocyte-macrophage progenitors (GMPs). These downstream
oligopotent progenitors then give rise to all of lineage-committed effector cells and
downstream mature blood cells.
However, recent studies suggested that alternative models for lineage
commitment during hematopoiesis should be considered. In 2008 Bhandoola’s gourp
demonstrated that the earliest thymic progenitors (ETPs) are not derived from lymphoidrestricted progenitors but from multipoient bone marrow progenitors, which lose B
potential either prethymically or intrathymically.5 Almost all ETPs derived from
multipotent progenitors possess both T and myeloid potential within the thymus.5 Later
on Stuart H. Orkin’s group proposed an alternative mouse hematopoietic hierarchy from
single-cell expression data which indicated that the MegE lineage priming occurred
within highly enriched HSCs.6 This is different from the model proposed by Jorden
Adolfsson et al and Cornelis J.H. Pronk et al which placed MegE lineage downstream of
MPP and CMP.7,8
Embryonic hematopoiesis
The first wave of hematopoiesis starts in the extraembryonic yolk sac at E7.5 and
later in allantois and placenta. However functional experiment showed that hematopoietic
cells generated in yolk sac prior to E9.5 lack colony forming unit-spleen (CFU-S)9 and
lack definitive HSCs prior to E11.5.10,11 The aorta-gonad-mesonephros (AGM) region of

1

Figure 1-1. The hierarchy of hematopoietic cells.
LT-HSC, long-term repopulating HSC; ST-HSC, short-term repopulating HSC; MPP,
multipotent progenitor; CMP, common myeloid progenitor; CLP, common lymphoid
progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte−macrophage
progenitor. The encircled pluripotent population, LT-HSC, ST-HSC and MPP are Lin-,
Sca-1+, c-kit+ as shown.
Reprinted with permission. Larsson J, Karlsson S. The role of Smad signaling in
hematopoiesis. Oncogene. 2005;24(37):5676-5692.12

2

the mouse embryo starts to make blood cells from E9.5 and was proven to be a powerful
source of definitive HSCs.10,11 From E12.5 hematopoiesis switches to fetal liver and
HSCs undergo dramatic expansion. Right before birth bone marrow becomes the major
site of hematopoiesis through the whole life. (Figure 1-2)
Hematopoietic Stem Cell
HSCs are rare population and occur at a frequency of 1 stem cell in 10,000 to
1,000,000 bone marrow cells. HSCs are derived from mesoderm and give rise to all the
downstream progenitor cells and mature blood cells. Hemogenic endothelium hypothesis
proposes that HSCs arise directly from committed endothelia cells (ECs) of the ventral
aspect of the dorsal aorta in the AGM13,14 which is distinct from the hemangioblast
hypothesis which supposes that a common bipotent precursor gives rise to both
vasculature and the blood cells. Initial understanding of HSCs started with the discovery
of CFU-S described by Till and McCulloch.15 They demonstrated that intravenously
injected bone marrow cells were capable of forming distinct hematopoietic colonies in
the spleen of irradiated mice, and these colonies contained erythrocytes, megakaryocytes
an granulocytes/macrophages.15 Later studies pointed out there are at least two type of
CFU-S: colonies that formed at day 8 after transplantation and those formed at day
12.16,17 They are referred as day 8-CFU-S and day12-CFU-S. Cells residing in day8CFU-S were more committed progenitors with little or no self-renewal capacity and cells
in day12-CFU-S contained certain self-renewing cells.18 Morrison and Weissman further
confirmed that LT-HSC and ST-HSC can only be purified from day-12 to day-14 CFUS1.
Functional characteristics of HSCs
The functional characteristics of HCSs are self-renewal and multilineage
differentiation potential.
Self-renewal
Self-renewal of HSCs is critical for HSC pool maintenance to prevent the
exhaustion of blood formation. It is usually achieved by either symmetric or asymmetric
cell division or both. Symmetric division will result in two identical daughter stem cells
or two lineage-restricted progenitors while asymmetric division will generate one
daughter stem cell and one differentiated cell19. Asymmetric cell division doesn’t
generate net increase of HSC numbers. Self-renewal potential of HSCs is associated with
the activity of telomerase20-22. Telemetric shortening during cell division usually results
in cell cycle arrest, chromosomal instability and replicative senescence and causes the
loss of self-renewal capacity of HSCs which directly reduces HSC pool size.

3

Figure 1-2. Timeline of hematopoietic events in the mouse conceptus.
Arrows above indicate the onset of specific hematopoietic cell generation and/or
appearance; arrows below indicate the earliest time of colonization of the secondary
hematopoietic territories. AGM, Aorto Gonado Mesonephros region.
Reprinted with permission: Dzierzak E, Speck NA. Of lineage and legacy: the
development of mammalian hematopoietic stem cells. Nat Immunol. 2008;9(2):129136.23
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Multilineage differentiation potential
Multilineage differentiation means HSCs are able to produce progeny that
contribute to all blood cell lineages.24-30 The decision of HSCs to self-renew or
differentiation may be random, but the external signals from bone marrow niche play role
in the cell fate decision of HSCs during lineage commitment through cell-cell or cellextracellular matrix (ECM) interactions or through cytokines, chemokines or other
extracellular molecules. Signaling pathways present in bone marrow niche, such as Wnt
pathway and Notch pathway, act on HSCs or downstream progenitors to regulate HSC
lineage commitment. Recent evidence showed multilineage priming is one mechanism
how HSCs maintain multilineage commitment potential without changing global gene
expression. Open chromatin structure of HSCs or multipotent progenitors leaves many
key cis-acting regulatory elements of lineage-affiliated genes accessible which allows
these genes to be available for transcription. Transcription factors which favor different
lineage commitment may negatively interact with each other resulting in the dominant
upregulation of a given program with the shutdown of other program consistent with
dominant lineage selected.
Hematopoietic stem cell characterization
Murine HSCs are a rare population capable of reconstituting recipients and reside
in fetal liver and adult BM. There are studies to characterize and purify hematopoietic
stem cells for decades. It becomes clear that combination of surface markers/dye
exclusion and in vivo/ex vivo functional assays is necessary to identify functional HSCs
which are able to reconstitute lethally irradiated hosts. More defined subpopulations with
distinct reconstitution capacity were identified with combination of newly discovered cell
surface markers by many groups. Here we focus on the phonotypical and functional
characterization of murine hematopoietic stem cells.
Cell surface antigens/receptors
In 1988 Weissman’s group first identified multilineage HSC as a highly enriched
rare population in lineage marker negative (Lin-), Sca-1+ and thy1.1low cells, which
represent about 0.05% of the whole bone marrow.27 Ikuta, K et al31 showed that both
HSCs and progenitors express Kit surface marker, but only Lin-c-Kit+Sca-1+ cells are
primitive HSCs and response better to SCF and stromal cells.32 The flk-2 gene, a tyrosine
kinase receptor, was shown not to be expressed in FR25 Lin-c-ktBR population which is
highly enriched for HSCs33 and flk-2 was characterized as HSC marker to further purify
LT-HSC from adult bone marrow cells as c-Kit+Lin-Sca-1+Flk-2- cells from mice.2 Flk-2
can only be used to separate adult HSCs as fetal liver HSCs express Flk-2. CD34 is a
human HSC marker.34 Unlike human HSCs, mouse long-term multilineage HSCs are
present in CD34lo/-c-Kit+Sca-1+Lin- fraction,30 providing a new marker to separate mouse
HSCs at a near homogenous level, even though only 20% of intravenously injected
CD34lo/-c-Kit+Sca-1+Lin- cells conferred long-term multilineage reconstitution.30
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However, in fetuses and neonates CD34 is also expressed in long-term repopulating
HCSs.35 So using CD34-LSK as a marker to purify HSCs is only suitable for mice older
than 10 weeks due to age-dependent CD34 expression in HSCs. More recently
combination of SLAM family member CD150 and CD48 with Lineage marker, Sca-1
and c-Kit was found to be able to purify more enriched functional long-term HCSs.36 One
out every 2.1 CD150+CD48-Sca-1+Lin-c-Kit+ cells gave long-term multilineage
reconstitution in lethally irradiated mice.36
Dye exclusion
Hoechst 33342low side population (SP) is a small subset of population of murine
bone marrow cells which is able to block the Hoechst efflux activity due to a multidrug
resistance protein (mdr) or mdr-like mediated efflux. SP was shown to be enriched about
1000 fold HSC activity and Hoechst 33342 was used to isolate quiescent and replicating
HSCs.37,38 Similar to Hoechst33342, Rhodamine123 (Rh123) is another vital dye used to
label relative more quiescent murine HSCs and Rh123low cells self-renew to a greater
degree than Rh123high population.39 Rh123low and Hoechst33342low population both
represent G0/G1 HSCs with higher level of self-renewal and long-term multilineage
reconstitution capacity, which were lost within S/G2/M subpopulation.39 Resistance to
active DNA replication provided these quiescent HSCs the radioprotection activity.
The phenotype of murine hematopoietic stem cells at different development
stages is summarized in Table 1-1.
Functional assay
In vitro functional assays developed for HSCs are cobblestone area-forming cell
(CAFC) assay and long-term culture-initiating cell (LTC-IC) assay. Actually they are not
able to identify true HSCs; instead they are the assays identifying relative immature cells
in culture. The first in vivo assay to assess HSC function is thought to be CFU-S15 until
the cells forming spleen colonies were proven to be hematopoietic progenitors with shortterm potential.18 To test repopulating HSC function long-term transplantation assay is
required.
Long-term repopulating assay
Long-term repopulating assay requires intravenous injection of test bone marrow
cells to irradiated or compromised hosts. Test cells and host cells should be
distinguishable from each other by different alleles of the hematopoietic cell marker
CD45.1 or CD45.2. In earlier studies cells were distinguished by different hemoglobin40
or gender.41 Peripheral blood (PB) is collected at various intervals and contribution of test
cells to myeloid, T lymphoid and B lymphoid lineage are assessed by flow cytometry.
LT-HSCs are considered to be present in test cells only when recipient PB contains
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Table 1-1.
stage.

Phenotype of murine hematopoietic stem cell at different development

HSC
Hemangioblast (Primitive streak, yolk
sac)
Pre-HSC (AGM)
HSC (AGM, placenta)
HSC (fetal liver)
HSC (bone marrow)

Flk-1(Kdr)+

Marker

CD34+CD41+Sca-1-CD45CD34+CD45+CD41+/-Sca-1+/Sca-1+CD34+CD45+Mac1+CXCR4+
c-kit+Thy1.1(CD90)lo Lin-Scahi (KTLS)
Sca-1+CD34+/-CD45+LinCD150+CD48-CD244- (SLAM)
Rh123low, Hoe33342low,PyroninYlow
5-FU resistant
Aldehyde dehydrogenasehigh
Fr25 (Small cells) LinSide-population cells
AGM, aorta gonado mesonephros; 5-FU, fluorouracil; HSC, hematopoietic stem cell;
SLAM, signaling lymphocyte activation molecule.
Reprinted with permission. Ratajczak MZ. Phenotypic and functional characterization of
hematopoietic stem cells. Curr Opin Hematol. 2008;15(4):293-300.42

7

donor- derived cells in the all triple lineages after at least 16 weeks post transplantation.
Long-term repopulating assay also can be used to evaluate HSC activity in genome
modified cells by retroviral delivery with fluorescence markers or leukemia-initiating
cells (LICs) from leukemia samples.

Competitive repopulation assay
In competitive repopulation assay test cells and standard cells are mixed at variety
of ratio, 1:1 ratio at most cases, and injected into hosts. Usually standard cells contain
specific number of whole bone marrow cells or HSCs which allows semi-qualify HSC
frequency relative to standard cells. Test cells and standard cells should be
distinguishable from each other. For more accurate evaluation of competitive
reconstitution unit (CRU) frequency limiting-dilution assay is used.
Limiting-dilution assay
Limiting-dilution assay allows evaluation of absolute CRU frequency (HSC
number) in test cells. It involves a titration of varying dose of test cells (at least 3 doses),
which are mixed with 1-2x105 competitors (contain about 5-10 CRU) and injected into
lethally irradiated hosts. Competitors are usually subjected to two rounds of bone marrow
transplantation prior to the limiting-dilution assay. The proportion of recipients whose
bone marrow cells are determined to contain >1% or >5% cells of test cell origin in all
three lineages (myeloid lineage, T lymphocyte lineage and B lymphocyte lineage) after at
least 16 weeks following transplantation is used to calculate the CRU frequency
generated by Poisson statistics.
Serial transplantation assay
Given population is transplanted into primary recipients, whose bone marrow
cells were harvested and transplanted into secondary recipients and further into tertiary
recipients. Serial transplantation assay is the most stringent HSC assay since only the
most primitive HSCs are able to yield long-term, multilineage repopulation through
multiple rounds of transplantation.
Regulation of Hematopoietic Stem Cell Pool
HSCs give rise to all the blood lineages throughout the life span; as a result HSC
pool should be well maintained. This usually involves the regulation of the balance of
HSC self-renewal and differentiation, HSC survival and death (apoptosis/necropsies),
lineage priming and selection and many other aspects of HSC activities by either intrinsic
or extrinsic signals or both. Intrinsic mechanism includes transcription factors, epigenetic
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modification, non-coding RNA, especially microRNA and extrinsic signals come from
microenvironment (bone marrow niche) where HSCs reside.
Transcription factors
Numerous of transcription factors are shown to play critical role in HSC selfrenewal or differentiation through gain of function or loss of function assays. They
include HOX genes, Gata2, Runx1, Gfi1 and many others. HOX genes are highly
conserved from Drosophila to mammals and play roles in embryonic patterning and
hematopoiesis. The detail of HOX gene function in normal and malignant hematopoiesis
will be discussed in later paragraphs. Gata2 is one of the six members of GATA family
in mammals. It is expressed in primitive hematopoietic cells and its expression level
declines gradually along hematopoietic differentiation.43,44 Gata2 knock-out mice die at
day 10-11 of gestation due to impaired primitive hematopoiesis, demonstrating that
Gata2 is essential for earliest stage of hematopoiesis during embryogenesis.43,44 Gata2 is
also crucial for adult HSCs and HPCs proliferation. Gata2 may preserve immature cell
pool by inhibiting hematopoietic precursor cell differentiation and also confers increased
quiescence of human HSCs and HPCs when expressed at high level.45,46 At meanwhile,
reciprocal expression pattern of Gata1 and Gata2 is critical for erythropoiesis and
erythroid homeostasis. Gata2 may function through SCL and active both Kit and Gata2
in immature erythroid cells.47
Epigenetic regulation
Epigenetic regulation, histone or DNA modification, allows changes of large set
of gene expression by influencing the accessibility of transcription factors to DNA and
altering transcription profile of cells. Epigenetic regulation includes methylation,
acetylation, phosphorylation, sumoylation and ubiquitylation. Here we focus on the
discussion how histone or DNA epigenetic modification regulates or maintains HSC
signature.
Histone hyperacetylation usually indicates ‘open’ chromatin whereas
deacetylation means ‘condensed’ chromatin. Histone acetylation is catalyzed by histone
acetyl transferase and histone deacetylation is catalyzed by histone deacetlylases
(HDACs). Histone methylation usually occurs on arginine or lysine residues. Methylation
on H3K4, H3K36 and H379 are associated with transcription activation while
methylation on H3K9, K3K27 and H4K20 are related to transcription repression. BMI1
belongs to Polycomb-group (PcG) proteins, which repress gene (such as HOX genes)
transcription through histone modification. Bmi-1-/- mice demonstrated reduced number
of adult HSCs but not fetal liver HSCs and defect in long-term reconstitution of both fetal
liver and adult HSCs48 while enforced expression of Bmi-1 augments HSC selfrenewal,49-51 indicating Bmi-1 is essential for self-renewing HCSs. Besides HSCs, Bmi-1
is also required for neuron stem cells self-renewal but not survival or differentiation.52 A
similar phenomenon was observed in the Mph1/Rae28 loss mice53 and MPH1/RAE28 is
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another member of PcG family which forms ploycomb complex 1 with M33, BMI1 or
MEL18 and SCMH1.54-58 In contrast, Ring1b loss mice59 or mice with hypomorphic
mutation of Eed60 or Suz1261,62 exhibited enhanced HSC or HPC activities.
Methylation of CpG in DNA is another major epigenetic modification. DNA
methylation is catalyzed by DNA methyltransferase (Dnmt1, Dnmt3a and Dnmt3b) and
methylation in promoter region is associated with gene silencing. Dnmt3a and Dnmt3b
execute de novo DNA methylation and play role in the regulation of cell differentiation.
CD34-LSK cells express both Dnmt3a and Dnmt3b. Disruption of Dnmt3a or Dnmt3b or
both do not affect either myeloid or lymphoid lineage differentiation potential while loss
of both Dnmt3a and Dnmt3b but not either one of them result in defect in long-term HSC
reconstitution.63 Later Challen et al64 applied serial transplantation on Dnmt3a-null HSCs
which demonstrated 200-fold expansion of phenotypic HSCs in secondary recipients
coupled with declined multi-lineage differentiation capacity with successive rounds of
transplantation. Expansion of Dnmt3a-null HSCs was associated with activation of HSC
self-renewal program including Runx1 and Gata3 indicating the essential role of Dnmt3a
in silencing self-renewal genes in HSCs and permission of hematopoietic
differentiation.64 Conditional knockout of Dnmt1 led to defects of HSC self-renewal,
bone marrow niche retention and generation of myeloid-restricted progenitors from
HSCs.65 Haploinsufficency of Dnmt1 was shown to be sufficient to impair self-renewal
of MALL-AF9-induced leukemia stem cells (LSCs) and similar effect66 was seen in BLymphoid leukemia with Dnmt1 hypomorphic allele.67 These studies indicated the role of
Dnmt1 in normal and malignant HSCs for regulation of self-renewal.
Signaling pathways
Wnt signaling pathway
Wnt signaling regulates both HSC self-renewal and differentiation. In mammals
Wnt proteins are present in primitive and definitive hematopoiesis sites. Wnt-5a and
Wnt-10b are expressed in murine yolk sac (E11), fetal liver (E14) and fetal liver HSCs.68
In vitro culture Wnt-5a was shown to have positive effect on proliferation of fetal liver
HSCs in an autocrine and paracrine manner, while monocyte and erythrocyte formation
were preferred from bone marrow HPCs in the present of soluble Wnt-5a.69
Overexpression of β-catenin, downstream executor of the Wnt signaling cascade,
enhances HSC self-renewal.70 Β-catenin also has been shown to promote T-ALL cells
survival, adhesion and proliferation, and it is undetectable in mature T cells.71 Whether βcatenin shared the same mechanism on HSCs self-renewal and leukemic cells
proliferation is not yet clear.
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Notch signaling pathway
Notch signaling requires physical interaction of Notch ligands and Notch
receptors, which are expressed in Notch-ligand-expressing cells and Notch-expressing
cells, separately. In bone marrow, HSCs express Notch and bone marrow stromal cells,
endothelial cells and fibroblasts, express Notch ligands, such as Jagged and Delta. Notch
signaling is critical for embryonic development as Jag1-deficient mice are embryonic
lethal due to the defects in the vasculature remodeling.72 Notch signaling plays a role in
modulating HSCs self-renewal, differentiation and proliferation. Jagged1 alone inhibited
proliferation and myeloid colony formation of CD34+ cells but enhanced erythroid
colony formation in the presence of stem cell factor (SCF).73 Activation of endogenous
Notch signaling with immobilized Delta-1enhanced proliferation of cord blood derivedCD34+ cells in vitro and myeloid-lymphoid repopulating ability in vivo.74 Expression of
the intracellular domain of Notch 1 can immortalized murine HSCs and immortalized cell
line was able to differentiate into both myeloid and lymphoid lineages.75
Phosphatidylinositol 3 kinase pathway
Phosphatidylinositol 3 kinase pathway (PI-3) kinase pathway promotes cell
growth, proliferation and survival. PI-3 kinase can be activated by receptor tyrosine
kinase or other signaling pathway and generate Phosphatidylinositol-3, 4, 5-trisphosphate
(PIP3). PIP3 further activates Art. Phosphorated Akt activates mammalian target of
rapamycine (mTOR) kinase. mTOR1 promotes cell growth and proliferation, while
mTOR2 regulates Akt activity. Pten negatively regulates PI-3 kinase pathway by
dephosphorylating PIP3, thus resulting in inhibition of cell growth, proliferation and
survival. Conditional knock-out of Pten from embryonic stem cells as well as neuron
stem cells can drive cells into cell cycle and enhance self-renewal.76-78 Deletion of Pten
from adult HSCs also increase cell cycle entry, leading to transient increase of HSC
numbers but depletion of HSCs in the mouse bone marrow in the end.79,80 Phenotype of
Pten deletion/inactivation demonstrated that Pten normally maintains HSCs in a quiescent
state. However, Pten deletion also drives leukemogenesis. Yilmaz reported
myeloproliferative disease which progressed to AML and ALL when Pten was
inactivated in murine hematopoietic system using flox-Mx-1-Cre system.79 Different role
of Pten deletion on HSCs depletion and leukemic stem cells generation suggests
independent mechanism of each phenomena caused by Pten inactivation.
TGF/BMP signaling pathway
TGF-β superfamily includes TGF-β/activin/nodal family, bone morphogenetic
protein (BMP)/growth and differentiation factor (GDF)/Muellerian inhibiting substance
(MIS) family. Upon binding of the ligands, activated type I and type II serine/threonine
kinase receptors form heterodimer and phosphorylate specific intracellular receptorregulated Smads (R-Smad), including Smad1,2,3,5,and 8. Smad1, Smad5 and Smad8 are
primary mediators of BMP signaling, while Smad2 and Smad3 transduce signal through
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TGF-β/activin receptors. Dimer of R-Smads forms complex with common partner, Smad4, and translocates into nucleus to transcriptionally regulate various target genes in a cellspecific and ligand-dose dependent manner. Inhibitory Smads (I-Smad), Smad6 and
Smad7, can negatively regulate TGF-β signaling pathway by interfering R-Smads and
receptor or R-Smads and Smad4 interaction or recruiting E3-ubiquitin ligases to degrade
receptors. Smad1 belongs to BMP signaling pathway. Many studies showed that BMP4
plays a key role in mesoderm induction and hematopoietic commitment and BMP4
knock-out mice displayed defects in mesoderm and blood island formation.81 For adult
HSCs, BMP4 may act as positive regulator of proliferation and survival. High
concentration treatment of BMP4 to human HSCs in vitro can enhance its engraftment in
nonobese diabetic-severe immunodeficiency (NOD/SCID) mice.82 At meanwhile, BMP4
signaling is also important in sonic hedgehog (SHH)-induced human progenitor
proliferation.83 Different from BMP4, TGF-β1 ligand-activated TFG-β signaling inhibits
HSCs proliferation and induces HSCs apoptosis in vitro. In vivo injection of TGF-β1 also
inhibits proliferation of murine multipotent hematopoietic progenitors in bone marrow.84
As negative regulator of TGF-β signaling, Smad7 is able to block all TGF-β signaling
pathways. Overexpression of Smad7 increases HSCs repopulating activity in serial
transplantation setting.85 Increased proliferation induced by Smad7 was not seen in
culture. This suggests signaling crosstalk between bone marrow cell and bone marrow
niche is required for Smad7 to increase HSCs self-renewal.
MicroRNAs
MicroRNAs are small, noncoding RNAs which regulate gene expression through
transcription or translation repression by interfering initiation of transcription or mRNA
destabilization. Dicer is an enzyme which cleaves double-stranded RNA (dsRNA) and
pre-microRNA (pre-miRNA) into small interfering RNA or and microRNA respectively.
Conditional deletion of Dicer led to loss of HSPCs due to significant increased apoptosis,
indirectly suggesting the role of microRNA in HSC maintenance.86 Several microRNAs
including Mir-125a, Mir-125b, Mir-126, Mir-130 and Mir-155, are highly enriched in
HSCs86-90 and dysregulation of some microRNAs are associated with human
hematopoietic malignancies such as MDS/AML,91 B-cell acute lymphoblastic
leukemia92,93 and chronic lymphocytic leukemia (CLL).94 miR-99b/let7e/miR-125a
cluster is highly expressed in LT-HSCs and overexpression of miR-99b-let7e-miR-125a
cluster or miR-125a alone was able to enhance HSC long-term multilineage
reconstitution.86 When overexpressed separately, only miR125a but not miR-99b, let7e
was able to amplify HSC pool size in vivo by protecting primitive hematopoietic cells
from apoptosis through downregulation of proapoptotic protein Bak1.86 MiR-125b is
another microRNA highly expressed in LSK cells. Overexpression of miR-125b
demonstrated reconstitution advantage at competitive transplantation setting but caused a
dose-dependent myeloproliferative disorder/myeloid leukemia.89 The observation of miR125b-induced HSCs expansion was confirmed in Ooi. A,G et al’s study, but they further
identified that miR-125b preferentially expanded Slamf1loCD34−LSK lymphoid-balanced
and the Slamf1negCD34−LSK lymphoid-biased cell, possessing a balanced
myeloid/lymphoid and lymphoid-biased cell output, respectively.88 Besides the regulation
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of HSC self-renewal, many microRNAs were implicated in regulating hematopoietic
progenitor cells (HPCs) differentiation, including miR-155 for lymphoid and myeloid
development,87,95,96 mir-233 for myeloid differentiation97,98 and the miR-181/miR150/miR-17-92 cluster for lymphoid differentiation.99-102 Taken together, microRNAs
regulate hematopoiesis at multiple levels including HSC self-renewal, HSC fate decision
and HPC differentiation.
HOX Gene Family
HOX genes are homeodomain-containing transcription factors. They were
initially characterized in Drosophila and involved in process of body pattern during the
embryo development as well as many adult processes including hematopoiesis. Hox gene
products share evolutionally conserved 60-amino-acid homeobox domain, which
specifies basic Helix-turn-helix DNA binding domain. Sequences flanking the
homeodomain have been shown to have either activation or suppression functions. In
Drosophila the HOX genes map to the antennapedia complex (Ant-C) and Bithorax
complex (BX-C), which are referred to HOM-C.103-105 Antp class genes include labial
(lab), proboscipedia (pb), Deformed (Dfd), Sex combs reduced (Scr), Antennapedia
(Antp), Ultrabithorax (Ubx) and abdominal-A (abd-A) (Figure 1-3). Abdominal-B (AbdB) is another homeotic selector gene and it is related to Antp class by its sequence but not
structure. Lab, the most 3’ gene is required for the most anterior HOM-C functional
domain while the most 5’ gene of the complex, Abd-B, is required for the posterior
abdominal segment development. In human and murine genomes there are 39 class I Hox
genes due to genome duplication. They are referred to HOXA, HOXB, HOXC, and
HOXD clusters, each of which contains 9 to 11 groups located on human chromosomes
7, 17, 12 and 2 or mouse chromosome 6, 11, 15 and 2 (Figure 1-3).96,97 In mammals Hox
genes carrying the same number in different clusters are paralogous and the paralogy is
complete only in groups 13, 9, and 4, which contain all four genes. All Hox genes have
the same 3’-to-5’orientation and according to their position within their respective gene
cluster 3’ Hox genes are expressed early on and at anterior locations whileas 5’ Hox
genes are expressed later developmental stage and at posterior locations during the
development. The correspondence between gene topology and the place and time of
transcription are referred to as spatial and temporal collinearities, respectively.
HOX gene upstream regulators
Retinoic acid, Trithorax group (Trx-G) and Polycomb group (PcG) genes were
shown to be upstream regulators of HOX genes in hematopoietic and non-hematopoietic
tissues. Due to lack of the evidence showing that retinoic acid treatment regulates HOX
gene expression in hematopoietic cells, here we focus Trx-G and PcG genes.
Trithorax is required for the maintenance of HOM-C genes expression in the
Drosophila.106 Mixed lineage leukemia (MLL) is the mammalian homolog of Trithorax
gene and is usually seen as part of fusion genes in leukemia such as infant biphenotypic
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Figure 1-3. A schematic structure of clustered HOX genes.
The 39 HOX genes are located on four different chromosomes. Homology of human
HOX genes HOX-C to Drosophila HOM-C genes is shown by colors. Blank squares
show missing genes.They play critical role in body patterning during embryo
development.
Reprinted with permission. Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of
HOX genes in normal hematopoiesis and acute leukemia. Leukemia. 2013;27(5):10001008.107
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leukemia108 and etoposide-induced leukemia.109 Mll-null mice are embryonic lethal due
to morphogenetic defects and hematopoietic abnormality.110 Disrupted Hox gene
expression pattern along the vertebral axis due to loss of Mll was also observed.110 Mllnull fetal liver HPCs showed reduced colony forming capacity and it can be due to the
effect of loss of Mll or disrupted downstream HOX genes on the growth of hematopoietic
precursors.111
As mentioned in previous paragraph PcG proteins maintain HOX genes in a
repressed status through histone modification. PcG genes are preferentially expressed in
differentiated bone marrow cells except Bmi-1,112 which is consistent with their role in
repressing HOX gene expression. Bmi-1 and Mph1/Rae28 are two well-studied PcG
genes regarding their roles in hematopoiesis and these studies were discussed in previous
section.
Hox cofactors
Homeodomain HOX proteins recognize and bind to specific TAAT DNA
consensus site which confers HOX genes limited specificity. HOX proteins cooperatively
bind to DNA with PBC, a group of three animo acid loop extension (TALE)
homeodomain-containing proteins. PBC gene family includes the pre-B-cell leukemia-1
(Pbx-1) and myeloid ectopic insertion site (Meis) families.113-116. HOX cofactors provide
further specificity and affinity of HOX proteins. PBX proteins do not have strong proteinDNA interaction, but they are able to form protein complex with HOX proteins from
paralog group 1 to 10, thus providing DNA-binding specificity of HOX proteins from
different paralog groups.116,117 HOX proteins from paralogs 1 to 8 form protein complex
with PBX through a tryptophan within a conserved YPWM motif118-121 while HOX
proteins from paralogs 9 to 10 utilize the tryptophan in a conserved ANW domain.121
HOX proteins which belong to paralogs 11-13 prefer to form complex with MEIS1
homeodomain proteins other than PBX,121,122 which was frequently detected in the
leukemia arising in BXH2 mice.123 However, dimeric complex of MEIS/MEIS-like
protein and PBX124-129 and trimeric complex of MEIS/MEIS-like protein-PBXHOX/HOX-like protein128-130 were also formed in myeloid leukemia cell lines or nonhematopoietic tissues.
Role of Hox genes in normal hematopoiesis
HOX genes are expressed in HSCs and progenitors in a lineage-specific or
differentiation stage-specific manner. Genes of HOXA clusters are more likely expressed
in myeloid cells, HOXB genes in erythroid lineage and HOXC genes in lymphoid cells.
HOXD genes play roles in limb development during embryogenesis but not in
hematopoiesis since lack of expression of HOXD gene in hematopoietic cells.131-133
Anterior 3’ end HOX genes including HOX1-6 are highly expressed in primitive HSCs
and are downregulated along the differentiation while posterior 5’ end HOX genes are
mostly expressed in committed hematopoietic cells.134
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Evidence has been provided by the loss of function and gain of function studies of
Hox genes in mouse models. HOX genes are actively involved in both embryonic and
adult hematopoiesis, maintaining or enhancing HSC self-renewal as well as blocking or
facilitating myeloid/lymphoid lineage differentiation (Table 1-2). Due to genetic
interactions between HOX clusters, results of knockdown or knockout studies sometimes
do not reflect the findings of overexpression studies.
Knockdown of human HOXA5 in hematopoietic organs led to increased erythroid
progenitor number and reduced myelomonocytic cells, while constitutive expression of
HOXA5 increased myeloid progenitor numbers and blocked erythroid
differentiation.135,136 Hoxa7 null mice displayed reduced megakaryocyte/erythroid
progenitors with reticulocytosis and thrombocytopenis, suggesting a role in
megakaryocyte and erythrocyte development.137 Knockout Hoxa9 caused more severe
phenotype than Hoxa7. Hoxa9 null mice displayed reduced lymphoid and myeloid cells
together with reduction in CLPs, CMPs and GMPs.137 Though aberrant expression of
Hoxa7 and Hoxa9 is the feature of leukemia harboring MLL mutations, Hoxa7 and
Hoxa9 are not necessary for MLL-GSA7-mediated leukemogenesis.137 Overexpression of
Hoxa9 increased HSC and myeloid progenitor pools and reduced pro-B progenitors.138
and further led to myeloid leukemia with long latency through collaboration with
MEIS1a but not PBX1b.139 Similar to Hoxa9, Hoxa10 was identified as pro-oncogenic
gene which can lead to increased myeloid blast cells in vitro, blocked erythroid
differentiation in methylcellulose, reduced B cell differentiation and enhanced
myelopoeisis in vivo when overexpressed in human purified CD34+ hematopoietic
progenitor cells.140 HOXB4 was shown to be one of the most promising factors which
can expand murine HSC in vitro and in vivo without compromising HSC multilineage
differentiation potential at a dose-dependent manner.141 However Hoxb4 knock-out
studies showed lacking entire Hoxb4 gene had little effect on hematopoiesis, with mild
reduction in the number of HPCs and HSCs in adult bone marrow and fetal liver without
multilineage differentiation perturbation.32 Other Hoxb genes were shown to be expressed
at 2.3-3.6 fold higher level in c-Kit+ fetal liver cells of Hoxb4 null mice, while the
expression level of Hoxb4 paralogs were not altered (Hoxa4, Hoxd4) or even reduced
(Hoxc4),142 suggesting other Hoxb genes’ but not Hoxb4’s paralogs’ duplicate roles in
hematopoiesis in Hoxb4 null mice. Biji142 et al also showed that loss of the Hoxb entire
cluster had little effect on murine fetal liver HSC self-renewal and differentiation
potential. c-Kit+ fetal liver cells from Hoxb1-Hoxb9-/- demonstrated downregluation of
almost all Hoxa genes expect Hoxa13, upregulation of Hoxc4, Hoxc9 and Hoxc11,142
indicative a complex network of genetic interaction between Hox genes in hematopoietic
cells. Roles of Hoxb3, Hoxb6, Hoxc3, HOXC4 and Hoxc8 in HSC maintenance and
myeloid, lymphoid and erythroid differentiation were elaborately described in many other
studies.143-149
Role of Hox genes in acute leukemia
Though Hox genes were showed to play roles in normal hematopoiesis, numerous
studies have shown that aberrant expression of some HOX genes are highly associated
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Table 1-2.

HOX gene studies.

HOX gene
HOXA5

Gain of function
↑Myeloid progenitors and block erythroid
differentiation.

Hoxa7
Hoxa9

HOXA10
Hoxb3
HOXB4/hoxb4

↑HSCs expansion and myeloid progenitor
proliferation. Block erythroid
differentiation and ↓pre-B-cell
differentiation.
↑↑ Blasts cells and myelopoiesis, ↓B-cell
differentiation and block erythroid
differentiation
Block B and T-cell differentiation and a
delay in myeloid precursor proliferation.
↑↑HSCs expansion.

Hoxb3/b4
Hoxb6

↑HSCs expansion and myeloid precursor
proliferation. ↓Erythropoiesis and
lymphopoiesis

Hoxc3
HOXC4
Hoxc8

Loss of function
↑Erythroid progenitors and
↓myelomonocytic cells.
↓MEP, reticulocytosis and
thrombocytopenia.
↓↓CMP, GMP, CLP, lymphoid
precursors, repopulating ability
and ↓ spleen cellularity and size.

↓↓ B-cell progenitors and BM
cellularity.
↓↓Hematopoietic organs
cellularity and size, ↓ HSCs and
HPs and ↑Hoxb genes.
↓↓ HSCs and HPs

Species

Reference

Human

135,136

Mouse

137

Mouse

137-139,150

Human

140

Mouse

143,144

Human/
Mouse

141,142,151,152

Mouse

153

↑Early erythroid progenitors.

Mouse

146,147

↓Erythroid progenitors.

Mouse

149

Human

148

Mouse

145

↑Early and committed myeloid and
erythroid progenitors.
↓↓Erythroid, granulocytes and
marcrophage colony formation
potential.

17

Table 1-2.

(Continued).

Abbreviations: CLP, common lymphoid precursors; CMP, common myeloid progenitors; GMP, granulocyte/monocyte precursors;
HOX, homeobox; HP, Hematopoietic progenitors; HSCs, Hematopoietic stem cells; MEP, megakaryocytic/erythroid progenitors.
Reprinted with permission. Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of HOX genes in normal hematopoiesis and
acute leukemia. Leukemia. 2013;27(5):1000-1008.107
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with hematopoietic malignancies through forming HOX fusion proteins, dysregulation by
their upstream regulators or other factors.
Since NUP89-HOXA9 fusion protein was identified in t(7;11)(p15;p15) positive
human myeloid leukemia154,155 due to chromosome translocation, many other HOX genes
have been shown to be NUP98 translocation partners including HOXA11,156,157
HOXA13,156 HOXD11,158 HOXD13159 and HOXC11160 in human acute myelogenous
leukemia (AML) and T-cell acute lymphocytic leukemia (T-ALL). NUP98 is a nuclear
pore complex protein and in NUP98 fusions N-terminal GLFG repeats of NUP98 gene
joins the C-terminal portion of HOX genes including homeodomain. NUP98 fragment
may lead HOX protein to bind to inappropriate target genes or dysregulate HOX target
gene expression. Retroviral delivery of NUP98-HOX fusion genes were proved to cause
myeloproliferative disease or AML in transplanted mice.161-163 Co-expression of MEIS1
can shorten the latency of NUP98-HOXA9-mediated AML in transplanted mice from
230 days to 142 days163 and induce myeloblastic leukemia together with NUP98HOXD13 fusion gene with latency of 75 days which was not seen in mice transplant with
cells only transduced with NUP98-HOXD13 alone.162 Combination of NUP98-HOXA9
and BCR-ABL or TEL-PDGFβR induced AML in transplanted mice which can’t be
induced by NUP98-HOXA9 alone or BCR-ABL alone or TEL-PDGFβR alone.164
Aberrant expression of HOX gene without chromosome translocation was also
actively involved in hematopoietic malignancies including AML and acute lymphoid
leukemia (ALL). It is usually caused by HOX gene upstream regulator. MLL maintains
HOX gene expression by direct binding to the proximal promoter.165 Oncogenic MLL
fusion proteins activate their transcriptional target at higher level than wild-type MLL166
and usually upregulate 5’ end Hoxa genes other than 3’ end Hoxa genes in mouse
immortalized cell lines in combination of Meis1.167 Earlier studies indicated expression of
Hoxa genes and Meis1 was required for MLL fusion proteins transforming activity,167 but
there are evidence showing involvement of Hoxa genes and Mesi1 varies in different
MLL fusion protein-induced leukemias. MLL-ENL and MLL-CBP were not able to
transform hematopoietic cells in Hoxa9 and Hoxa7 null background167,168 while Hoxa7
and Hoxa9 do not contribute to the initiation of MLL-GAS7- and MLL-AF9-mediated
leukemogenesis in mice.137,169 The possibility is that non-Hox gene targets of MLL fusion
protein are sufficient to induce leukemias in mice, thus Hoxa9 or Hoxa7 are not long
required for these MLL fusion protein-mediated leukemogenesis. CDX2 gene is another
HOX gene upstream regulator which is highly expressed in 90% of human AML cases in
the form of either wild-type CDX2 or ETV-fused CDX2. Overexpression of Cdx2 alone is
sufficient to upregulate Hox genes, Hoxb3, Hoxb6, and Hoxb8 or Hoxb9, Hoxa10, Hoxb5,
and Hoxa7, in mouse myeloid progenitors.170 CDX2 transforming actively is dependent
on its N-terminal transactivation domain, which critical for CDX2 to dysregulate Hox
gene expression.170 Nucleophosmin 1 (NPM1) is the protein located in nucleolus and can
be translocated into nucleoplasm during serum starvation or anticancer drug treatment.
Normal NPM1 dosen’t regulate HOX gene expression. Relocation of NPM1 into
cytoplasm (NMPc+) upregulates a set of HOX genes in AML cases.171,172 But the
molecular association of NPMc+ and dysregulation of HOX genes is not yet clear.
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HOXB4
HOX family members play an important role in body patterning during
embryogenesis and demonstrated lineage-specific function through life in variety of
tissues including the hematopoietic organs.173 In hematopoietic organs Hoxb4 is
expressed in mouse Lin-Sca1+c-kit+ (LSK) cells with long-term repopulating capacity and
AGM-derive CD45+CD144+ cells which are enriched with HSCs.174 With undetectable
Hoxb4 expression level in fetal liver HSCs Hoxb4 may not be critical for expansion of
fetal liver HSCs.174 Hoxb4 expression undergoes down-regulation with hematopoietic
differentiation. Specific expression of HOXB4 in HSCs suggests HOXB4’s important
role in HSC self-renewal. However, loss of Hoxb4 studies revealed mild phenotype
which seems to contradict to the observation from HOXB4 overexpression studies.
Hoxb4-deficient mice had mild reduction in HSC numbers in both bone marrow and fetal
liver without altering cell cycle distribution and compromised competitive repopulating
capacity observed in both primary and secondary recipients.152 Moderate phenotype seen
in Hoxb4-deficient mice may be due to compensation effect from other Hox genes. Or it
suggests Hoxb4 plays less prominent role in non-stressed status of hematopoiesis and
enhances proliferative rate of HSCs in the transplantation setting which demands higher
level of proliferation.
HOXB4 role in embryonic stem cell derived hematopoiesis
Hoxb4 is selectively expressed in murine AGM-derived HSCs but not fetal liver
HSCs, indicating Hoxb4’s role in HSCs specification but not amplification during
embryogenesis. Cheryl D. Helgason et al175 showed overexpression of HOXB4 enhanced
erythropoieitic and primitive hematopoietic differentiation potential of mouse ESCs with
increased number of erythroid colony-forming (CFC-E) progenitors and mixed-lineage
(granulocyte/erythroid/macrophage/megakaryocyte) colony-forming (CFC-GEMM)
progenitors in culture. Later on George Daley’s group demonstrated that enforced
expression of HOXB4 promoted murine embryonic body (EB)-derived CFU-GEMM
formation which expressed HSC markers (c-Kit and CD31) and differentiation markers
of myeloid, lymphoid and erythroid lineages and conferred cells isolated precirculation
murine yolk sac as well as EB-derived hematopoietic cells with myeloid and lymphoid
engraftment potential in lethally irradiated mice.176 Similar results were also observed by
other groups.177 When it comes to human ESCs, HOXB4 overexpression by vector
transfection and direct delivery of recombinant HOXB4 fusion protein also exhibited the
similar outcome on human ESCs, leading to expansion of erythroid and
myeloid/monocytic progenitors in culture.178,179,180
HOXB4 overexpression enhances adult HSC self-renewal
Keith Humphries’s group showed that overexpression of HOXB4 in murine
primitive bone marrow cells by retroviral gene delivery significantly increased CRU
frequency in lethally irradiated mice, achieving 1.4 fold increase above normal bone
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marrow values while control cells only led to 3% recovery of normal value.141 Further
studies showed HOXB4-transduced HSCs did not expand above normal HSC levels of
unmanipulated mice in extended observation,181,182 indicating there were counterregulatory signals to regulate HOXB4-mediated HSC expansion in transplanted mice.
Besides in vivo expansion of HSCs in transplanted mice, HOXB4 overexpressing HSCs
were able to achieve 40-fold net HSC increase in vitro and retain lymphoid-myeloid
repopulating potential.183 Both retroviral transfer of HOXB4 cDNA and direct delivery of
the HOXB4 homeoprotein demonstrated certain level of expansion of human LTC-ICs
and NOD-SCID mouse repopulating cells from human cord blood CD34+ cells.151,184
Later on Xiao-Bing et al185 claimed species-specific differences in the potency of
HOXB4-mediated HSC expansion which was highly dependent on HOXB4 expression
level. HOXB4 expanded canine and mouse CD34+ cells best and had the least efficiency
on human or nonhuman primate CD34+ cells in vitro.185 Immortalized mouse
hematopoietic cells by HOXB4 maintained short-term and long-term repopulating
capacity without developing leukemia.185 HOXB4 protein is subjected to CUL4-mediated
degradation and degradation-resistant HOXB4 markedly enhanced human CD34+ cells
maintenance in vitro and in transplanted NOD/SCID/IL2R-γnull (NSG) mice with
multilineage engraftment.186
HOXB4 role in leukemogenesis
It is believed that overexpression of HOXB4 enhanced murine HSC expansion in
vitro and in vivo without causing hematopoietic disorders or malignancies.141,181-183
Compared with other oncogenic HOX proteins,139,143,147,162-164 HOXB4 was considered as
the most optimal factor to expand HSCs till recent report which described two cases of
myeloid leukemias in HOXB4 transplanted large animals.187 Primitive status of the
leukemia cells was dependent on the sustained HOXB4 expression, indicating HOXB4
overexpression played a key role in the leukemic transformation in these large animals.187
Integration site determined by LAM-PCR and activation of integration site nearby genes,
PRDM16 and MYB, raised the possibility that gamma retrovirus integration-induced
mutagenesis was involved in the leukemogenesis in the three large animals.187 So far this
is the only report of HOXB4-associated AML and it may due to high level of the HOXB4
expression achieved in the transplanted CD34+ cells.
Prdm Gene Family
PRDM (PRDI-BF1 and RIZ homology domain containing) family is a subfamily
of the SET domain containing proteins and consists of 16 orthologs in rodents.188 They
are all characterized by a N-terminal PR domain which is 20-30% identical to the SET
domain present in histone lysine methyltransferase (HMTs) (Figure 1-4).189 PR domain
is present in all family members and is followed by repeated zinc fingers except
PRDM11 (Figure 1-5).189 Although most PRDM proteins contain PR domains, HMT
activity was only detected in the PR domains of PRDM2, PRDM8 and PRDM9.190-192
PRDM2 and PRDM8 were reported as repressive di-methylation of lysine9 of histone
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Figure 1-4. The domain structure of the mouse PRDM1–16 proteins.
Illustrations of the protein domain structure of the PRDM family members 1–16. These
illustrations are drawn to scale based on a sequence analysis. Zinc fingers are represented
by blue boxes and the PR domain by a red box. Those proteins for which a nervous
system specific expression pattern is reported in this study are indicated with asterisks.
Reprinted with permission. Kinameri E, Inoue T, Aruga J, et al. Prdm proto-oncogene
transcription factor family expression and interaction with the Notch-Hes pathway in
mouse neurogenesis. PLoS One. 2008;3(12):e3859.189
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Figure 1-5. Structural and regulatory features of PRDM16.
(A) PRDM16 domain structure and binding sites. After the N-terminal PR domain, the
protein has a zinc finger DNA binding domain, a proline-rich domain, a repressor
domain, another zinc finger DNA-binding domain, and a C-terminal acidic domain. The
PR region corresponds to a SET domain, an 130-amino acid, evolutionarily conserved
sequence motif with histone methyltransferase activity. The ten zinc finger domains
correspond to the classical C2H2-type, in which the first pair of zinc-coordinating
residues are cysteines, and the second pair are histidines, conferring zinc-dependent
DNA- or RNA-binding properties. Two regions in PRDM16, namely zinc-finger (ZF)1
and ZF2, have been identified to bind to PPARg, whereas C-terminal-binding proteins
(CtBPs) have been shown to bind to a PLDLS motif at. (B) Schematic representation of
brown adipocyte determination by PRDM16
Reprinted with permission. Fruhbeck G, Sesma P, Burrell MA. PRDM16: the
interconvertible adipo-myocyte switch. Trends Cell Biol. 2009;19(4):141-146.193
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H3 (H3K9me2) HMTases191,194 while PRDM9 as activating tri-methylation of lysine4 of
histone H3 (H3K4me3) HMTases.192 Other PRDM proteins without intrinsic
methyltransferase activity recruit histone-modifying enzymes to achieve epigenetic
regulation of gene expression, including HMTs, PRMT5 (Protein methyltransferase 5),
LSD1 (lysine-specific demethylase1, Kdm1a), histone deacetylase (HDACs) and histone
acetyltransferase (HATs) p300/CBP and P/CAF, by forming protein complex or through
their own zinc figure domains or proline-rich domains. Besides histone-modifying
enzymes, PRDM proteins also recruit histone-modifying enzyme-associated corepressors. CtBP (C-terminal binding protein) is one of the co-repressors frequently
bound by PRDM2, PRDM3 and PRDM16 though their PLDLS CtBP-binding sites.195-201
PRDM protein also can bind to DNA directly through their zinc finger domains. Zinc
fingers of PRDM1 are able to recognize specific DNA binding sequence GAAAG and
mediate PRDM1-DNA interaction.202 PRDM3 contains two zinc finger domains: the Nterminal zinc fingers and C-terminal zinc fingers (Figure 1-4). N-terminal zinc fingers
prefer to bind a GATA-like motif further from transcription start site (TSS)203 and Cterminal zinc fingers bind an ETS-like sequence which is close to TSS.204 These two
binding patterns of PRDM3 are exclusive to each other which means PRDM3 only binds
to either of these two motifs, but not to both at the same promoter. In summary PRDM
proteins regulate gene expression as HMTs or through recruiting other HMTs or direct
bind to gene expression regulatory elements. Forming complex with a wide range of
different HMTs or selective target binding sites provide Prdm proteins a contextdepended regulation activity.
PRDM proteins play roles in normal tissue specification as well as cancer and
other diseases. PRDM1 is primarily identified as transcription repressor and it maintains
photoreceptor identity and neonatal enterocyte by repressing alternative differentiation
programs.205-209 Even more PRDM1directs and maintains mast cell differentiation
through maintaining other differentiation initiation at a repressive state.210 During plasma
cell differentiation PRDM1 directly represses Myc through recruitment of HDACs211 and
represses Ciita through LSD1.212 PAX5 and BCL6, both are required for B cell fate
specification, are downregulated by PRDM1 during plasma cell differentiation. RNAi
targeting Prdm16213,214 and Prdm16 mutant studies214 demonstrated that Prdm16 is
essential for brown adipose tissue (BAT) maturation by preventing skeletal myocytes respecification and white adipose (WAT) tissue differentiation. Enforced expression of
Prdm16 induced brown adipogenesis from myoblasts by activating PPARγ
transcriptional function through direct protein-protein interaction.214 Many PRDM
proteins also play roles in primordial germ cells and hematopoietic stem cells. The fact
that certain cancer cells share the self-renewal machinery with normal stem cells
indicates dysregulation of PRDM may be involved in tumorigenesis. Prdm3 and Prdm16
maintain long-term and short-term hematopoietic cells.215-218 However, both PRDM3 and
PRDM16 were original identified in acute myeloid leukemias. Expression of PRDM3 and
PRDM16 that lack partial PR domain leads to myeloid leukemia and adult T-cell
leukemia due to chromosome translocation events or viral vector insertional
activation.219-227 Prdm1 and Prdm14 are essential for pluripotent primordial germ cells
(PGCs) generation and Prdm1 mutants and Prdm14 mutants were not able to generate
PGCs.228-231 Prdm14 is also required to maintain mouse ESCs at pluripotent state even
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though Prdm14 is not required for mouse ESC derivation. Knockdown of Prdm14 in
mouse ESCs led to downregulation of ESC genes and activation of extraembryonic
endoderm program.232-234 Aberrant expression of PRDM14 was detected in breast cancer
due to gene amplification on chromosome 8q13235 and human lymphoid neoplasms. Gain
of function assay of Prdm14 in transplanted mice provided the evidence of the
association of Prdm14 with lymphoid leukemia initiation in vivo.236
PRDM16 protein domain
PRDM16, which is also named as MEL1 (MDS1/EVI1 like gene 1), was first
characterized from t(1;3)(p36;q21)-positive MDS/AML patient leukemia cells.237 MEL1
is highly homologous to MDS1/EVI1 with first 222 amino acid sequence homologous to
the PR domain of MDS1 and remaining sequence homologous to the EVI1 (ecotropic
viral integration site 1).237 There is a PR domain at the N-terminal of MEL1 protein,
repressor domain (RD) in the middle of the protein and two DNA binding domains which
contain either 7 or 3-C2H2 type zinc figure repeats. PR domain of MEL1 protein is 52%
identical to the N-terminal PR domain of the MDS1 protein and the RD contains a
consensus binding sequence for the CtBP2.237 Later study found out there were actually
three transcription start sites in MEL gene, one in exon 1 and two in exon2, which
generated two protein products, 170kD MEL1 and 150kD MEL1S.238 MEL1S is the main
isoform expressed in t (1; 3) (p36; q21)-positive AML cells and is translated from the
internal initiation codon ATG579 in exon4.238 MEL1S protein lacks most of the PR
domain compared with MEL1 protein.238 Aberrant expression of MEL1S gene due to
chromosome translocation and vector insertional activation was associated with
MDS/AML and T-cell leukemia.223-226,238-240 Prdm16 is mouse homolog of human
PRDM16/MEL1 and its protein structure is shown in Figure 1-5.
PRDM16 expression pattern and functions
In mouse embryo Prdm16 mRNA was first detected on E9.5 predominately in the
neuroepithelum lining the telencephalic vesicle (TV), mesenchyme of the first branchial
arch and dorsal aspect of somites and further expanded to the neuroepithelium of the
hindbrain and in the optic stalk (OS), mesenchyme of the second and third branchial
arches, limb bud (LB) and the facio-acoustic preganlion complex (FACP) on E10.5.241
During E11.5 to E12.5 Prdm16 expression expanded to liver, heart, lung epithelium
stomach, duodenum and brain, especially in neuroepithelium lining the third ventricle,
Meckel’s cartilage (MC) and future nasal spetum (NS) in the orofacial region and dorsal
root ganglia (DRG).241Prdm16 showed much broader expression pattern on E14.5,
encompassing mutli tissues including brain, olfactory epithelium (OE), testis, pancreas,
kidney adrenal gland (AG), lung, DRG, cartilage primordial of the ribs (CPR), limbs,
retina and in the lens also.241 Widespread expression of Prdm16 in mouse embryo
suggests role of Prdm16 in tissue/organ specification or growth.
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Denis, R.W et al identified PRDM16 as a SMAD3 binding protein mouse in
orofacial tissue during E12.5 to E14.5, but PRDM16/SMAD3 interaction did not
significantly alter TGFβ signaling.242 Although the molecular mechanism of Prdm16
during orofacial development is not clear, great progress has been made to understand the
role of Prdm16 in BAT differentiation. There is evidence showing that PRDM16
functions as a co-regulatory protein controlling molecular switch between white fat and
brown fat identity (Figure 1-5).185,201,202 Prdm16 transcript is highly expressed in primary
brown fat tissue and immortalized brown fat cell lines and overexpression of PRDM16
was able to induce BAT phenotype from PPAR-γ expressing white fat precursors or
fibroblasts.213 PRDM16-mediated identity switching between white and brown adipose
tissue was achieved by binding partner switching. Mouse PRDM16 directly binds to
CtBP-1 and CtBP-2 as co-repressors to transcriptionally repress WAT differentiation
program through direct interaction with the promoter of white fat specific genes.214 When
CtBP-1 and CtBP-2 are replaced by PGC-1α (PPAR-γ-coactivator-1α) and PGC-1β
(PPAR-γ-coactivator-1β), transcription activity of PGC-1α and PGC-1β are increased and
activate brown fat genes.214 However, switching cell identity between skeletal muscle and
BAT mediated by PRDM16 in Myf5+ myoblasts is not involved in white adipogenesis,
suggesting independent molecular mechanism of repression of skeletal muscle
differentiation.214 Enforced expression of PRDM16/C-EBP-β complex in myf5+
myoblasts is sufficient to initiate BAT differentiation program by inducing the PPARγ
and PGC-1α expression.243 Recent study showed euchromatic histone-lysinemethyltransferase 1(EHMT1), the enzymatic component of PRDM16 transcriptional
complex, determines BAT fate versus muscle cell lineage by stabilizing PRDM16 protein
and controlling H3K9 methylation status of the muscle-specific gene promoters.244
Besides PRDM16’s role in promoting BAT identity, there is also evidence
showing that PRDM16 executes important function in developing telencephalon through
repressive regulation of Hes1189 and functions as H3K9me1 methyltransferase to
maintain the integrity of mammalian heterochromatin.245 In the next two paragraphs I
will focus on the Prdm16’s role in normal and leukemic hematopoiesis.
PRDM16’s role in normal hematopoiesis
Prdm16 transcript is preferentially expressed in purified LT-HSC, ST-HSCs and
MPPs.215,216 Enforced expression of Prdm16 on mouse adult CD150+CD48-Lin- cells led
to enhanced HSC reconstitution capacity and poorly differentiated myeloid cells in
recipients’ bone marrow, which developed splenomegaly and myeloproliferation 20
weeks post transplantation.246 Loss of Prdm16 depleted fetal liver and new born liver
HSPCs, leaving remaining neonatal and adult HSCs with compromised long-term
reconstitution capacity and Prdm16-/- HSCs contain increased proportion of HSCs
undergoing apoptosis/cell death and active cell division.215,216 Gene expression data from
Prdm16-/- HSCs suggested that Prdm16 regulates multiple pathways/regulators to
maintain HSC function, including p53 related apoptotic pathway, cell cycle regulator
Cdkn1a, transcription factors critical for HSC maintenance and Wnt signaling pathway
components Wnt3a and Ryk206. Gathering all the data, it suggests Prdm16 is required
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for fetal and adult HSC maintenance and overexpression of Prdm16 is able to enhance
HSC activity in vivo. However, the fact that enforced expression of Prdm16 in HSCs led
to undifferentiated HSCs in vitro and myeloproliferation in recipients unveiled Prdm16’s
oncogenic potential, which may be related to the function of human PRDM16 in AML.
The role of PRDM16/sPRDM16 in hematopoietic malignancies will be discussed in the
following paragraphs.
PRDM16’s role in leukemic hematopoiesis
Most evidences of association between PRDM16 and hematopoietic malignancies
come from the studies of human AML involved chromosome translocation. Since
PRDM16/MEL1 was first isolated from t(1;3)(p36;q21)-positive MDS/AML patient
leukemia cells,237 there are growing evidences showing sPRDM16/MEL1S, lacking most
of PR domain, is the major isoform highly expressed in t(1;3)(p36;q21)-positive
MDS/AML as fusion partner with RPN1238,239 and t(1;21)(p36;q22)-positive therapyrelated MDS/AML as fusion partner of RUNX1.224,225,247 The RUNX1-PRDM16 gene is
highly homologous to MDS1/EVI1 gene,237 suggesting RUNX1-PRDM16 may share
similar mechanism in leukemic progress. sPRDM16 is also overexpressed in adult T cell
leukemia with normal karyotype leukemias due to hypomethylation of regions
surrounding sPRDM16 transcription start site223. Instead, the full-length PRDM16 is
silenced by DNA hypermethylation of its promoter.223 This provided alternative
epigenetic mechanism of aberrant and predominant expression of sPRDM16 in T-cell
leukemia. Overexpression of sPRDM16 but not full length of PRDM16 led to myeloid
leukemia in p53 null mice, indicating the cooperative effects of sPRDM16 and loss of
p53 in murine AML pathogenesis.248 Du. Y et al showed Prdm16 is one of the frequent
MSCV integration spots resulting in aberrant expression of sPRDM16, but not PRDM16,
which led to immortalization of murine bone marrow progenitors.227 Upregulation of
sPrdm16 due to insertional activation by γ-retroviral SIN vector is sufficient to induce
leukemia in mice.240 In summary, sPRDM16 plays role in leukemogenesis through
chromosome translocation, promoter hypomethylation or vector insertional mutagenesis
although the molecular mechanism is still unclear.
Thesis
Unlike oncogenic HOX genes like HOXA9 and HOXA10, HOXB4 overexpression
can mediate murine HSC expansion in vivo without leading to hematopoietic
malignancies. Though many studies were carried out to identify HOXB4 target genes and
these studies offered some insights regarding the mechanism of HOXB4-mediated HSPC
expansion in vitro, survival and specification of ES cells, there are still questions listed
below remaining unknown regarding HOXB4-mediated HSC expansion.
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Questions
1. What are HOXB4’s transcriptional target genes in transplanted mice?
2. What are the pathways HOXB4 functions through to achieve robust HSC
expansion in vivo?
3. What is the mechanism by which HOXB4 avoids leukemogenesis in
transplanted mice?
Hypothesis
By reviewing previous literatures about HOXB4-mediated HSC expansion;
Prdm16’s role in HSC maintenance; association of sPrdm16activation with leukemia in
HOXB4 transplanted animals, we generated our hypothesis to answer the questions
above. The hypothesis is:
HOXB4 downregulates Prdm16 to avoid leukemia in transplanted mice, cooverexpression of sPrdm16 and HOXB4 will lead to hematopoietic cell transformation.
Rationales
The Rationales of the hypothesis are listed as follows:
1. Overexpression of HOXB4 leads to murine HSC expansion without causing
hematopoietic malignancies.
2. Activation of sPrdm16 due to vector integration promotes leukemogenesis in
HOXB4-overexpressing cells in large animals.
3. Growth of leukemia cells from HOXB4-transplanted animal is dependent on
the sPrdm16 expression.
4. PRDM16 expression is upregulated in HOXA9-asscoated leukemias.
5. Aberrant expression of sPRDM16 due to chromosome translocation or
promoter hypomethylation is frequently detected in MDS/AML or adult T cell
leukemias.
6. Overexpression of sPRDM16 led to myeloid leukemia in p53-null mice.
7. Enforced expression of sPrdm16 blocks G-CSF induced granulocytic
differentiation in L-G3 cells.
Specific aims
1. Identify target genes and pathways regulated by HOXB4 in LSK cells from
recipient mice at 6, 12 and 20 weeks post transplantation.
2. Find out and validate the mechanism by which HOXB4 avoid leukemia in
vivo.
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Approach
Specific aim 1
To identify HOXB4 transcriptional target genes and its regulated pathways we
will perform gene expression profiling on HOXB4-overexpressing LSK cells from
transplanted mice at 6, 12 and 20 weeks following transplantation. A two-factor ANOVA
analysis will be applied to identify differentially expressed target genes and Gene Set
enrichment assay (GSEA) and MetaCore pathway analysis will be used to identify
pathways regulated by HOXB4. Quantitative real-time PCR will be performed to validate
differential gene changes in CD34-/low LSK cells, which are highly enriched with HSCs.
Gene expression array provided by Hartwell Center for Bioinformatics and
Biotechnology of St. Jude Children’s Research Hospital requires at least 100ng mRNA
with concentration of at least 33ng/ul. The major challenge of perform gene expression
array on rare population is inadequate mount of RNA. In this study we plan to apply
expression on LSK cells, which is about 0.3% of total bone marrow cells. Our HOXB4
retroviral vector can achieve about 30% transduction and around 90% for GFP vectors.
Trial experiments showed that we are able to extract enough RNA for microarray from 35 mice.
Specific aim 2
To identify the mechanism by which HOXB4 avoids leukemia in transplanted
animals we will screen the differentially regulated transcriptional target genes generated
from microarray discussed above. They can be genes (1) critical for HSC differentiation
or apoptosis, (2) tumor suppressors upregulated by HOXB4, (3) oncogenes
downregulated by HOXB4. To validate the potential factor involved in avoiding
leukemia, target gene will be overexpressed or knockdown using lentiviral vector under
the context of HOXB4 overexpressing to screen leukemia in transplanted mice.
We have generated and well characterized lentiviral overexpression and
knockdown vectors that can be used in this study. We also developed efficient HSC or
HPC transduction protocol which allows us to generate enough double positive cells for
transplantation. Flow cytometry core, Pathology department and Animal Resource Center
of St. Jude Children’s Research Hospital are able to offer us professional assistance for
cell sorting and analysis, animal necropsy, animal care.
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CHAPTER 2. IDENTIFICATION OF HOXB4 TRANSCRIPTIONAL TARGET
GENES IN PRIMITIVE HEMATOPOIETIC CELLS IN VIVO
Introduction
As mentioned earlier overexpression of HOXB4 leads to marked murine HSC
expansion in vivo without causing hematopoietic malignancies. Little is known about the
mechanism how HOXB4 expands HSCs and at meanwhile prevents leukemogenesis. To
understand the regulatory role of HOXB4 in HSCs expansion, many studies were carried
out to screen HOXB4’s direct or indirect target genes and pathways important for HSCs
maintenance, proliferation and differentiation. Microarray data from either enriched adult
HSCs or embryonic derivatives expressing HOXB4 demonstrated that HOXB4
transcriptionally activates c-Myc249 and down-regulates genes involved in TNF-α and
FGF signaling in bone marrow cells,250 thus proving beneficial for HSCs self-renewal.
Gp49a, Laptm4b and Hemgn were identified as HOXB4 downstream targets and
suggested to be potentially important for HSCs’ stemness or expansion of myeloid
progenitors in vitro.251,252 These earlier studies suggested that HOXB4 controls HSC or
myeloid progenitors through multiple mechanisms such as apoptosis and symmetric
division/proliferation. However, it is noticed that none of the previous studies focused on
HOXB4 targets in primary primitive hematopoietic populations in vivo. To overcome the
limits of previous screenings we decide to screen HOXB4’s target genes in LSK cells
during different phases of the reconstitution in vivo.
To screen HOXB4 target genes and pathways in LSK cells from transplanted
mice, we plan to transplant HOXB4 overexpressing bone marrow cells to lethally
irradiated mice and extract RNA of LSK cells from recipients at 6, 12 and 20 weeks
following transplantation for expression array assay. Compared with previous studies
done on manipulated cells lines or by using in vitro system, target genes identified from
transplant mouse model will be more informative about how HOXB4 expands HSCs in
vivo.
Materials and Methods
Vector cloning
The retroviral vectors MSCV-ires-GFP and MSCV-HOXB4-ires-YFP have been
described previously.251
Retroviral vector preparation
Retroviral vectors of MSCV-ires-GFP or MSCV-HOXB4-ires-YFP were
prepared as described before.251 The helper-free recombinant retroviral vector supernatant
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was freshly collected from the GPE+86 producer cells and filtered through 0.45 µm pore
filter for transduction.
Bone marrow cells isolation, culture, transduction and transplantation
All animal experiments were carried out according to protocols approved by the
St. Jude Institutional Animal Care and Use committee. To harvest primitive bone marrow
cells, 5-Fluorouracil (5-FU) (150 mg/kg) was injected intravenously into 6 to 8-week-old
female c57BL/6J mice. 5 days after injection bone marrow cells were flushed with 21gauge needles from both femurs and tibias in to ice cold DPBS containing 2% FBS. 5-FU
treated were cultured in DMEM supplemented with 15% fetal bovine serum (FBS), 50
units/ml penicillin, 50 units/ml streptomycin, 2mM L-glutamine, 20 ng/ml recombinant
mouse IL-3, 50 ng/ml human IL-6, and 50 ng/ml mouse SCF (R&D Systems,
Minneapolis, MN).
To transduce bone marrow cells with gamma retroviral vector, 5-FU treated BM
cells were prestimulated with cytokine mixture mentioned in the previous paragraph for
48 hours to induce quiescent hematopoietic stem cells to enter cell cycle. After two days’
prestimulation 1x106 bone marrow cells were transduced with fresh unconcentrated
supernatant from GPE+86-derived producer cells containing MSCV-HOXB4-ires-YFP or
MSCV-ires-GFP retroviral vectors in 6-well plates preloaded with 25ug/ml retronectin
(Takara). After two to four daily exposures to vector, 1 to 2 million transduced cells were
injected into the lateral tail vain of lethally irradiated (1100cGy) female C57Bl/6L mice.
Transplanted mice were under Baytril water administration for 3 weeks post
transplantation and Baytril water was changed weekly.
Cell separation
BM cells were stained with Sca-1-PE, c-Kit-APC and a PE-Cy7 conjugated
lineage antibody mixture (CD4, CD8, Gr1, Ter119 and NK1.1) (BD Bioscience). GFP+
or YFP+ LSK cells were isolated by flow cytometry.
Colony forming assay
Total 500 vector positive LSK cells from HOXB4 or GFP transplanted mice at 12
and 20 weeks post transplantation were into 1ml MethoCult GF M3434 methylcellulose
medium (StemCell Technologies, Vancouver, BC, Canada) containing various cytokines
supporting growth of clonogenic myeloid progenitor cells. After 7 days, primary (1°)
colonies were scored, collected, resuspended, and re-plated at 1x104 cells/ml density into
the M3434 methylcellulose medium for 14 days culture. The generated secondary (2°)
colonies were scored to quantitate the expansion of myeloid progenitors.
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Microarray expression analyses and real-time RT-PCR
Total RNA from sorted LSK cells was extracted using RNAqueous®-Micro kit
(Life Technologies). Approximately 20ng total RNA was processed using NuGEN WTA
pico v2 and Encore Biotin labeling modules and 6ug of biotin-labeled cDNA was
hybridized overnight to HT_MG-430_PM microarray chips (Affymetrix). Hybridized
arrays were scanned using the Gene Titan system and signals were summarized using the
RMA method (Partek Genomics Suite v6.5). Differentially expressed transcripts between
GFP+ LSK and HOXB4+ LSK cells were identified from triplicate, independently
derived from pools of cells at various time points using a two-factor ANOVA model. The
Benjamini-Hochberg method253 was used to estimate the False Discovery Rate (FDR).
Pathways activated or repressed by HOXB4 expression were identified by GSEA254 using
curated pathways obtained from the MolSigDB (Broad Institute) and Ingenuity Pathways
(Ingenuity, Inc.). MetaCoreTM software (GeneGo, Philadelphia, PA) was also used to
identify significant biological pathways defined by specific differentially expressed
genes.
To validate gene expression changes detected in microarray study, GFP+ or
HOXB4-YFP+ CD34-/low LSK cells were sorted from transplanted mice 20 weeks post
transplantation. Total RNA sorted cells were reverse transcribed using SuperScript VILO
cDNA Synthesis Kit (Life Technologies). Resulting cDNAs were quantitated by qRTPCR assay using Power SYBR® Green PCR Master Mix (Life Technologies). The
relative expression levels for specific transcripts were calculated using the 2ΔΔCT method
normalized to the internal control gene Gapdh.
Results
HOXB4+LSK cells demonstrated enhanced hematopoietic progenitor cell selfrenewal in vitro
To demonstrate HOXB4-enhanced hematopoietic progenitors’ clone forming
capacity in vitro, 500 HOXB4-YFP+ LSK cells or control GFP+ LSK cells from 12 and 20
weeks transplant mice were plated into MethoCult GF M3434 to score the secondary
colony numbers. HOXB-LSK from 12 week transplanted mice generated 169 secondary
colonies, about 9 times more than GFP control LSK cells from the same time point
(P<0.01) (Figure 2-1). HOXB4-LSK cells from 20 weeks transplant mice generated 395
secondary colonies, 15 times more than GFP control LSK cells at same time point
(P<0.01) (Figure 2-1). Increased secondary colony number generated from HOXB4-LSK
at both 12 and 20 weeks post transplantation indicated enhanced hematopoietic
progenitor cell self-renewal in vitro. It also suggested RNA samples collected from the
same batch of cells for microarray were validated.
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Figure 2-1. Secondary colony numbers generated from 1x104 GFP-LSK cells or
HOXB4-LSK cells at 12 or 20 weeks post transplantation.
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Global gene expression changes in HOXB4-transduced LSK cells at various time
points after transplant
To identify both direct and indirect transcriptional target genes of HOXB4 in
HSCs, we generated a MSCV-HOXB4-ires-YFP vector and a control GFP vector based
on the MSCV γ-retroviral vector (Figure 2-2A). Groups of mice were transplanted with
transduced bone marrow cells and then euthanized at 6, 12, and 20 weeks after transplant
for gene expression analysis (Figure 2-2B). Gene expression profiling was performed on
HOXB4-YFP or control GFP-expressing bone marrow LSK cells isolated by cell sorting
(Figure 2-2C). At most time points, sufficient amounts of RNA were isolated for
microarray analysis (Table 2-1). For all time points, three independent transplant
experiments and cell isolation procedures were performed to establish reproducibility.
Principal component analysis (PCA) using all expression profiles measured by the
microarray revealed significant clustering within experimental groups (Figure 2-3A).
The GFP samples and the HOXB4 samples separated across the first principal component
indicating the most significant source of expression variation was associated with
presence or absence of HOXB4 expression. Within the GFP treatment arm, the 12 and 20
week samples grouped closely together. Within the HOXB4 treatment arm, the 12 and 20
week samples also grouped together and were statistically distinct from the GFP-control
groups (Figure 2-3A). The 6 week samples from the HOXB4 treatment arm were
separated from the 12 and 20 week HOXB4 samples, demonstrating distinct
transcriptional profiles exist at these two time points. A heat map representation of all
expression profiles shows reproducible gene expression changes in HOXB4-transduced
LSK cells that evolve between 6 and 20 weeks after transplant (Figure 2-3B). These gene
expression patterns were consistent in triplicate samples from both groups and were
highly reproducible within each experimental arm.
Identification of specific changes in gene expression in HOXB4-transduced LSK
cells
To identify either direct or indirect HOXB4 target genes, we applied a two-factor
ANOVA model to identify probe sets with >0.5 log difference and with a FDR of <0.05
in the HOXB4 versus the GFP groups at given time points. In the HOXB4-LSK cells, a
total 520 and 1712 probe sets were identified with significant differential expression at 12
weeks and 20 weeks when compared with control GFP-LSK cells (Figure 2-4A, B).
When 6 week HOXB4 samples were compared with the 12 and 20 week HOXB4
samples, 379 and 622 probe sets showed >0.5 log deference and FDR<0.05 respectively
(Figure 2-4C, D). However, no significant differential gene expression was noted
between 12 and 20 week in HOXB4+ LSK cells, demonstrating that the major
transcriptional events in HOXB4 transduced cells occur by 12 weeks after
transplantation. Heat maps of the top 35 over and under-expressed genes at 20 weeks
show reproducible and significant differences in HOXB4samples versus GFP samples
(Figure 2-4E).
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Figure 2-2. Experimental design of HOXB4 target gene analysis in transplanted
murine HSCs.
(A) Schematic diagram of HOXB4 retroviral and GFP control vectors used to transduce
5-FU treated bone marrow cells. (B) Time line of transduction and mouse transplantation
assay. (C) Flow cytometry sorting strategy for transduced LSKs. Bone marrow cells
isolated from recipients were first gated for lineage negative cells, then for cKit+, Sca-1+
marker status, and then for vector expression based on GFP or YFP expression. Sorted
GFP/YFP+ LSK cells were used for subsequent gene expression analyses.
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Table 2-1.
Summary of RNA samples submitted for microarray from GFP or
HOXB4 group at 6 weeks, 12 weeks and 20 weeks.
Group

Time Point

HOXB4

6 weeks

Recipient
No.
2

LSK No.
12653

Amount of RNA
(ng)
38.045*

HOXB4

6 weeks

2

33599

51.2*

HOXB4

6 weeks

4

178567

65.15*

GFP

12 weeks

2

103797

24.365*

GFP

12 weeks

2

132398

43.09*

GFP

12 weeks

3

32196

37.505*

HOXB4

12 weeks

2

232034

153.7*

HOXB4

12 weeks

2

145500

158.35*

HOXB4

12 weeks

3

280349

209.8*

GFP

20 weeks

2

25532

33.782*

GFP

20 weeks

2

261449

221.4

GFP

20 weeks

2

11181

93.76*

HOXB4

20 weeks

2

139257

172.54

HOXB4

20 weeks

2

166132

252.2

HOXB4

20 weeks

2

200269

411

* indicates the samples from which RNA was concentrated using sodium acetate
precipitation.
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Figure 2-3. PCA and heat map representation of HOXB4-induced expression
profiles in bone marrow LSK cells.
(A) PCA using all probe sets where each symbol represents an separate experiment as
indicated by the legend, with red symbols denoting HOXB4 samples and blue symbols
the GFP controls. The GFP+ LSK cells and HOXB4+ LSK cells segregate into
statistically separate groups across PC1 axis. HOXB4-LSK cells harvested at 6 weeks are
distinct from 12wk and 20wk HOXB4-LSKs across the PC2 axis. (B) Heat map of gene
expression alterations seen across all probe sets, with triplicate samples per experimental
arm and time points as indicated by the labels. Red indicates over-expressed probe sets
relative to GFP controls while green indicates under-expressed probe sets.
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Figure 2-4. Identification and validation of HOXB4 target genes.
Bland-Altman plots showing comparative gene expression between (A) 12wk HOXB4LSKs and 12wk GFP-LSKs (B) 20wk HOXB4-LSKs and 20wk GFP-LSKs (C) 12wk
HOXB4-LSKs and 6wk HOXB-LSKs and (D) 20wk HOXB4-LSKs and 6wk HOXB4LSKs. The y-axis indicates the magnitude of change and the x-axis the average of the
signal. The red dots represent differentially expressed probe sets with a >0.5 log
differential expression and false discovery rate (FDR) <0.05. (E) Heat map of the top
upregulated and downregulated genes from 20wk HOXB4-LSKs compared with 20wk
GFP-LSKs. Red represents upregulated genes and blue boxes represent downregulated
genes. (F) Quantitative RT-PCR measurement of differential gene expression for 13
HOXB4-regulated genes in CD34-/low LSK cells at 20 weeks post transplantation. The
fold change is indicated for HOXB4 cells relative to GFP cells. (G) Quantitative RT-PCR
for expression of Prdm16 mRNA in LSK cells harvested from transplanted mice at 6
weeks and 39 weeks post transplantation.
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CD34-/low LSK cells were isolated 20 weeks after transplant. Reverse qRT-PCR
was used to measure mRNA levels for a subset of differentially expressed transcripts
potentially involved in HSC regulation (Figure 2-4F). GATA2 is a zinc-finger
transcription factor that is required for adult HSC development44 and was increased 4 fold
in HOXB4 transduced HSCs. Hemgn was identified as a HOXB4 direct target in HOXB4
transduced hematopoietic progenitor cells in our previous study251 and was increased 3.0
fold relative to that seen in GFP control cells (Figure 2-4F). TGF-beta signaling is a
negative regulator of HSC proliferation and utilizes SMAD proteins as downstream
effector molecules84. Expression of Smad1 and Smad7 were 3.6 and 2.4 fold up-regulated
by qRT-PCR in HOXB4-transduced CD34-/low LSK cells (Figure 2-4F).
A 3-18 fold down-regulation of Prdm16 was noted in all 4 microarray probes
from the HOXB4 samples at 20 weeks. PRDM16 is a SET domain-containing protein
associated with epigenetic remodeling and is required for brown fat
determination197,213,214 and adult murine HSC and neural stem cell maintenance.215 We
noted a 58.1 fold down-regulation of Prdm16 mRNA by qRT-PCR in HOXB4 samples
compared with GFP controls at 20 weeks (Figure 2-4F). A time course of Prdm16
mRNA expression showed large decreases in Prdm16 transcripts in HOXB4-LSK cells at
6 weeks and 39 weeks respectively (Figure 2-4G), demonstrating that downregulation of
Prdm16 occurs at both early and late times after transplant.
HOXB4 overexpression results in gene expression changes associated with HSC selfrenewal and lymphoid-myeloid differentiation
To further define the regulatory pathways underlying HOXB4-dependent HSC
expansion, we performed GSEA with curated gene sets associated with signaling,
metabolic, and differentiation pathways. HOXB4 expression at 20 weeks after transplant
produced significant activation of genes associated with HSC function (Figure 2-5A).255
This trend was also seen at 12 weeks in the HOXB4 arm but did not reach statistical
significance. Activation of genes associated with long term hematopoietic stem cell
potential was also observed in HOXB4-transduced LSK cells at 20 weeks but not at 12
weeks (FDR < 0.05). The highest over-expressed genes in the HSC pathways included
Jun, Evt1, Smad7, Angpt1, Laptm4b, Hoxa5, and Hoxa10 (Figure 2-5B).
The top canonical pathways activated and repressed in HOXB4-LSK cells at 20
weeks (Tables 2-2, 2-3) include multiple signaling, differentiation, and metabolic
pathways. In particular, a distinct B cell differentiation pathway (Ingenuity, Inc.) was
activated in HOXB4+ LSK cells at both 12 and 20 weeks (Figure 2-5C). Rag2, Rag1,
Pax5, Bcl11a and other genes important for B cell differentiation were activated in
HOXB4+ LSK cells (Figure 2-6A). Pathway analysis of differentially expressed
transcripts using MetaCoreTM software identified several myeloid differentiation
pathways as being activated by HOXB4 in LSK cells (Figure 2-5D). These included
Development_Transcription regulation of granulocyte development and Development_GCSF-induced myeloid differentiation as the top two most significantly activated pathways
in 12 and 20 weeks HOXB4-LSK cell samples (Figure 2-5D). Overexpressed genes in
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Figure 2-5. GSEA and MetaCore pathway analysis of HOXB4 responsive genes.
(A) GSEA analyses for HOXB4 regulated genes identified for hematopoietic stem cell
pathways. For each GSEA, the nominal p-value and FDR q-value are shown below each
pathway graph. Statistical significance was validated for both pathways in 20 week
samples. (B) Heat map gene expression changes in individual gene probe sets within the
Hematopoiesis Stem Cell pathway and Hematopoiesis Stem Cell Long Term pathway in
LSKs analyzed at 12 and 20wks after transplant. Red boxes represent upregulated genes
and blue boxes represent downregulated genes. (C) GSEA analysis B cell differentiation
pathway genes altered by HOXB4 in 12 and 20 week LSK samples. Statistical parameters
are listed below each analysis. (D) Pathway analysis of differentially expressed probe sets
using MetaCoreTM program analysis showing the top 10 pathways regulated by HOXB4
at 12 (yellow) and 20 weeks (blue) post transplantation. The x-axis scale shows the 10log (p-value) of each pathway.
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Table 2-2.

Pathways activated in HOXB4-LSKs at 20 weeks.
Name

Size

ES

NES

NOM p-val

FDR q-val

KEGG_PRIMARY_IMMUNODEFICIENCY

35

0.67463

2.02402

0

0.013965

REACTOME_THROMBIN_SIGNALING_THR
OUGH_RPOTINASE_ACTIVATED_RECEPT
ORS

27

0.63399

1.84257

0.00168

0.16151

IP_B_CELL_DIFFERENTIATION

20

0.690918

1.83225

0

0.12314

BIOCARTA_RHO_PATHWAY

32

0.605903

1.82660

0.00543

0.102322

KEGG_VASCULAR_SMOOTH_MUSCLE_CO
NTRACTION

108

0.479403

1.82660

0

0.166082

BIOCARTA_BCR_PATHWAY

33

0.59260

1.77393

0.00347

0.151108

BIOCARTA_PGC1A_PATHWAY

22

0.64729

1.75932

0.00355

0.156613

REACTOM_INHIBITION_OF_INSULINE_SE
CREATION_BY_ANDRENALINE_NORADR
ENALINE

30

0.59687

1.74797

0.001694

0.159273

BIOCARTA_CTCF_PATHWAY

23

0.62738

1.747828

0.005300

0.141576

REACTOME_SIGNAL_AMPLIFICATION

31

0.582232

1.74742

0.003442

0.127858
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Table 2-3.

Pathways activated in GFP-LSKs at 20 weeks.
Name

Size

ES

NES

NOM p-val

FDR q-val

KEGG_LYSOSOME

116

-0.59061

-2.2849

0

0.00143257

REACTOME_P53_INDEPENDENT_DNA_DAM
AGE_RESPONSE

42

-0.68597

-2.2615

0

7.16E-04

REACTOME_CDT1_ASSOCIATION_WITH_TH
E_CDC6_ORC_ORIGIN_COMPLEX

45

-0.67419

-2.2377

0

4.78E-04

KEGG_PROTEASOME

44

-0.67331

-2.2255

0

7.14E-04

REACTOME_ELECTRON_TRANSPORT_CHAI
N

62

-0.62747

-2.2045

0

5.71E-04

REACTOME_METABOLISM_OF_CARBOHYD
RATES

110

-0.5745

-2.1961

0

4.76E-04

REACTOME_STABILIZATION_OF_P53

45

-0.6662

-2.1781

0.002341

5.99E-04

REACTOME_SCF_SKP2_MEDIATED_DEGRA
DATION_OF_P27_P21

50

-0.6433

-2.1659

0

8.47E-04

REACTOME_CYCLIN_E_ASSOCIATED_EVEN
TS_DURING_G1_S_TRANSITION_

56

-0.62507

-2.1562

0

7.53E-04

KEGG_PENTOSE_PHOSPHATE_PATHWAY

26

-0.7229

-2.1551

0

6.78E-04
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Figure 2-6. Activation of B cell differentiation and Granulocyte development/ GCSF-induced myeloid differentiation in 12wk and 20wk HOXB4-LSKs.
(A) Heat map of genes of B CELL DIFFERENTIATION pathway activated in 12wk and
20wk HOXB4-LKSs. (B) Demonstration of activated components in granulocyte
development and G-CSF-induced myeloid differentiation signaling pathways in 12wk
and 20wk HOXB4-LKSs.
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these pathways included genes encoding the G-CSF receptor as well as C/EBPalpha,
Myeloblastin, Lactoferrin, Leukocyte elastase, and Gp91-phox (Figure 2-6B).
Altogether, these results suggest HOXB4’s function may also include lineage-specific
priming events in committed cells that are present within the heterogeneous LSK
population.
Discussion
Advantage of gene profiling study in LSK cells from HOXB4 transplanted mice
Enforced expression of HOXB4 causes a controlled expansion of murine HSCs in
vivo until HSC numbers approximate that seen in untransplanted mice. The genes that
control this expansion have not been previously identified and are likely relevant for the
physiologic regulation of HSC pool size or leukemogenesis in transplanted mice. Prior
gene expression profiling studies have identified various HOXB4 target genes in different
systems250-252,256,257 yet these studies show little overlap in identified target genes. None
of these previous studies included analyses of primary adult HSCs derived directly from
HOXB4 transplanted animals. Even less is known about how HOXB4 transcriptional
events are dynamically regulated at various times during HSC reconstitution. This study
addresses these questions by defining the HOXB4 transcriptional program directly in
LSK cells (HSC-enriched population) derived from the bone marrow of transplanted
mice at multiple time points. Although majority of LSKs are composed of restricted
progenitors, expression changes of genes critical for HSCs function were validated on
CD34-/low LSK cells, which are high enriched with HSCs. Quantitative real-time PCR on
CD34-/low LSK cells confirmed the gene expression changes of key HSC regulators shown
in gene expression array.
Mechanism of well-maintained HSC pool size by HOXB4
Our gene expression array data (PCA and heat map) showed that the HOXB4
gene expression pattern in transplanted LSK cells was fully established by 12 weeks after
transplant. This is consistent with the known kinetics of HOXB4-induced HSC expansion
in which HSC numbers in the bone marrow were normal and stable by 12 weeks after
transplant, but not at 8 weeks.181,182 The fact that the kinetics of the gene expression
changes correlate with the plateauing of HSC numbers further establish that HOXB4
mediated HSC effects are transcriptionally mediated. GSEA showed that both short and
long term HSC expression profiles were activated by HOXB4 expression and involved
regulation of a number of genes known to be important for HSC function and selfrenewal.
When taking close look at the genes critical for HSC proliferation, quiescence and
apoptosis, Smads, Gata2, Bcl3 and Prdm16 would be executors which regulate HSC pool
size in HOXB4 transplanted mice. SMAD-1 (R-Smad) and SMAD-7 (I-Smad) are
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mediators of TGF-β/BMP signaling pathway, which execute ligand-specific regulation of
HSC proliferation, differentiation and apoptosis and in some cases bone marrow niche is
required. Smad1 and Smad7 were upregulated in HOXB4-LSK/CD34-/low LSK cells.
Smad7 increases HSC self-renewal in vivo while effect of Smad1 on adult HSC is not
clear, although Smad1 was required for embryonic hematopoiesis. Considering Smad1 is
activated by TGF-β1 receptor which has negative effect on HSC self-renewal and
differentiation and promotes HSC apoptosis, we assume that activation of Smad1 in
HOXB4 transplanted mice had negative regulation of HSC pool size. The ultimate
outcome is decided by the balanced effect of Smad1 and Smad7. GATA2, a transcription
factor inhibiting hematopoietic precursor from differentiation and maintaining HSC/HPC
at quiescent state,45,46 was upregulated by HOXB4 in LSK cells. It suggests GATA2’s
role in maintaining HSC pool size. Another mechanism for HOXB4 to regulate HSC pool
size is downregulation of Bcl3. BCL3 is a potential anti-apoptotic effector in HSCs and
repression of Bcl3 results in increased apoptosis in HSCs, thus prevent HSC ‘runaway’
expansion. PRDM16 is another positive regulator of HSC which was marked
downregulated by HOXB4. Prdm16 null mice are embryonic lethal because of loss of
fetal liver HSCs due to enhanced apoptosis.215,216 Repression of Prdm16 expression can
introduce apoptosis in HOXB4-LSKs, thus maintain HSC pool at physiological level.
(Figure 2-7)
In addition to these HSC signatures, network analyses revealed gene sets
enrichment associated with B-cell and myeloid differentiation programs. Activation of
these differentiation programs could reflect expression of lineage-associated genes that
result from asymmetric HSC divisions producing committed progenitor cells. This is
consistent with the widely held viewpoint that HSC pool size is regulated by establishing
equilibrium between commitment/differentiation versus HSC self-renewal fates. The
LSK cell pool contains seven functionally distinct subpopulations of HSCs and MPPs
with myeloid-biased or lymphoid-biased or myeloid-lymphoid balanced reconstitution
capacity in transplanted mice.258 Our data suggest that HOXB4 overexpression can
induce both symmetric and asymmetric HSC replication in a balanced manner that leads
to a stable HSC pool size by 12 weeks.
To validate the hypothesis of the regulation of HSC pool size in HOXB4
transplanted mice discussed above, limiting dilution assay to assess the HSC frequency
should be performed.
Mechanism how HOXB4 prevents leukemia in transplanted mice
Overexpression of HOXA9 or HOXA10 can lead to myeloid leukemia because of
increased HSC/HPC pool size and blocked downstream differentiation, during which
collaboration of MEIS1 is required.138-140 It is known that HOXB4, unlike oncogenic
gene HOXA9 and HOXA10, doesn’t cause hematopoietic malignancies in transplanted
mice. Differentiation permission of proliferating HSCs is the key to prevent leukemia.
GSEA and MetaCore pathway analysis indicate HOXB4 activates B cell and myeloid
lineage differentiation, thus preventing accumulation of undifferentiated HSCs in bone
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Figure 2-7. Regulation of HSC pool size in HOXB4 transplanted mice.
Genes known important for HSC function, Smad1, Smad7, Gata2, Bcl3 and Prdm16,
were regulated to maintain HSC pool size at physiological level. Maintenance of HSC
pool size was achieved through regulation of HSC self-renewal, differentiation and
apoptosis.
Modified with permission. Larsson J, Karlsson S. The role of Smad signaling in
hematopoiesis. Oncogene. 2005;24(37):5676-5692.12
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marrow niche which could potentially lead to leukemia. However the molecular
mechanism of the differentiation permission in HOXB4 expressing HSCs is not clear.
PRDM16 as mentioned before is required for HSC maintenance
duringembryogenesis215,216 and its aberrant expression is frequently detected in
MDS/AML or T-ALL patients.223-225,237-239,247,259,260 Downregulation of Prdm16 by
HOXB4 can serve a mechanism to prevent leukemia in transplanted mice. Due to
chromosome translocation or vector insertional activation, short form of PRDM16
(sPRDM16) lacking most of the PR domain is the major isoform expressed in leukemia
patients. Overexpression of sPRDM16 but not full length of PRDM16 led to myeloid
leukemia in p53 null mice.248 To prove the hypothesis that repression of Prdm16 is the
mechanism to prevent leukemogenesis in HOXB4 transplanted mice, we plan to screen
leukemia in transplanted mice receiving HOXB4 and sPRDM16 co-expressing cells in
mice. We expect to detect myeloid leukemia in transplanted mice. It may require long
latency or we will not detect any leukemia, which suggests additional genetic lesions are
required to initiate leukemic transformation.
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CHAPTER 3.

DOWNREGULATION OF PRDM16 PREVENTS LEUKEMIA IN
HOXB4 TRANSPLANTED MICE
Introduction

Enforced expression of HOXB4 leads to increased HSC self-renewal without
causing hematopoietic malignancies in transplanted mice141,181. Benign HSC expansion in
vivo makes HOXB4 a perfect tool to expand HSCs for blood diseases. To identify the
mechanism how HOXB4 prevents leukemogenesis, we investigated the expression
profiling of HOXB4 expressing LSKs from transplanted, which suggested activated
lineage priming and downregulation of AML-associated gene Prdm16 would be the
reason. We focused on the study of sPrdm16 because of the association of sPrdm16 with
human MDS/AML and T-TALL.239,247,260 Humphries group also reported the vector
insertional activation of sPrdm16 which plays role in the myeloid leukemia developed in
large animals transplanted with HOXB4 transduced CD34+ cells.187 At meanwhile
Forget’s group screened 52 HOXB4 transplanted mice and 2 mice developed AML at 4
and 9.5 months, respectively, following transplantation. Both leukemias were passaged
by serial transplantation of leukemic bone marrow or spleen cells into WT recipient mice.
Leukemia 1(L1) showed expression of Mac-1 and Gr-1 myeloid markers as well as
CD16/32 and Sca1 (Figure 3-1A) and the second leukemia case (L2) demonstrated
expression of myeloid (Gr-1, Mac-1), erythroid (Ter119), and B lymphoid (B220)
markers (Figure 3-1B). Interestingly, identification of vector insertion sites revealed an
intragenic integration in intron 1 of the Prdm16 gene and another integration event
approximately 50kb upstream of Notch1 gene (Figure 3-2A). Increased levels of
sPrdm16 and Notch 1 mRNA were confirmed in L2 leukemia cells (Figure 3-2B).
Activation of sPrdm16 in large animals and mice suggested sPrdm16’s role in initiation
or maintenance of leukemia in HOXB4 transplanted animals. However, we do not
exclude other molecular changes which also can contribute to the leukemic
transformation, because other pro-oncogenes were also activated by vector integration
together with sPrdm16. In the following studies we decided to focus on sPrdm16 to
initiate the further exploration of the mechanism how HOXB4 avoids leukemia in
transplanted mice.
Building on our gene expression array data, independent leukemia screening by
Forget’s group and previous literature reports, we generated the hypothesis that
downregulation of Prdm16 is the specific mechanism for HOXB4 to prevent leukemia in
transplanted mice. To test the hypothesis we overexpressed HOXB4 and sPrdm16 in
hematopoietic primitive cells and screen leukemia in the transplanted mice receiving the
co-expressing cells. If repression of Prdm16 serves as a major factor limiting
hematopoietic cell transformation, we expect to detect leukemia developed from HOXB4
and sPRDM16 co-overexpressing cells. Leukemias to be detected are most likely myeloid
leukemias. We do not expect leukemia in sPRDM16 only group because both p53 loss
and sPrdm16 activation are required for leukemogenesis.248 If we did not detect any
leukemia, it can due to the following reasons. (1) Additional genetic lesions are required
for leukemic transformation. (2) sPrdm16 overexpression vector induces an inappropriate

48

Figure 3-1. HOXB4-mediated leukemia in transplanted mice.
(A) Immunophenotying of bone marrow cells from recipients displaying leukemia cases
L1 and L2. The y-axis shows the indicated cell surface markers identified by antibody
staining and the x-axis shows GFP expression associated with the HOXB4 vector.
Expression of mono-myeloid cell surface markers (Mac-1, CD16/32, Gr-1) and also
erythroid (Ter119) and B lymphoid (B220) markers are shown. A smaller percentage of
the leukemic cells also expressed the stem cell markers c-Kit and Sca1. (B) Retroviral
insertion sites in L2 were identified by splinkerette PCR. The location of the 2 insertion
sites in the adjacent to Notch1 and within Prdm16 and shown schematically along with
the orientation of the vector at the insertion site.
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Figure 3-2. Vector insertion site-mediated oncogene activation in HOXB4mediated leukemia 2 in transplanted mice.
(A) Retroviral insertion sites in L2 identified by splinkerette PCR. The location of the 4
insertion sites were identified in intervening sequences and 6 insertion sites were between
genes. (B) Northern blot analysis of relevant oncogenic mRNAs from control and
HOXB4 leukemic cells from L2. The control cells consisted of bone marrow cells of
mice transplanted with normal BM cells transduced with the "empty" MSCV/GFP vector;
lane labeled GFP. There is a markedly increased level of Prdm16 mRNA and a mild
increase (~2 fold) of Notch1 mRNA in L2 BMCs compared to control BMCs. Actin
serves as an internal loading control.
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overexpression level of sPrdm16 or (3) repression of sPrdm16 is not the reason why
HOXB4 doesn’t cause leukemia in transplanted mice.
Materials and Methods
Vector cloning
The retroviral vectors MSCV-HA-HOXA9-ires-GFP and MSCV-HOXA10-iresGFP were kindly provided by Dr. Keith Humphries (Terry Fox Laboratory, Vancouver,
Canada).
Murine sPrdm16 cDNA (nucleotide 664-3822 of Mus musculus Prdm16
transcript, NM_00117795) was generated by PCR using a mouse Prdm16 cDNA
(Thermo, Clone ID 6409778) as template. The sPrdm16 cDNA was inserted into the
CL20 MSCV-ires-mCherry lentiviral vector using EcoRI site to generate the CL20
MSCV-sPrdm16-ires-mCherry vector. The CL20 MSCV-ires-mCherry vector was
derived originally from pCL20c MSCV-GFP vector.23
The CL20i4r-EF1α-HOXB4-P2A-GFP lentiviral vector was generated by PCR
using the MSCV-HOXB4-ires-YFP retroviral vector as template. An EcoRI-HOXB4P2A-GFP-NotI fragment was generated by PCR and was digested with EcoRI and NotI
and used to replace the hgcOPT fragment in CL20i4r-EF1α-hgcOPT lentiviral vector261
To generate MSCV-HOXB4-ires-mCherry vector, HOXB4 cDNA was released
from MSCV-HOXB-ires-YFP retro viral vector using EcoRI site and ligated into MSCVires-mCherry lentiviral backbone between MSCV LTR and Internal ribosome entry site
(IRES) fragment.
Retroviral vector preparation
A polyclonal ecotropic retroviral producer GPE+86 cells of MSCV-HA-HOXA9ires-GFP and MSCV-HOXA10-ires-GFP was generated using calcium phosphate
transient transfection. 1 µg pCAGGS-VSVG and 5 µg old-gap-pol helper plasmids were
co-transfected with 10 µg MSCV-HA-HOXA9-ires-GFP or MSCV-HOXA10-ires-GFP
vector into 10x106 cycling 293T cells using 50ul 2.5M calcium chloride (CaCl2) and 1x
HBSS. Retroviral vector supernatant was harvested 48 hours post transfection, pooled,
filtered through 0.45 µm PVDF filter (Millipore, Billerica, MA), and used to transduce
the cycling GPE+86 cells in the presence of 5 µg/ml protamine. The transduced GFP
positive GPE+86 cells were sorted and expanded in culture to establish stable retroviral
vector producer lines.
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Calcium phosphate transfection and vector concentration for lentiviral vector
Six hours before transient transfection approximately 10x106 HEK293T cells were
seeded in 10-cm non-treated plates in 10ml DMEM supplemented with 10% FBS, 50
units/ml penicillion, 50 units/ml streptomycine and 2mM L-glutamine. For production of
10 plates of lentiviral vectors 10ug transgene containing vector, 60ug CAG-Kgp1-1, 20ug
pCAGG-VSVG and 20ug CAG-RTR2 were mixed with water and 500ul 2.5M CaCl2 up
to 5ml final volume. 2x HBSS was added to DNA- CaCl2 mix drop wise while vortexing.
1ml DNA- CaCl2-HBSS mix was added into to each HEK293T plate and cells were
incubated at 37ºC in 5% carbon dioxide. Medium was changed with 8ml X-vivo-10 for
each plate 18 hours after transfection and supernatant containing lentiviral vector was
harvested 42 hours post transfection. Supernatant was filtered with 0.45um low protein
binding filter (Millipore, Billerica, MA). One day before vector concentration Beckman
Coulter SW28 rotor, swinging buckets with centrifuge tube adaptors and rotor tubes were
kept at 4ºC. Centrifugation tubes were sprayed with 70% ethanol and 30ml of the virus
supernatant was added into centrifuge tube. Supernatant was spin at 25K rpm at 4ºC for
90 minutes. As soon as spin was over, supernatant was removed and 250ul X-vivo-10
was added to each centrifugation tube. And centrifuge tubes were kept on ice overnight.
Next day lentiviral particles were collected, aliquot into certain volume desired and
stored at -80ºC.
Bone marrow cells isolation, culture and transduction
Harvest and retroviral transduction of 5-FU treatment bone marrow cells were
carried out as described in Chapter 2. 5-FU treated bone marrow cells were transduced
with MSCV-ires-GFP, MSCV-HOXB4-ires-YFP, MSCV-HA-HOX9-ires-GFP or
MSCV-HOXA10-ires-GFP retroviral vector, respectively.
To harvest lineage-depleted bone marrow cells, whole bone marrow cells were
isolated from 6 to 8 week old c57BL/6J mice and Lineage positive cells were depleted
with Lineage Cell Depletion Kit, Mouse (Miltenyl Biotec) and LS columns (Miltenyl
Biotec) according to manufacture instructions.
To co-overexpress sPrdm16 and HOXB4, lineage-depleted bone marrow cells
from 6-8 weeks-old female C57Bl/6L mice were transduced with concentrated CL20i4rEF1α-HOXB4-P2A-GFP and CL20-MSCV-sPrdm16-ires-mCherry vectors concurrently
for 4 continuous days. Transduced bone marrow cells were subjected to colony forming
assay and transplantation assay described in following paragraphs.
In vitro expansion assay
After transduction, transduction efficiency was evaluated by flow cytometry 2
days post last transduction. The transduction efficiencies were about 50% for GFP
control vector, 10-30% for HOXB4 vector, 20-50% for HOXA9 vector and 20-30% for
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HOXA10 vector. For liquid culture and CFU-C assays, cells were diluted with nontransduced cells to achieve the similar GFP percentage (about 10%), and then 5x105
normalized cells were cultured in cytokine-supplemented medium. YFP or GFP
percentage was determined by flow cytometry and cells were counted every 3 days
during the culture to evaluate growth advantage. 500 normalized cells cultured in M3434
methylcellulose medium for colony forming assay. Colony replating and colony scoring
were described in Chapter 2.
For HOXB4 and sPrdm16 co-overexprssion experiment fluorescence-activated
cell sorting (FACS) was used to sort HOXB4 and sPRDM16 double positive cells, which
were subjected into colony forming assay in vitro. Plating of cells and colony scoring
were described in chapter 2.
Transplantation assay
To evaluate Prdm16 expression level in GFP+, HOXB4+, HOXA9+ and HOXA10+
primitive bone marrow cells at 6 weeks post transplantation, transplantation of transduced
bone marrow cells were conducted as described in Chapter 2.
To screen leukemia in HOXB4 and sPrdm16 co-expressing bone marrow cells
5x10 or 1x106 unsorted co-transduced bone marrow cells were injected into lethally
irradiated B6.SJL-PtprcaPepcb/BoyJ mice (Jackson Lab, stock number: 002014).
5

Fluorescence-activated cell sorting
To isolate each compartments of BM cells, whole BM cells were stained with
different antibody cocktails. For CD34-/low LSK cells, CD34high LSK cells, CMP, GMP
and MEP, cell were stained with CD34-PE, Sca-1-Percp5.5, c-Kit-APC, FcɛR-Alexa700
and a PE-Cy7 conjugated lineage antibody mixture (CD4, CD8, Gr1, Ter119 and NK1.1)
(BD Bioscience). To separate mature BM cells from each lineage, cells were stained with
Gr1-APC-Cy7, Mac1-Alexa700, B220-FITC, CD3-APC, NK1.1-PE, and Ter119-PE-Cy7
(BD Bioscience).
To isolate LSK cells, staining was carried out in the same way described in
Chapter 2.
To isolate vector positive CD150+CD48-LSKs, CD150+CD48+LSKs and CD150CD48 LSKs from GFP, HOXB4, HOXA9 or HOXA10 transplanted mice, bone marrow
cells from recipients were stain with Sca1-PE (BD Bioscience) and PE-conjugated
microbeads (Miltenyl Biotec). Sca1-PE positive cells were selected by LS column
(Miltenyl Biotec) and further stained with CD150-PE-Cy7, CD48-APC, c-kit-APC-e780
and lineage cocktail-e605 antibodies (BD Bioscience).
+
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Stained cells were subject to FACS and each population was identified and sorted
according to isotype and single color controls.
Real-time PCR assay
Total RNA extraction, reverse transcription and qRT-PCR assay were conducted
as described in Chapter 2.
Western blot
Total protein lysate extraction of HOXB4 or sPrdm16 transduced NIH-3T3 cells
and western blot were carried out as described28. HOXB4 protein was probed using
0.1ug/ml I12 rat anti-mouse HOXB4 antibody (Developmental Studies Hybridoma Bank,
University of Iowa) followed by HRP-conjugated goat anti-rat secondary antibody (Santa
Cruz Biotechnology) and sPRDM16 protein was probed with 0.1ug/ml sheep anti-mouse
PRDM16 polyclonal antibody (R&D systems) followed by HRP-conjugated donkey antisheep secondary antibody (R&D systems).
Immunofluorescence staining and confocal imaging
Murine erythroid leukemia (MEL) cell line was transduced with MSCV-sPrdm16ires-mCherry vector to achieve 100% transduction efficiency. Cells transduced with
MSCV-ires-mCherry vector were used as control. 2x106 transduced MEL cells were
plated into Retronectin (Takara) coated cover slides 48 hours after transduction for 24
hours. Next day MEL cells were washed with 1ml warm DPBS twice gently and fixed
with 4% paraformaldehyde at room temperature (RT) for 1hour. Cells were gently
washed with DPBS twice before permeabilized with 0.1% triton100 in DPBS for 15 mins
at RT. After permeabilization cells were treated with Image-it TX signal enhancer
(Invitrogen) for 30 mins at RT. Cells were stained with 10ug/ml sheep anti-mouse
PRDM16 polyclonal antibody (R&D systems) in DPBS containing 10% normal donkey
serum (Sigma) at 4 ºC overnight. Cells were washed by ice cold DPBS for 5 mins for
three times next day before incubation with donkey-anti-sheep Alexa488 at 1:100
dilution in DPBS with 10% normal donkey serum at RT for 1hour. Cells were rinsed with
DPBS 3 times for 5mins each and stained with DAPI for 10 mins at RT and further rinsed
with DPBS and were mounted for confocal image capture with Zeiss LSM 510 confocal
microscope.
Southern blot
NIH-3T3 cells were transduced with CL20-MSCV-sPrdm16-ires-mCherry vector
to achieve ~60% transduction efficiency. Mock or CL20-MSCV-ires-mCherry control
vector transduced cell were used as control. Genomic DNA was extracted with
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ArchivePure DNA Cell/Tissue kit (5 PRIME). 10ug genomic DNA was digested with 40
unites of DraI (NEB) at 344bp upstream of rev response element (RRE) and 102bp
downstream of mCherry element to release 7.18kb fragment. Genomic DNA migrated in
0.8% agarose gel at 20V overnight, was transferred to Nytran SPC membrane (Fisher
Scientific) and was hybridized dCTP-P32 labeled probe fragment complementary to RRE
at 42ºC overnight. Blot was washed and image was scanned next day.
Results
Endogenous Prdm16 expression in LT-HSC and ST-HSCs
The endogenous Prdm16 expression pattern consists of relatively high expression
in CD34-/lowSca1+c-kit+Lin- long term hematopoietic stem cells (LT-HSCs) and to a lesser
extent in CD34highSca1+c-kit+Lin- short term HSC cells (ST-HSCs) (Figure 3-3).
Endogenous expression levels were about 120 fold higher in LT-HSCs than in total bone
marrow cells. Prdm16 mRNA was down-regulated in myeloid and lymphoid progenitors
at various stages of development as well as in mature blood cell lineages (Figure 3-3).
These results showed that Prdm16 expression is largely restricted to LT-HSCs where
Prdm16 is required for HSC maintenance and function215,216.
Overexpression of HOXA9 and HOXA10 led to growth advantage and enhanced
colony forming capacity in vitro
To exam whether overexpression of HOXA9 or HOXA10 was able to expand
hematopoietic progenitors and enhance their self-renewal capacity in vitro, we transduced
5-FU treated bone marrow cells with retroviral vector containing either HOXA9 or
HOXA10 cDNA. Cells overexpressing HOXB4 were included as positive control and
control GFP transduced cells as negative control. During 15 days’ culture HOXB4,
HOXA9 and HOXA10 expressing cells showed significant grow advantage over control
transduced cells. GFP or YFP percentage of HOXB4, HOXA9 or HOXA10 increased
from about 10% to 85.87%, 93.83% and 96.47%, respectively (Figure 3-4A). Colony
forming capacity was also enhanced in HOXB4, HOXA9 and HOXA10 expressing cells
(Figure 3-4B).
Prdm16 is not expressed in cultured LSKs
Endogenous Prdm16 was shown to be highly expressed in WT murine LT-HSC
and ST-HSC in previous experiment. We also assessed Prdm16 transcript level in
HOXB4, HOXA9 and HOX10 transduced LSK cells at day 4, 8 and 13 days post
transduction in vitro. Compared with WT LSK cells, there wasn’t detectable Prdm16
transcript in GFP control transduced LSK cells in vitro and overexpression of HOXB4,
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Figure 3-3. Quantitative real-time PCR of endogenous Prdm16 mRNA levels in
various sorted progenitor and stem cell populations.
Endogenous Prdm16 was highly expressed in LT-HSCs and maintained relative high
expression level in ST-HSCs. No or low level of Prdm16 transcript was detected in
downstream progenitors and mature cells in bone marrow. Gapdh mRNA was used as a
loading control and the level of Prdm16 mRNA expression in whole bone marrow was
set at a relative value of 1.0. CMP: common myeloid progenitor; GMP: granulocytemonocyte progenitor; MEP: magakarocyte-erythroid progenitor.
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Figure 3-4. Growth advantage and enhanced myeloid progenitor self-renewal
observed in HOXB4, HOXA9 and HOXA10 transduced cells in vitro.
(A) HOXB4, HOXA9 and HOXA10 demonstrated significant growth advantage over
GFP control transduced cells during 15 days’ culture. (B) HOXB4, HOXA9 and
HOXA10 generated significant more secondary colonies than untransduced or GFP
transduced cells. HOXA9 and HOXA10 demonstrated more robust colony forming
capacity than HOXB4.
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HOXA9 and HOXA10 were not able to alter Prdm16 expression as they did in
transplanted mice (Figure 3-5).
Prdm16 downregulation is restricted to HOXB4-expressing HSCs in vivo
HSC positive regulator, Prdm16, was downregulated in HOXB4-LSKs during the
reconstitution, suggesting downregulation of Prdm16 can be a counter-regulatory signal
which controlls HSC pool size or prevents leukemia in vivo. HOXA9 and HOXA10 are
known oncogene, overexpression of which causes unlimited HSC expansion and
leukemia in transplanted mice. We compared Prdm16 expression level in HOXB4,
HOXA9 or HOXA10 expressing CD150+CD48-LSKs (SLAM), CD150+CD48+LSKs and
CD150-CD48+LSKs (restricted progenitors) in transplanted mice at 6 weeks post
transplantation. Compared with control GFP-SLAMs, Prdm16 was 13.5 fold
downregulated in HOXB4-SLAMs, but 5 fold upregulated in HOXA9-SLAM and 1.8
fold upregulated in HOXA10-SLAMs (Figure 3-6). Both HOXA9-SLAMs and
HOXA10-SLAMs showed opposite trend of Prdm16 expression compared to HOXB4SLAMs (Figure 3-6), indicating HOXB4 specifically downregulates Prdm16 to limit
HSC pool size or to prevent leukemia. At meanwhile Prdm16 expression level was not
detachable in CD150+CD48+LSKs and CD150-CD48+ LSKs in all groups (Figure 3-6),
suggesting HOXB4 specific downregulation of Prdm16’s was restricted in HSC
compartment but not in downstream differentiated compartments.
Lentiviral sPrdm16 construct and sPRDM16 protein expression
To overexpress HOXB4 and sPRDM16 in mouse bone marrow cells, we
generated lentiviral vector containing either HOXB4 with a GFP reporter gene driven by
Ef1α promoter or sPrdm16 with a linked mCherry gene downstream of MSCV promoter
(Figure 3-7A). Western blot of vector transduced NIH-3T3 cells confirmed robust
expression of HOXB4 and sPRDM16 protein (Figure 3-7B) and sPRDM16 protein was
localized in nucleus when overexpressed in MEL cell line (Figure 3-7C).
Low transduction efficiency of sPrdm16 overexpression vector
To generate HOXB4 and sPRDM16 co-expressing cells, Lin- cells were
transduced with HOXB4 and sPrdm16 vectors concurrently for 4 days (Figure 3-8A).
Transduction efficiency of the bone marrow cells was evaluated 5 days post last
transduction. We observed low proportion of cells expressing sPRDM16-mCherry
protein (Figure 3-8B).
We followed sPrdm16-mCherry marking of transduced WT and p53 null cells in
culture for up to 20 days post transduction. Rapid depletion of sPrdm16-mCherry positive
WT and p53 null cells was detected as early as 4 days post transduction (Figure 3-9A).
Depletion of sPRDM16 expressing cells could be due to cellular toxicity caused
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Figure 3-5. Relative Prdm16 expression in HOXB4, HOXA9 and HOXA10
transduced LSKs in vitro.
Prdm16 transcript was measured in GFP, HOXB4, HOXA9 or HOXA10 transduced
LSKs 4 days, 8 days and 13 days after transduction. Prdm16 transcript was not detected
in cultured LKSs in vitro compared with wild type LSKs. Gapdh mRNA was used as an
endogenous control and the level of Prdm16 mRNA expression wild type LSKs was set
at a relative value of 1.0.
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Figure 3-6. Downregluation of Prdm16 is restricted in HOXB4 expressing HSCs
in vivo.
Prdm16 expression in HOXB4-SLAM was downregulated while upregulated in HOXA9SLAM and HOXA10-SLAM at 6 weeks post transplantation. Expression of Prdm16 was
not expressed in CD150+CD48+LSKs and CD150-CD48+ LSKs in all groups. Gapdh
mRNA was used as an endogenous control and the level of Prdm16 mRNA expression
wild type LSKs was set at a relative value of 1.0.
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Figure 3-7. Lentiviral vectors engineered to overexpress sPrdm16 and HOXB4.
(A) Schematic representation of lentiviral vectors to overexpress HOXB4 and sPrdm16.
The promoters and fluorescent reporter genes used are indicated. The 400bp chromatin
insulator (i4r) was used as indicated to protect from position effects. (B) Western blot
analysis of HOXB4 and sPrdm16 expression in NIH-3T3 cells transduced with the
indicated vectors. Note the lower background band seen on the sPrmd16 blot is also
present with the “empty” vector control. (C) Immunofluorescence staining of sPrdm16
protein in MEL cell line.sPrdm16 protein was expressed in the nucleus. Green: sPrdm16;
Blue: Dapi
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Figure 3-8. Low transduction of sPrdm16 vector in murine bone marrow cells.
(A) Concurrent transduction includes 4 days transduction with two vectors
simultaneously on Lin- bone marrow cells followed by FACS-based sorting 2 days after
transduction. (B) Low co-transduction efficiency of sPrdm16 vector with GFP control
vector or HOXB4 vector on BM cells evaluated 5 days post transduction.
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Figure 3-9. Depletion of sPRDMdfdf16 expressing cells was not due to vector
rearrangement.
(A) GFP or mCherry marking of bone marrow cells in culture starting from 2 days post
transduction. Experiment was done on either WT or P53 null mice. (B) Southern blot of
NIH-3T3 cells transduced with CL20-MSCV-sPrdm16-ires-mCherry. CL20-MSCVsPrdm16-ires-mCherry plasmid was used as positive control.
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by unphysiologically high sPRDM16 protein level or vector instability during vector
genome integration. So we tested sPrdm16 vector rearrangement in transduced NIH-3T3
cells by southern blot. Compared with plasmid control, no rearrangement and deletion
occurred between RRE and mCherry fragment in sPrdm16-mcherry transduced sample
(Figure 3-9B), suggesting reduced sPrdm16-mcherry marking in bone marrow cells was
not due to vector rearrangement.
Increased colony forming capacity of HOXB4 and sPRDM16 coexpressing cells
To test whether sPRDM16 and HOXB4 cooperate to enhanced hematopoietic
progenitor cell self-renewal in vitro. Single and double transduced cells were sorted by
flow sorting and analyzed for myeloid progenitor self-renewal using a serial replating
assay. Cells transduced with the HOXB4 vector alone formed about 160 secondary
colonies per1x104 cells plated while sPrdm16-transduced cells formed about 70
secondary colonies (Figure 3-10). The HOXB4 and sPRDM16 double positive group
formed over 300 secondary colonies, significantly more than the HOXB4 only group
(p<0.01) (Figure 3-10). This result demonstrates that HOXB4 and sPRDM16 synergize
to enhance hematopoietic progenitor cell self-renewal.
Enforced co-expression of sPRDM16 and HOXB4 causes preleukemia in mice
We also transplanted co-transduced bone marrow cells into lethally irradiated
recipient mice. Reconstitution with cells expressing the sPrdm16 vector was generally
very low, presumably reflecting the low titer of this vector or direct toxic effects of
enforced sPrdm16 expression. However, a large number of HOXB4 and sPrdm16 double
positive cells were detected in the peripheral blood in 2 of 12 recipients at 12 weeks after
transplantation. In these two cases (#890 and #894), expansion of HOXB4 and sPrdm16
double positive blood cells occurred as early as 6 weeks after transplantation and further
increased over time. When mouse #894 was euthanized at 12 weeks post transplantation,
52.8 % of peripheral blood cells and 97.1% of bone marrow cells co-expressed the
HOXB4 and sPrdm16 as determined by flow cytometry (Figure 3-11A). These double
positive cells showed the Gr-1+, Mac-1+ myeloid phenotype.
Bone marrow cells from mice #890 and #894 were used for secondary
transplantation experiments. Secondary recipients from case #894 did not engraft with
donor cells. In contrast, secondary recipients generated from #890 (#10037, #10038 and
#10040) were all repopulated with HOXB4 and sPrdm16 co-expressing cells in
peripheral blood and bone marrow. At 12 and 16 weeks after transplant, pathological
examination revealed prominent myeloid dysplasia with increased myeloid blasts in the
bone marrow; consistent with myelodysplasia and pre-leukemia (Figure 3-11B). Taken
together, this experiment directly shows that HOXB4 and sPrdm16 overexpression
collaborate to promote preleukemia in a fraction of secondary transplant recipients.
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Figure 3-10. Secondary colony numbers by myeloid CFU-C assay on sorted
transduced cells as a measure of self-renewal capacity.
Cells were transduced with control vectors or mock transduced, or with single HOXB4 or
sPrdm16 vectors, or co-transduced with both HOXB4 and sPrdm16 vectors as indicated.
After a primary CFU-C assay, cells were replated and colonies scored based on 10,000
cell inputs. Error bars show the standard deviation for multiple experiments and statistical
comparisons are indicated above the histograms.
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Figure 3-11. Enforced co-expression of HOXB4 and sPrdm16 enhances HPC selfrenewal in vitro and induces myeloid pre-leukemic transformation in transplanted
mice.
(A) Flow cytometry analyses of HOXB4 and sPrdm16 double positive cells in peripheral
blood (PB) and bone marrow cells (BMC) of two primary recipients, # 890 and # 894.
The top row shows staining for the donor background CD45.1, the middle row shows
expression of the sPrdm16 vector marker (mCherry) and the HOXB4 vector marker
(GFP), and the last row shows expression of the Mac-1 and Gr-1 myeloid markers. Note
the expansion of double positive myeloid cells in each of these cases. (B) Bone marrow
cytospin photomicrographs of secondary recipients (#10037 and #10040) derived by
transplantation from donor #890. Insets show higher magnification of the myeloid blasts
seen in these cases, which comprised 30-50% of the cells on these slides.
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Discussion
Our gene expression array data from HOXB4 expressing LSK cells demonstrated
marked downregulation of Prdm16. By reviewing previous literature and independent
screening of HOXB4 transplanted mice, we hypothesized that downregulation of Prdm16
is the specific mechanism how HOXB4 prevent leukemia in transplanted mice. Here we
talk about ‘HOXB4-specific mechanism’ because HOXA9 and HOXA10, oncogenic
HOX factors, upregulated Prdm16 expression up to about 50 fold in HSCs compared
with HOXB4. Differential regulation of Prdm16 by HOXB4, HOXA9 and HOXA10 was
not seen in culture, as Prdm16 expression was no longer detectable in vitro, suggesting
extrinsic factors present in bone marrow niche are required to maintain Prdm16
expression in HSCs. However, there are no available methods for phenotypically
identifying HSCs in these long term cultures. While we gated on LSK cells after various
times in culture, published data262,263 suggests that these markers, or any other for that
matter, are not adequate for prospective identification of HSC-enriched populations in
vitro.
To further validate that downregulation of Prdm16 is responsible for preventing
leukemic transformation in HOXB4 transplanted mice, we can co-overexpressed HOXB4
and sPRDM16 in murine primitive bone marrow cells to induce leukemia. At meanwhile
knockdown Prdm16 in HOXA9 or HOXA10 transplanted mice prior or after leukemia
onset will be anther experiment to test sustained expression of Prdm16 as a major player
in leukemogenesis. But this part of experiment will not be included in this project.
We designed lentiviral vectors to overexpress HOXB4 and sPRDM16 in murine
hematopoietic primitive cells. HOXB4 and sPRDM16 protein expression was confirmed
in transduced NIH-3T3 cells. However, we noticed very low (less than 5%) cotransduction efficiency of sPrdm16 with control GFP vector and HOXB4 vector. This
may reflect the low titer of the sPrdm16 vector. But it also can be due to vector
rearrangement during integration. Southern blot done on sPrdm16 transduced NIH-3T3
cells detected intact transgene fragment, excluding the possibility of vector
rearrangement. As mentioned above, Prdm16 is selectively expressed at high level in
HSCs. sPRDM16 expression level of by overexpression vector probably was not
favorable in transduced progenitor cells in culture. This explains why Prdm16 was not
detectable in culture cells and marked decreased proportion of Prdm16 transduced cells in
vitro.
Though low transduction of Prdm16 vector makes it difficult to overexpress
Prdm16 using constitutive overexpressing vector, we were able to purify 500 double
transduced cells for colony forming assay to test both factors’ effect on the self-renewal
capacity of myeloid progenitors. We injected bulk transduced cells for transplantation
assay to screen leukemia in mice due to inadequate mount of double cells for
transplantation. Since we hypothesize that downregulation of Prdm16 prevents
leukemogenesis inHOXB4 transplanted mice, we expect leukemia derived from only
HOXB4 and sPrdm16 double positive cells but not any other populations. We detected
two preleukemia cases (myeloid dysplasia) out of 12 primary recipients at 28 weeks and
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32 weeks following primary transplantation. Long latency of leukemogenesis reflects the
low number of leukemia initiating cells due to the poor co-transduction efficiency or the
requirement of additional mutations for the leukemic transformation. The mechanisms by
which sPrdm16 cooperates with HOXB4 are yet undefined. Expression of sPRDM16
blocks granulocyte-colony stimulating factor (G-CSF)-induced myeloid
differentiation198,238,239 and over-expression of sPRDM16 in mice causes a
myeloproliferative disorder and leukemia in p53-null bone marrow cells.248 Therefore, in
the context of HOXB4-induced HSC expansion, downregulation of Prdm16 functions to
induce hematopoietic differentiation, thus preventing leukemia in vivo.
To address the low transduction efficiency of sPrdm16 lentiviral vector, TetOn
inducible vector which is able to activate transgene expression upon doxycycline
induction at dose-dependent manner can be a great replacement of constitutive
overexpression vector. We decide to establish TetOn-sPrdm16 transgenic mouse to
further study the role of Prdm16 in HSC expansion and leukemogenesis. The advantage
of transgenic mouse over the vector transduction is the stable and predictable transgene
integration rather than random vector integration between one transduction and another.
We plan to transplant sPrdm16 transgenic bone marrow cells into wild type recipients to
avoid side effect of sPRDM16 overexpression in other organs.
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CHAPTER 4.

DOWNREGULATION OF PRDM16 IS REQUIRED FOR
HOXB4-MEDIATED HSC EXPANSION
Introduction

In previous chapter downregulation of Prdm16 was shown as HOXB4-specific
mechanism to prevent leukemia in transplanted mice. Besides avoiding leukemic
transformation, well-regulated HSC pool size in HOXB4 recipient mice is another feather
of HOXB4-mediated HSC expansion,141,181,182 mechanism of which is not clear.
Induction of differentiation, apoptosis or quiescence in HSCs post dramatic proliferation
can contribute to maintain HSC pool size at physiological level. Prdm16 is selective
expressed in LT-HSCs.215,216 Sustained expression of Prdm16 HSCs can maintain HSC’s
quiescence, and loss of Prdm16 may drive HSC into cell cycle, thus allowing
proliferation and expansion. Given the fact that loss of Prdm16 indeed increased the
frequency of HSCs in S/G2/M phase of the cell cycle,215,216 and Prdm16 was markedly
repressed by HOXB4 in vivo, we hypothesize that HOXB4 downregulates Prdm16 to
allow HSC to undergo proliferation. To test the hypothesis we will assess CRU frequency
in HOXB4 transplanted mice present or absent of sPrdm16 overexpression. Considering
the poor transduction of sPrdm16 lentiviral vector, we will generate TetOn-sPrdm16
transgenic mice, bone marrow of which will be used for experiments. We expect
sPRDM16 protein expression upon doxycycline administration in transgenic bone
marrow cells and lower CRU frequency in HOXB4 and sPRDM16 coexpressing cells
than HOXB4 only expressing cells.
Materials and Methods
Vector cloning
To generate TetOminiCMV-sPrdm16-P2A-GFP-rGBpA vector, sPrdm16 cDNA
was released from MSCV-sPrdm16-ires-mCherry vector using EcoRI and replaced in
front of HOXB4 cDNA in EF1a-HOXB4-P2A-GFP vector to generated EF1a-sPrdm16HOXB4-P2A-GFP vector. Synthesize partial sPrdm16-P2A fragment was generated by
Biomatik with DraIII in 5’end and BsmBI in the 3’ end, which was replaced with partial
sPrdm16-HOXB4-P2A fragment in EF1a-sPrdm16-HOXB4-P2A-GFP vector. In the end
Ef1a-sPrdm16-P2A-GFP vector was established. Fragment sPrdm16-P2A-GFP was
further released from backbone with EcoRI and NotI and EcoRI site in the 5’ end was
blunted using Klenow. Lentiviral vector pHAGE2-TetOminiCMV-Oct4F2AKlf4-iresSox2E2AcMyc-W was offered by Charles Sherr in St. Jude Children’s Research
Hospital. Fragment Oct4F2AKlf4-ires-Sox2E2AcMyc was removed from backbone
using NotI and ClaI and NotI site present in backbone was blunted by Klenow. sPrdm16P2A-GFP fragment was ligated into the pHAGE2-TetOminiCMV backbone to generate
pHAGE2-TetOminiCMV-sPrdm16-P2A-GFP lentiviral vector. rGBpA fragment was
amplified by PCR from Prdm16 knockdown vector and further digested by HindIII to
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release the exact rGBpA fragment. Previous generated pHAGE2-TetOminiCMVsPrdm16-P2A vector was digested with NotI and blunted by Klenow. HindIII digested
rGBpA was also blunted by Klenow and replaced into pHAGE2-TetOminiCMVsPrdm16-P2A after P2A fragment to generate pHAGE2-TetOminiCMV-sPrdm16-P2ArGBpA vector. pHAGE2-TetOminiCMV-sPrdm16-P2A-rGBpA circular vector was
digested by XhoI and NotI to release linearized TetOminiCMV-sPrdm16-P2A-rGBpA
for microinjection.
CMV-rtTA lentiviral vector was kindly provided by Dr. Charles Sherr in St. Jude
Children’s Research Hospital.
Calcium phosphate transfection and vector concentration for lentiviral vector
Calcium phosphate transfection and ultracentrifugation of TetOminiCMVsPrdm16-P2A-GFP lentiviral vector were carried out in the same way described in
Chapter 3.
sPRDM16 protein induction in vitro
Prior to microinjection of linearized plasmid to mice zygotes, NIH3T3 cells were
co-transduced with TetOminiCMV-sPrdm16-P2A-GFP and CMV-rtTA lentiviral vectors.
48 hours post transduction, NIH3T3 cells were treated with 0ng/ml, 0.1ng/ml, 1ng/ml,
10ng/ml, 100ng/ml and 1000ng/ml of doxycycline for 48 hours and doxycycline was
withdrew from medium. GFP fluorescence was evaluated by flow cytometery after 48
hours’ induction and 5days’ withdraw and protein expression was examined by western
blot after 48 hours’ induction.
Mouse strain maintenance and breeding
All mouse maintenance and breeding procedures were carried out according to
protocols approved by the St. Jude Institutional Animal Care and Use committee.
Transgenic founder mice were bred with B6.Cg-Gt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J
mice (Jackson Lab, stock number 006965) to generate N1 mice carrying both transgene
and rtTA knockin gene and then further bred with B6.CgGt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J mice to generate rtTA homozygote transgenices.
Polymerase chain reaction (PCR) genotyping
To confirm the presence of transgene in the genome of progenies, PCR to amplify
the fragment between sPrdm16 cDNA and green fluorescence protein (GFP) was used for
genotyping. Genomic DNA was extracted from tails and about 10ng of genomic DNA
was subjected to PCR with HotMaster Mix (5 PRIME). PCR primer sequences were
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GCTGGAGGAAGAGGATGATG (forward) and GAACTCCAGCAGGACCATGT
(reverse) and expected PCR product size was 892bp. At meanwhile PCR to amplify
endogenous Actin was carried out as control reaction.
To confirm presence of rtTA knockin sequence in the genome of progenies, PCR
was carried out according to Jackson Lab’s instruction. Mutant reverse primer
oIMR8052-- GCG AAG AGT TTG TCC TCA ACC, WT reverse primer oIMR8546-GGA GCG GGA GAA ATG GAT ATG and common primer oIMR8545-- AAA GTC
GCT CTG AGT TGT TAT were used for genotyping. Expected size of WT product is
about 650 bps, size of rtTA heterozygote is 340bp and 650bp and rtTA homozygotes is
340bp.
No template control and WT control were included for both PCR reactions.
Doxycycline drinking water administration
To induce transgene expression in vivo, transgenic mice or transplanted mice
were subjected to 2mg/ml doxycycline (Sigma) treatment in drinking water with
50mg/ml sucrose (Sigma). Drinking water without doxycycline was used as control.
Drinking water was filtered with Corning disposable sterile filter system (Corning) and
changed every 3 days.
Western blot
PCR positive transgenic mice and control littermates were under 2mg/ml
doxycycline treatment for continuous 7days. GFP positive and negative BM cells were
sorted. 1x106 sorted cells were washed with 1ml ice cold DPBS, resuspended with 50ul
ice cold DPBS with 2x Halt Protease Inhibitor Cocktail with EDTA (Thermo Scientific
Pierce) and 50ul Laemmli sample buffer (Bio-Rad) supplemented with 2Mercaptoethanol (Sigma) and boiled at 99 ºC for 5 minuts before being placed on dry ice.
40ul cell lysate (from 4e5 cells) were load in 4%-12%SDS-PAGE gel (Invitrogen) for
protein detection. sPRDM16 protein was probed with 0.1ug/ml sheep anti-mouse
PRDM16 polyclonal antibody (R&D systems) followed by HRP-conjugated donkey antisheep secondary antibody (R&D systems). GFP protein was probed with rabbit GFP
antibody (Cell signaling) at 1:5000 dilution followed by HRP-conjugated goat anti-rabbit
secondary antibody (Santa Cruz Biotechnology). GAPDH protein was probed with
mouse anti-mouse GAPDH antibody (Millipore) at 1:50000 dilution followed by HRPconjugated goat anti-mouse IgG1 antibody (Santa Cruz Biotechnology).
Southern blot
About 3-10ug tail genomic DNA was digested with sphI-HF in 40ul reaction at 37
ºC for 8 hours to check transgene copy number or digested with DraI and PshAI to check
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transgene integrity. DNA gel electrophoresis, transfer and hybridization and image
detection was carried as described in chapter 3. The probe used for hybridization was
complementary to GFP sequence.
Fluorescence in situ hybridization (FISH)
Bone marrow cells from transgenic mice were submitted to Cytogenetic Shared
Resource of St. Jude Children’s Research Hospital to determine integration localization
of transgene by FISH. Purified TetOminCMV-sPrdm16-P2A-GFP-rGBpA plasmid DNA
was labeled with a green-dUTP by nick translation and chromosome control clone was
labeled with a red-dUTP. Labled probes were combined with sheared mouse DNA and
hybridized to matophase chromosomes derived from the bone marrow cells. The
chromosomes were stained with DAPI and analyzed.
Fluorescence flow cytometry analysis
To detect phonotypical HSC and MPP frequency in transplanted mice, bone
marrow cells were stained with CD150-PE-Cy7, CD48-APC, Sca-1-Percp5.5, c-KitAPC-eF780, CD45.2-V500 and eF605 conjugated-lineage cocktail (BD Bioscience).
SLAM (CD150+CD48-Sca-1+c-Kit+Lineage-) and MPP (Sca-1+c-Kit-Lineage-) population
were gated according to isotype and single color controls.
Limiting dilution assay
For limiting dilution assay to assess CRU frequency, BM cells of transgenic mice
were harvested 5 days after 5-FU treatment, prestimulated as describe in chapter 2. After
prestimulation 5x105 bone marrow cells were transduced with MSCV-HOXB4-iresmCherry vector overnight. Control vector MSCV-ires-mCherry vector was included as
control. Next day after transduction 5x105 or 1x106 were injected into lethally irradiated
B6.SJL-PtprcaPepcb/BoyJ mice (Jackson Lab). Recipients were under Baytril water
treatment for 3 weeks followed by doxycycline (2mg/ml) treatment. Drinking water
without doxycycline was used as control. Bone marrow cells were harvested from
primary recipients at 18 weeks post transplantation and 320, 1600, 8000, 4x104 and 2x105
bone marrow cells were injected into letherally irradiated B6.SJL-PtprcaPepcb/BoyJ mice
(Jackson Lab) together with 2x105 B6.SJL-PtprcaPepcb/BoyJ (Jackson Lab) bone
marrow cells. Recipients’ PB was analyzed 18 weeks post secondary transplantation.
Mouse with more than 1% mCherry marking in each lineage (Gr1 and Mac1, CD3, B220,
Ter119) was considered as a positive recipient. CRU frequency was calculated using LCalcTM software (Stemsoft Sotfware Inc. version 1.1).
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Results
Vector construction
We generated lentiviral vector to overexpress murine sPrdm16 driven by
TetOminiCMV promoter followed by P2A-GFP (Figure 4-1A). For microinjection to
generate TetOminiCMV-sPrdm16-P2A-GFP-rGBpA transgenic mice, rBGpA fragment
was ligated into vector after GFP. Linearized TetOminiCMV-sPrdm16-P2A-GFPrGBpA DNA fragment (Figure 4-1A) was injected in fertilized zygotes at singe cell
stage.
Dose-dependent induction of sPRDM16 and GFP protein
NIH-3T3 cells were co-transduced with TetOminiCMV-sPrdm16-P2A-GFP and
CMV-rtTA vectors (Figure 4-1A) and further induced by 0-1000ng/ml doxycycline for
48 hours in vitro. 0ng/ml, 0.1ng/ml and 1ng/ml doxycycline did not induce significant
GFP expression (baseline), 10ng/ml doxycycline led to mediate GFP induction while
100ng/ml and 1000ng/ml doxycycline achieved maximum induction of GFP expression
(Figure 4-1B). GFP expression decreased to baseline 5 days after doxycycline was
withdrew (Figure 4-1B). sPRDM16 and GFP protein was detected in 10ng/ml, 100ng/ml
and 1000ng/ml samples 48 hours after induction by western blot, which was consistent
with GFP fluorescence signal by flow cytometry (Figure 4-1C). sPRDM16 and GFP
protein expression showed nice linear correlation (Figure 4-1C). Both protein inductions
were maximized at dose of 100ng/ml without no further increase of protein expression at
1000ng/ml doxycycline (Figure 4-1C).
Generation and validation of TetO-sPrdm16 transgenic mice
To achieve inducible sPRDM16 protein expression in mouse bone marrow cells,
we generated TetO-sPrdm16 transgenic mice. Transgenic founder mice carrying one
allele of transgene was bred with B6.Cg-Gt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J mice
(Jackson Lab, stock number 006965) to generate N1 mice, which were able to expression
sPRDM16 protein under doxycycline induction (Figure 4-2). N1progenies were further
bred with rtTA*M2 mice to achieve two allele of rtTA gene in genome.
PCR amplifying the transgene region was carried out on mouse tail genomic DNA
to check the presence or absence of transgene in mouse genome. PCR primers were
designed to amplify between sPrdm16 and GFP region to yield 892bp product as shown
in lane 1, 5, 9, 11 and positive control (Figure 4-3A, B). Total 21 PCR positive
transgenic founders were identified, 7 of which were c57BL/6J strain and others were
FVB strain. PCR were carried out on N1 genomic DNA and 17 out of 21founders had
germline transmission to N1 and following progenies. PCR was carried out according to
Jackson Lab’s instruction to detect WT, heterozygotes and homozygotes of rtTA gene.
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Figure 4-1. Dose-dependent induction of sPRDM16 and GFP protein with TetOn
inducible system.
(A). Schematic diagram of TetOminiCMV-sPrdm16-P2A-GFP and CMV-rtTA lentiviral
vectors and linearized TetOminiCMV-sPrdm16-P2A-GFP-rBGpA. (B) GFP fluorescence
detected in transduced NIH-3T3 cells 48 hours post Doxcycline induction and decreased
back to baseline 5 days after Doxycycline withdraw.(C): sPRDM16 and GFP protein was
detected in induced NIH-3T3 cells at dose of 10, 100 and 1000ng/ml Doxycycline after
48 hours’ induction.
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Figure 4-2. Schematic diagram of TetO-sPrdm16 transgenic mice generation.
Transgenic founder mice were Bred with B6.Cg-Gt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J
mice to generate N1 mice carrying both transgene and rtTA knockin gene.

75

Figure 4-3. TetO-sPrdm16 transgenic mice PCR genotyping.
(A). Forward and reverse primers designed to amplify partial sPrdm16-P2A-GFP region
to detect presence of transgene in mouse genome. (B). Example of sPrdm16 transgene
PCR genotyping. Lane 1, 5, 9 and 11 are transgene positive compared with non-template
control (NTC), wild type (WT) control and positive control (P.C). (C). Example of rtTA
knockin gene PCR genotyping. Compared with NTC, WT and rtTA+/+ control, lane 1 and
2 are rtTA+/- and lane 3-7 are rtTA+/+.
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Expected size of WT product is about 650 bps (WT control lane), size of rtTA
heterozygote is 340bp and 650bp (lane 1 and 2) and rtTA homozygotes is 340bp (lane 37) (Figure 4-3C). 2mg/ml Doxycycline in drinking water was given to three litters of N1
mice with germline transmission for 7 days to detect GFP fluorescence in nucleated cells
from PB.by flow cytometry. 9 out of 17 founders’ N1 progenies demonstrated inducible
and reversibl GFP expression in PB with different level of GFP induction efficiency
(Figure 4-4A, B).
To check transgene copy number and integrity in mouse genome, southern blot
was carried out on founders (8012, 8005, 8080, 8018 and 8017) and progenies with the
best GFP induction. Southern blot of founder 8012, 8080, 8018 and 8017 showed single
copy of transgene with one integration in mouse genome while founder 8005 had more
than one integration and more than one copy of transgene (Figure 4-5A). We also
detected rearranged or deletion of transgene from 8005 genome (Figure 4-5A). To
segregate rearranged or deleted transgene we further bred 8005 with B6.CgGt(ROSA)26Sor<tm1(rtTA*M2)Jae>/J mice and carried out southern blot on four N1
progenies (8096, 8098, 8100 and 8219) of founder 8005. Only one copy of transgene
with one integration was detected in 8098 and 8219 (Figure 4-5B) and no rearrangement
or deletion detected in 8098 progenies (8489, 8491 and 8493) (Figure 4-5C). We named
the transgenic line established from founder 8005 with on copy of transgene as 8005S.
Finally we generated three independent TetO-sPrdm16 transgenic lines: 8012 8005S
(with one copy, no rearrangement) and 8080.
To further identify transgene localization, bone marrow cells from each transgenic
line was submitted for FISH. Integration site of transgene in 8012 line was chromosome
19B-C1 region, chromosome 3C-D region for 8005S line and chromosome 2C-1 region
in for 8080 line (Figure 4-6A).
Western blot was carried out on transgenic bone marrow cells to detect sPRDM16
and GFP protein expression. PCR positive transgenic mice and litter mate control were
under 2mg/ml doxycycline induction for 7 days. Sucrose water without doxycycline was
used as control. Due to incomplete induction in bone marrow cells, GFP positive cells
were sorted for western blot to increase the sensitivity. Singlets from control bone
marrow cells were also sorted for protein detection. sPRDM16 and GFP were only
expressed in transgenic bone marrow cells under doxycycline induction while sPRDM16
and GFP was not detected in control (Figure 4-6B) WT bone marrow cells in the
presence or absence of doxycycline as well as non-induced transgenic bone marrow cells
(Figure 4-6B). This result indicates specificity of gene induction and protein expression
in TetO-sPrdm16 transgenic mice.
Transgenic mice from 8012 line were under doxycycline induction for 39 days
and bone marrow was analyzed for GFP induction in different lineages. Overall GFP
induction showed doxycycline dose-dependent induction in HSC, progenitors, B cell and
myeloid cells, but very low induction in MEPs which can’t be enhanced by higher dose
of doxycycline (Figure 4-7). No GFP was detected in WT bone marrow present or absent
of doxycycline (Figure 4-7). 2mg/ml doxycycline reached the maximal induction which
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Figure 4-4. GFP expression in peripheral blood of N1 progenies.
(A). Different level of GFP% of peripheral blood of 9 founders’ N1 progenies 7 days post
Doxycycline induction in drinking water. X-axis is founder ID and number of N1 of each
founder tested. (B). Flow diagram of GFP expression in top 3 GFP induction N1s of each
founder. Note GFP expression post doxycycline induction and diminished GFP
expression once doxycycline was withdrew for 7 days.
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Figure 4-5. Southern blot of TetO-sPrdm16 transgenic mice.
(A). Southern blot on five transgenic founders showed 8005 carried more than one copy
of transgene with multiple integrations. Rearrangement or deletion of transgene was also
detected in 8005 genome. Other 4 transgenic founders demonstrated single copy of
transgene with one integration. No rearrangement or deletion was found in those
founders. (B). Southern blot on 8005 and its N1 progenies. Segregation of multiple
integration occurred in N1 progenies. 8096 and 8100 carried the same integration pattern
as founder 8005 while 8098 and 8219 carried only on copy of transgene with one
integration. (C). Southern blot on 8005 N1 progeny (8098) and N2 progenies (8489, 8491
and 8493). N2 progenies inherited transgene integration pattern from 8098. One copy of
transgene with one integration was detected in N2 progenies, without rearrangement or
deletion.
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Figure 4-6. TetO-sPrdm16 transgene integration site by FISH and protein
expression in transgenic bone marrow cells.
(A). FISH conducted in transgenic mouse bone marrow cells showed transgene
localization in mouse genome. Integration site of transgene in 8012 line was chromosome
19B-C1 region, integration site in 8005S line was chromosome3C-D region and
chromosome 2C-1 region in 8080 line. (B). sPRDM16 and GFP protein expression in
transgenic bone marrow cells under the Doxycycline induction in vivo in all three
founder lines. No sPRDMd16 and GFP protein expression was detected in wild type bone
marrow cells and un-induced transgenic bone marrow cells. GAPDH was used as loading
control for western blot. WT: wild type. Tg: Transgenics. Dox: Doxycycline.
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Figure 4-7. GFP percentage in HSC, progenitor and mature lineages in transgenic
bone marrow 39 days post doxycycline induction.
(A). GFP percentage in singlets, B cells and Myeloid cells from transgenic bone marrow.
(B). GFP percentage in HSC and progenitors from transgenic bone marro.
(A) and (B) both demonstrated doxycycline dose-dependent GFP induction in mature,
HSC and progenitor cells. Note low GFP induction in MEPs.
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was not further increased by 5mg/ml (Figure 4-7). As a result 2mg/ml doxycycline will
be used for the future experiment. TetOn-sPrdm16 transgenic mouse model is a useful
tool to study role of sPrdm16 on HSC activity because of efficient induction of sPrdm16
in HSCs.
Overexpression of sPrdm16 abolishes HOXB4-mediated HSC expansion
To evaluate sPrdm16’s effect on phonotypical HSC (CD150+CD48-Sca-1+cKit+Lineage-) and MPP (Sca-1+c-Kit-Lineage-) frequency in HOXB4 expressing cells in
vivo, bone marrow harvested from 18 weeks’ recipients were subjected to SLAM and
MPP surface markers staining. mCherry and mCherry+sPrdm16 transplanted mice served
as control. sPRDM16 alone didn’t alter MPP frequency compared with mCherry control
transduced bone marrow cells. HOXB4 significant increased MPP frequency up to about
5% of marking cells (Figure 4-8). Different from MPP, HSC frequency was doubled by
sPRDM16 and further increased by HOXB4 (Figure4-8). However, sPRDM16 and
HOXB4 double positive cells contained less HSCs, similar to control group (Figure 4-8).
Results above suggest HOXB4 with or without sPRDM16 expression is able to increase
MPP frequency. HOXB4, consistent with previous reports, increased the HSC frequency,
which was diminished by sPRDM16 to control level. Lower HSC number but not MPP
number implied that sustained expression of sPRDM16 is able to abolish HOXB4mediated HSC expansion but not MPP expansion. However, cell surface marker staining
can be altered by certain transcription factor or microRNA expression86. The effect of
HOXB4 and sPRDM16 on HSC frequency should be further confirmed by limiting
dilution assay.
Limiting dilution assay was carried out to assess sPRDM16’s effect on functional
HSC frequency. Compared with mCherry only group, sPRDM16 didn’t significantly alter
HSC frequency in recipient mice but HOXB4 recipients had about 10 time more HSCs
compared with control (Table 4-1). When sPRDM16 was overexpressed in HOXB4
expressing cells, HSC frequency was reduced about 25% relative to HOXB4 only group,
indicating sustained expression of sPRDM16 in HOXB4 expressing cells indeed reduces
HSC frequency and repression of Prdm16 by HOXB4 is necessary for HOXB4-mediated
HSC expansion.
Discussion
PRDM16 is a hematopoietic stem cell regulator. It plays role in fetal liver HSC
and neonatal HSC maintenance.215,216 It is preferentially expressed in quiescent LTHSCs,215,216 indicating its potential role in maintaining LT-HSC cell at quiescent status.
Downregulation of Prdm16 was observed in HOXB4-expressing HSCs in vivo, raising
the hypothesis that HOXB4 downregulates Prdm16 to drive HSCs to enter cell cycle to
expand. To test the hypothesis we generated TetOn-sPrdm16 transgenic mice. Unlike
constitutive overexpression vector, stable transgenic mouse model can avoid variation of
gene expression and reduce the risk of vector rearrangement due to multiple
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Figure 4-8. MPP and HSC frequency on marking cells.
HOXB4 but not sPrdm16 increases MPP frequency. Sustained expression of sPRDM16
in HOXB4 expressing cells maintain the same MPP frequency as HOXB4+ cells.
sPRDM16 alone and HOXB4 alone both are able to increase HSC frequency about 2-2.5
fold. Sustained expression of sPRDM16 in HOXB4 expressing cells decreased HSC
frequency to control level.
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Table 4-1.
Group
mCherry

HSC frequency in HOXB4 and sPRDM16 transplanted mice.
Dose Response Tested

2e5
4e4
8000
1600
320
mCherry+sPRDM16 2e5
4e4
8000
1600
320
HOXB4
2e5
4e4
8000
1600
320
HOXB4+sPRDM16 2e5
4e4
8000
1600
320

3
0
0
0
0
3
0
0
0
0
7
5
0
0
0
5
4
0
0
0

7
6
7
6
7
7
4
6
4
7
7
7
7
6
6
5
7
7
6
7
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HSC
HSC low HSC high
frequency frequency frequency
1 in
462,515

1 in
1,416,998

1 in
150,967

1 in
431,177

1 in
1,327,869

1 in
140,009

1 in
43,606

1 in
92,131

1 in
20,639

1 in
56,949

1 in
123,518

1 in
26,256

transductions. CMV promoter incorporated in TetOn construct allows moderate
expression of sPRDM16 and may avoid cellular toxicity due to high level of PRDM16
expression driven by MSCV promoter used in previous study. TetOn-sPrdm16 construct
allows dose-dependent gene activation by adding different mount of doxycycline, which
can prevent cellular toxicity. Expression of GFP was linearly correlated with sPRDM16
expression level due to P2A element between sPrdm16 and GFP cDNA in the construct,
which is usually not seen in IRES containing constructs. As a result, GFP intensity is a
great indicator of sPRDM16 expression level. Since vector transduction resulted in
limited number of Prdm16 transduced cells, transgenic mouse model is a great tool for in
vivo study as it doesn’t require transductions and transgene can be activated in vivo
directly.
We generated three TetOn-sPrdm16 transgenic mouse lines. When induced,
sPrdm16-GFP showed different induction efficiencies among 3 lines as well as different
lineages within each transgenic line. The variation of sPrdm16 activation efficiency in
each line may be due to the unique integration site of plasmid. We observed dosedependent GFP induction in mouse bone marrow as well as PB with best induction in
SLAM population and worst in MEPs. Best GFP induction in SLAM cells, which are
highly enriched HSCs, is consistent with highest endogenous Prdm16 expression
compared with other lineages. However we noticed poor induction in MEPs though
rtTAM2 was reported to have best induction efficiency in MEPs compared with other
versions of rtTAs.264 Low induction efficiency of sPRDM16 on MEPs can be due to the
sPRDM16 toxicity on MEPs which led to the elimination of MEPs from bone marrow.
Although there was differential expression level of sPRDM16 cross the lineages, high
induction efficiency of sPRDM16 on HSCs and progenitors except MEPs makes the
TetOn-sPrdm16 transgenic mouse a great tool to study the role of sPRDM16 on HSC’s
activity.
To address why HOXB4 downregulates Prdm16 in transplanted mice, SLAM
frequency and CRU were assessed in HOXB4 transplanted mice under the context of
sustained expression of sPRDM16 through doxycycline induction. In HOXB4 only group
SLAM frequency and CRU were increased compared to control group. There were
reduced SLAM frequency and CRU in HOXB4 and sPRDM16 co-expressing group,
indicating sustained expression of sPRDM16 can abolish HOXB4-mediated HSC
expansion. Although changes in SLAM frequency and CRU in HOXB4 and sPRDM16
coexpressing group were in the same trend, decrease in CRU was less significant than
SLAM frequency. SLAM frequency was calculated on gated HOXB4 and sPRDM16
double positive cells while CRU was assessed on the coexpressing group containing
about 50% HOXB4 single positive cells and only 10-30% HOXB4 and sPRDM16 double
positive cells. With less double positive cells and more HOXB4 cells, effect of double
positive cells on CRU could be compensated by HOXB4 single positive cells, which led
to less significant changes in CRU than SLAM frequency.
It is striking to detect less HSC when sPRDM16 was expressed in HOXB4 cells
as PRDM16 was reported as a critical factor for HSC maintenance. We hypothesize that
PRDM16 maintain HSC stemness by maintaining HSC quiescence. HOXB4 represses
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Prdm16 to release HSC to cell cycle, thus expands HSC in vivo. To test this hypothesis
cell cycle status can be evaluated in HOXB4 and sPRDM16 expressing cells from
transplanted mice and we expect cell cycle arrest of double positive cells. At meanwhile
enhanced apoptosis or downstream differentiation of HSCs also can be the alternative
explanation of reduced HSCs by sustained sPRDM16 expression on HOXB4 cells.
In this chapter we generated TetOn-sPrdm16 inducible transgenic mouse model
which demonstrated doxycycline dose-dependent sPRDM16/GFP expression in
hematopoietic lineages except MEPs. Using this mouse model we showed that sustained
expression of sPRDM16 on HOXB4 expressing cells can abolish HOXB4-mediated HSC
expansion in transplanted mice. Mechanism how sPRDM16 decreases HSC frequency
under the context of HOXB4 overexpression is not included in this chapter but can be
explored in the future studies.
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CHAPTER 5.

DISCUSSION

Significance
The object of this study is to understand molecular mechanism of HOXB4mediated HSC benign expansion in vivo. It started with gene expression array of HOXB4
expressing LSK cells from transplanted mice and then we focused on Prdm16, one of the
most significant downregulated genes, to study its role on HOXB4-HSC benign
expansion. Results of this study revealed some interesting aspects of HOXB4-mediated
HSC expansion.
HOXB4 is a global regulator of HSC self-renewal
In this study gene expression prolife of HOXB4 expressing LSKs cells from
transplanted mice revealed a dynamic transcriptional network of HOXB4 during the
reconstitution. In order to expand HSCs, HOXB4 activated hematopoietic stem cell
pathway and hematopoietic stem cell long term pathway. Expression of genes regulating
HSC function were altered by HOXB4, such as Hemgn, Gata2, N-myc, Pten, Bcl-3,
Prdm16, Jun, HOXA9 and many others, which led to balanced HSC expansion. Besides
HSC expansion, HOXB4 also facilitate B cell lineage and myeloid lineage priming at
LSK cell level. As a result of differentiation permission, HOXB4 is able to control the
HSC pool size and prevent the leukemia, a great feature of HOXB4 but not seen in any
other oncogenic HOX factors such as HOXA9 and HOXA10. In summary HOXB4 is a
global regulator of HSC self-renewal. HOXB4-mediated benign HSC expansion is not
achieved by a single downstream target or pathway. It is an outcome of highly complex
regulation of genes and pathways playing roles in HSC proliferation, differentiation and
apoptosis, which leads to balanced HSC expansion. Besides the knowledge we gained in
this study, role of HOXB4 in HSC expansion in vivo is a very interesting topic in the
hematology field and worthwhile for further exploration.
Differential regulation of Prdm16 transcript by HOXB4 and HOXA9/A10
Our study revealed that downregulation of Prdm16 is unique for HOXB4 but not
for HOXA9 and HOXA10 in HSCs. HOXB4, HOXA9 and HOXA10 belong to HOX
family. HOX genes all bind to a similar set of ‘AT’-rich DNA binding site through their
homeodomain and the non-homeodomain adjacent to the homeodomain offer additional
HOX-DNA-binding specificity. A bacterial one-hybrid approach (B1H) and in vivo
protein-binding microarrays (PBMs) showed that the ‘AT’-rich DNA consensus
sequences HOXB4 and HOXA9/A10 recognize and bind to are different (Figure 5-1),
suggesting HOXB4 and HOXA9/A10 may bind to different region of Prdm16 promoter
or enhancer. This can be one of the mechanisms of differential transcription regulation of
Prdm16 by HOXB4 and HOXA9/A10. There is a study suggesting that HOX gene can
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Figure 5-1. Comparison of in vitro and in vivo Hox-binding site preferences.
Shown are LOGO diagrams summarizing Hox-binding site preferences for Hox4 and
Hox9-13 groups. The column on the left lists the LOGOs generated using the binding
sites identified by the B1H method. The column on the right lists the LOGOs generated
using the protein-binding microarrays. Y-axis is nucleotide frequency.
Modified with permission. Mann RS, Lelli KM, Joshi R. Hox specificity unique roles for
cofactors and collaborators. Curr Top Dev Biol. 2009;88:63-101.
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use transcription repressors as HOX cofactors in gene repression. Selectively using
repressor by HOXB4 but not HOXA9 and HOXA10 can be the explanation of HOXB4mediated Prdm16 repression. HOX collaborators are another group of proteins which
binds to HOX factors or HOX-targeted elements to determine target genes are activated
or repressed. Protein-protein interaction between HOX factors and collaborators may
form enhanceosome-like structure on HOX-targeted region to activate target genes
expression. HOXB4 and HOXA9/A10 may form transcription complex with different
collaborators and determine whether to active or repress Prdm16 transcription.114
HOXB4 doesn’t cause leukemia unless pro-oncogenes are activated
HOXB4 is always considered as a safe factor to expand HSCs, because
overexpression of HOXB4 doesn’t lead to hematopoietic malignancies. Safety issue was
brought back to discussion when the two myeloid leukemia cases from a dog and a
macque who received HOXB4 transduced CD34+ cells187 were reported. In our
independent screening we also detected two myeloid leukemias derived from HOXB4
expressing cells in transplanted mice. Both studies revealed additional genetic lesions in
leukemic cells due to vector integration and activation of sPrdm16 was common in both
studies, indicating HOXB4 is doesn’t transform hematopoietic cells unless additional
oncogenes are activated and activation of sPRDM16 is one of the factors contributing to
the leukemogenesis. Leukemic cells line generated from the leukemic dog demonstrated
sPRDM16-dependent growth in vitro. However, it is possible the leukemias with
sPrdm16 activation may be purely due to sPrdm16 expression and HOXB4 was not at all
involved. In our study we didn’t detect any hematopoietic malignancies when sPrdm16
was overexpressed alone. Shing D.C et al also claimed that sPrdm16 was not oncogenic
in WT mice but in p53 null mice.248 Both studies suggest sPrdm16 alone is not sufficient
to cause leukemia. So our screening together with previous literature reports support the
synergistic role of HOXB4 and sPRDM16 in leukemogenesis.
Oncogenic potential of sPRDM16
sPRDM16 is the short form of PRDM16 with partial deletion of N-terminal PR
domain. sPRDM16 but not PRDM16 is considered as a proto-oncogene189 and is
associated human hematopoietic malignancies. Absence of the PR domain may count for
the oncogenic potential of sPRDM16. PR domain is 20-30% identical to SET domain,
indicating the potential role of PRDM16 as a methyltransferase. sPRDM16 is highly
homologous to EVI1, zinc finger part of MDS1/EVI1 (PRDM3) protein. EVI1 is
oncogenic and aberrant expression of EVI1 is detected in about 10% of AML cases265
and is able to induce MDS in mice.266 Similar to Prdm16, EVI1 gene expression is
upregulated in NUP98-HOXA9-expressing leukemia cells.267 Several mechanisms have
been identified to contribute to the leukemogenic activity of EVI1 which can be shared
by sPRDM16. EVI1 exerts negative regulation on TGF-β signaling pathway through the
repression of Smad3 function, which promotes cellular proliferation and affects cellular
differentiation. EVI1 also suppresses the JNK-1-mediated phosphorylation of c-JUN or
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inhibits interferon-α signaling to exert anti-apoptotic effects.268,269 Recent studies showed
that EVI recruits and forms protein complex with several Polycomb proteins to PTEN
locus and switch PTEN promoter from H3K27Ac status to H3K27m3 status to repress
Pten expression, which activates PI3K/ARK/Mtorc1 signaling in leukemia cells.270,271
Mechanisms of leukemogenic potential of EVI1 mentioned above suggest that EVI1
unique regulation of certain pathways and recruitment of epigenetic modifiers confer
EVI1’s oncogenic activity and lack of HMT activity from PR domain is not the reason.
sPRDM16 can induce leukemia in the similar manner as EVI1 due to the structural and
biology similarities between them.
MDS/AML genetic lesion is missing from HOXB4/sPrdm16 preleukemia model
When sPrdm16 and HOXB4 were co-overexpressed, only 2 out of 12 recipients
developed preluekmias at 28 or 32 weeks post transplantation. Two preleukemic cases
represent MDS/AML phenotype with normal karyotype. Low incidence may be due to
low cotransduction efficiency. However, the long latency for leukemogenesis indicates
activation sPrdm16 and HOXB4 are not sufficient to cause leukemic transformation.
MDS/AML is a heterogeneous group of hematopoietic stem cell disorders and acquired
mutations such as NPM1272, TET2273 and FLT3274 were well characterized in sporadic
cases of AML. Submicroscopic deletion of 5q was recently identified in a patient with
MDS presenting with normal karyotype resulting in loss of tumor suppressor CTNNA1
and HSPA9.275 ASXL1frameshift/stop mutation (591*), EZH2 point mutation (R690H),
RUNX1 frameshift/ stop mutations (c.474dupT and c424_425ins11bp) and TET2
frameshift/stop mutations (c.1510_1513delAAAA and R1465*) were also detected as
MDS-associated mutations.275,276 RUNX1 mutations are frequently detected in de novo
AML with noncomplex karyotype and were proposed as clinical biomarkers for disease
progression of MDS to AML.277 Harriet Holme et al278 reported genetic categorization of
27 families with familial MDS/AML, revealing heterozygous mutations in the GATA2
gene (c.121C>G p.Pro41Ala; c1187G>A p. Arg396Gln and c1061C>T, p.Thr354Met),
TERT mutations, TERC mutations and RUNX1 mutation. There are also MDS/AML
cases with unidentified mutations. One or many of the mutations mentioned above may
be required for the complete MDS/AML transformation in our HOXB4 and sPrdm16
transplanted animals, missing which led to delayed onset of the leukemias.
Repression of Prdm16 may promote cell enter cell cycle and facilitate HOXB4mediated HSC expansion
Expansion of HSCs requires HSCs to enter cell cycle. PRDM16 shared high
similarity of MDS1/EVI1protein, suggesting the PRDM16 may share similar mechanism
how MDS1/EVI1 regulate HSC self-renewal can. MDS1/EVI1 was shown to be negative
cell cycle regulator, loss of which led to increased proportion of active dividing HSCs
and HSC exhaustion.218 Endogenous Prdm16 is highly expressed in quiescent LT-HSCs
and loss of Prdm16 increased the proportion of HSCs undergoing active cell
division.215,216 We detected marked repression of Prdm16 in HOXB4-HSCs. It is
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possible that HOXB4 represses Prdm16 to release HSCs from cell cycle arrest state.
When sPrdm16 expression is sustained in HOXB4 expressing cells, HSC proliferation
can be suppressed, which results in reduced phonotypical and functional HSCs number
observed in this study, supporting the hypothesis that repressing Prdm16 in HOXB4
expressing cells is required for HOXB4-mediated HSC expansion. Loss of Prdm16 also
induces apoptosis/cell death in HSCs.215,216 Repression of Prdm16 by HOXB4 can be a
mechanism to induced apoptosis in unwanted proliferating HSCs, which is contradict to
our previous finding that HOXB4 indeed protects hematopoietic progenitors from
apoptosis. Although how HOXB4 downregulates Prdm16 in transplanted mice is
unknown, but it is clear sustained expression of sPrdm16 decreased HSC frequency in
HOXB4 transplanted mice. In conclusion, repression of Prdm16 is required for HOXB4mediated HSC expansion in vivo.
Future Directions
HOXB4-mediated HSC expansion is an interesting topic. Findings of our study
revealed the unique regulation of Prdm16 by HOXB4 during HSC expansion in vivo.
Considering the limitations discussed above, several experiments can be carried out to
improve this study.
Our study showed significant downregulation of Prdm16 by HOXB4 in
transplanted mice. To address the question how HOXB4 downregulates Prdm16, ChIP
assay can be performed. We have generated HOXB4-dependent myeloid cell line. This
cell line contains Gr1-Mac1-FcɛR- primitive population which demonstrated HOXB4dependent proliferation and myeloid progenitor self-renewal capacity. We have
conducted ChIP assay using I12 HOXB4 monoclonal antibody and HOXB4 protein
enrichment was nicely achieved. However, ChIP-seq data showed low signal-to-noise
ratio which makes peak calling impossible. High noise can be due to low specificity of
the HOXB4 antibody or non-stringent washing condition, both can be improve by
changing to a ChIP-grade antibody and more stringent washing solution. But non-specific
binding of HOXB4 to mouse genome due to high expression level of HOXB4 by
overexpression vector can also contribute to the high noise. Lower the protein expression
by switching to weak promoter probably can decrease the noise.
As mentioned above another question is not answered by our study is how
downregulation of Prdm16 contributes to the HSC expansion in HOXB4 transplanted
mice. Given the fact that loss of Prdm16 release HSC into cell cycle,215,216 repression of
Prdm16 can set HSC at active proliferation state, thus allowing HSC expansion. To test
the hypothesis, cell cycle analysis can be done on HSC compartment of HOXB4 and
sPRDM16 co-expressing cells and we predict higher proportion of G0 cells in HOXB4
and sPRDM16 double positive HSCs than HOXB4 single positive HSCs.
Prdm16 was claimed as a hematopoietic stem cell regulator.216 Mechanistic
studies regarding its role in hematopoietic specification and HSC maintenance are
lacking. Numerous studies have identified molecular mechanism of Prdm16-mediated
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brown fat maturation, including complex elements, upstream regulators and downstream
pathways. Prdm16 was also reported to maintain heterochromatin integrity through its
H3K9me1 methyltransferase activity. As one of the long-term directions, molecular
interaction of Prdm16 with other factors and involvement of Prdm16 in epigenetic
modification during embryonic and adult hematopoiesis can be explored, findings of
which will provide great insight of HSC biology.
Our study showed that oncogenic HOXA9 and HOXA10 upregulated Prdm16 up
to about 50 fold compared with HOXB4 in HSC compartment, suggesting aberrant
expression of Prdm16 could be a major player in HOXA9 or HOXA10-associated
leukemia initiation or maintenance. If so, overexpression of HOXA9/10 in Prdm16 null
HSCs but not WT HSCs will not lead to leukemia. It will be exciting to confirm the role
of Prdm16 and identify Prdm16 pathway in HOXA9/10-asscoiated leukemia. Drug
screening can be conducted to identify promising compounds targeting Prdm16 pathway
associated with HOXA9/10 leukemia.

92

LIST OF REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.

Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic
stem cells is deterministic and isolatable by phenotype. Immunity. 1994;1(8):661673.
Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell
differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad
Sci U S A. 2001;98(25):14541-14546.
Kondo M, Weissman IL, Akashi K. Identification of clonogenic common
lymphoid progenitors in mouse bone marrow. Cell. 1997;91(5):661-672.
Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid
progenitor that gives rise to all myeloid lineages. Nature. 2000;404(6774):193197.
Bell JJ, Bhandoola A. The earliest thymic progenitors for T cells possess myeloid
lineage potential. Nature. 2008;452(7188):764-767.
Guo G, Luc S, Marco E, et al. Mapping cellular hierarchy by single-cell analysis
of the cell surface repertoire. Cell Stem Cell. 2013;13(4):492-505.
Adolfsson J, Mansson R, Buza-Vidas N, et al. Identification of Flt3+ lymphomyeloid stem cells lacking erythro-megakaryocytic potential a revised road map
for adult blood lineage commitment. Cell. 2005;121(2):295-306.
Pronk CJ, Rossi DJ, Mansson R, et al. Elucidation of the phenotypic, functional,
and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell
Stem Cell. 2007;1(4):428-442.
Medvinsky AL, Samoylina NL, Muller AM, Dzierzak EA. An early pre-liver
intraembryonic source of CFU-S in the developing mouse. Nature.
1993;364(6432):64-67.
Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by
the AGM region. Cell. 1996;86(6):897-906.
Muller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E. Development
of hematopoietic stem cell activity in the mouse embryo. Immunity.
1994;1(4):291-301.
Larsson J, Karlsson S. The role of Smad signaling in hematopoiesis. Oncogene.
2005;24(37):5676-5692.
Boisset JC, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C.
In vivo imaging of haematopoietic cells emerging from the mouse aortic
endothelium. Nature. 2010;464(7285):116-120.
Bertrand JY, Chi NC, Santoso B, Teng S, Stainier DY, Traver D. Haematopoietic
stem cells derive directly from aortic endothelium during development. Nature.
2010;464(7285):108-111.
Till JE, Mc CE. A direct measurement of the radiation sensitivity of normal
mouse bone marrow cells. Radiat Res. 1961;14:213-222.
Iscove NN, Till JE, McCulloch EA. The proliferative states of mouse
granulopoietic progenitor cells. Proc Soc Exp Biol Med. 1970;134(1):33-36.

93

17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.

Iscove NN, Messner H, Till JE, McCulloch EA. Human marrow cells forming
colonies in culture: analysis by velocity sedimentation and suspension culture. Ser
Haematol. 1972;5(2):37-49.
Wu AM, Till JE, Siminovitch L, McCulloch EA. A cytological study of the
capacity for differentiation of normal hemopoietic colony-forming cells. J Cell
Physiol. 1967;69(2):177-184.
Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in
development and cancer. Nature. 2006;441(7097):1068-1074.
Sekulovic S, Gylfadottir V, Vulto I, et al. Prolonged self-renewal activity
unmasks telomerase control of telomere homeostasis and function of mouse
hematopoietic stem cells. Blood. 2011;118(7):1766-1773.
Morrison SJ, Prowse KR, Ho P, Weissman IL. Telomerase activity in
hematopoietic cells is associated with self-renewal potential. Immunity.
1996;5(3):207-216.
Allsopp RC, Cheshier S, Weissman IL. Telomere shortening accompanies
increased cell cycle activity during serial transplantation of hematopoietic stem
cells. J Exp Med. 2001;193(8):917-924.
Dzierzak E, Speck NA. Of lineage and legacy: the development of mammalian
hematopoietic stem cells. Nat Immunol. 2008;9(2):129-136.
Fleischman RA, Custer RP, Mintz B. Totipotent hematopoietic stem cells: normal
self-renewal and differentiation after transplantation between mouse fetuses. Cell.
1982;30(2):351-359.
Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic
behavior of hematopoietic stem cells. Cell. 1986;45(6):917-927.
Harrison DE, Astle CM, Lerner C. Number and continuous proliferative pattern of
transplanted primitive immunohematopoietic stem cells. Proc Natl Acad Sci U S
A. 1988;85(3):822-826.
Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of
mouse hematopoietic stem cells. Science. 1988;241(4861):58-62.
Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term
hematopoiesis in the mouse. Genes Dev. 1990;4(2):220-232.
Smith LG, Weissman IL, Heimfeld S. Clonal analysis of hematopoietic stem-cell
differentiation in vivo. Proc Natl Acad Sci U S A. 1991;88(7):2788-2792.
Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic
reconstitution by a single CD34-low/negative hematopoietic stem cell. Science.
1996;273(5272):242-245.
Ikuta K, Weissman IL. Evidence that hematopoietic stem cells express mouse ckit but do not depend on steel factor for their generation. Proc Natl Acad Sci U S
A. 1992;89(4):1502-1506.
Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, Suda T. In vivo and
in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells.
Blood. 1992;80(12):3044-3050.
Orlic D, Fischer R, Nishikawa S, Nienhuis AW, Bodine DM. Purification and
characterization of heterogeneous pluripotent hematopoietic stem cell populations
expressing high levels of c-kit receptor. Blood. 1993;82(3):762-770.

94

34.
35.
36.
37.
38.
39.
40.
41.
42.
43.

44.
45.
46.
47.
48.
49.

Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a
candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A.
1992;89(7):2804-2808.
Matsuoka S, Ebihara Y, Xu M, et al. CD34 expression on long-term repopulating
hematopoietic stem cells changes during developmental stages. Blood.
2001;97(2):419-425.
Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM
family receptors distinguish hematopoietic stem and progenitor cells and reveal
endothelial niches for stem cells. Cell. 2005;121(7):1109-1121.
Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and
functional properties of murine hematopoietic stem cells that are replicating in
vivo. J Exp Med. 1996;183(4):1797-1806.
Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is
expressed in a wide variety of stem cells and is a molecular determinant of the
side-population phenotype. Nat Med. 2001;7(9):1028-1034.
Fleming WH, Alpern EJ, Uchida N, Ikuta K, Spangrude GJ, Weissman IL.
Functional heterogeneity is associated with the cell cycle status of murine
hematopoietic stem cells. J Cell Biol. 1993;122(4):897-902.
Harrison DE. Competitive repopulation: a new assay for long-term stem cell
functional capacity. Blood. 1980;55(1):77-81.
Szilvassy SJ, Humphries RK, Lansdorp PM, Eaves AC, Eaves CJ. Quantitative
assay for totipotent reconstituting hematopoietic stem cells by a competitive
repopulation strategy. Proc Natl Acad Sci U S A. 1990;87(22):8736-8740.
Ratajczak MZ. Phenotypic and functional characterization of hematopoietic stem
cells. Curr Opin Hematol. 2008;15(4):293-300.
Tsai FY, Orkin SH. Transcription factor GATA-2 is required for
proliferation/survival of early hematopoietic cells and mast cell formation, but not
for erythroid and myeloid terminal differentiation. Blood. 1997;89(10):36363643.
Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking
the transcription factor GATA-2. Nature. 1994;371(6494):221-226.
Minegishi N, Suzuki N, Yokomizo T, et al. Expression and domain-specific
function of GATA-2 during differentiation of the hematopoietic precursor cells in
midgestation mouse embryos. Blood. 2003;102(3):896-905.
Tipping AJ, Pina C, Castor A, et al. High GATA-2 expression inhibits human
hematopoietic stem and progenitor cell function by effects on cell cycle. Blood.
2009;113(12):2661-2672.
Tripic T, Deng W, Cheng Y, et al. SCL and associated proteins distinguish active
from repressive GATA transcription factor complexes. Blood.
2009;113(10):2191-2201.
Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult selfrenewing haematopoietic stem cells. Nature. 2003;423(6937):302-305.
Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal of hematopoietic
stem cells mediated by the polycomb gene product Bmi-1. Immunity.
2004;21(6):843-851.

95

50.
51.
52.
53.
54.
55.
56.
57.
58.
59.

60.
61.
62.
63.
64.
65.

Rizo A, Dontje B, Vellenga E, de Haan G, Schuringa JJ. Long-term maintenance
of human hematopoietic stem/progenitor cells by expression of BMI1. Blood.
2008;111(5):2621-2630.
Rizo A, Olthof S, Han L, Vellenga E, de Haan G, Schuringa JJ. Repression of
BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and
induces apoptosis. Blood. 2009;114(8):1498-1505.
Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1
dependence distinguishes neural stem cell self-renewal from progenitor
proliferation. Nature. 2003;425(6961):962-967.
Ohta H, Sawada A, Kim JY, et al. Polycomb group gene rae28 is required for
sustaining activity of hematopoietic stem cells. J Exp Med. 2002;195(6):759-770.
Alkema MJ, Bronk M, Verhoeven E, et al. Identification of Bmi1-interacting
proteins as constituents of a multimeric mammalian polycomb complex. Genes
Dev. 1997;11(2):226-240.
Gunster MJ, Satijn DP, Hamer KM, et al. Identification and characterization of
interactions between the vertebrate polycomb-group protein BMI1 and human
homologs of polyhomeotic. Mol Cell Biol. 1997;17(4):2326-2335.
Hashimoto N, Brock HW, Nomura M, et al. RAE28, BMI1, and M33 are
members of heterogeneous multimeric mammalian Polycomb group complexes.
Biochem Biophys Res Commun. 1998;245(2):356-365.
Tomotsune D, Takihara Y, Berger J, et al. A novel member of murine Polycombgroup proteins, Sex comb on midleg homolog protein, is highly conserved, and
interacts with RAE28/mph1 in vitro. Differentiation. 1999;65(4):229-239.
Shao Z, Raible F, Mollaaghababa R, et al. Stabilization of chromatin structure by
PRC1, a Polycomb complex. Cell. 1999;98(1):37-46.
Cales C, Roman-Trufero M, Pavon L, et al. Inactivation of the polycomb group
protein Ring1B unveils an antiproliferative role in hematopoietic cell expansion
and cooperation with tumorigenesis associated with Ink4a deletion. Mol Cell Biol.
2008;28(3):1018-1028.
Lessard J, Schumacher A, Thorsteinsdottir U, van Lohuizen M, Magnuson T,
Sauvageau G. Functional antagonism of the Polycomb-Group genes eed and
Bmi1 in hemopoietic cell proliferation. Genes Dev. 1999;13(20):2691-2703.
Micklem HS, Ford CE, Evans EP, Ogden DA, Papworth DS. Competitive in vivo
proliferation of foetal and adult haematopoietic cells in lethally irradiated mice. J
Cell Physiol. 1972;79(2):293-298.
Majewski IJ, Blewitt ME, de Graaf CA, et al. Polycomb repressive complex 2
(PRC2) restricts hematopoietic stem cell activity. PLoS Biol. 2008;6(4):e93.
Tadokoro Y, Ema H, Okano M, Li E, Nakauchi H. De novo DNA
methyltransferase is essential for self-renewal, but not for differentiation, in
hematopoietic stem cells. J Exp Med. 2007;204(4):715-722.
Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem
cell differentiation. Nat Genet. 2012;44(1):23-31.
Trowbridge JJ, Snow JW, Kim J, Orkin SH. DNA methyltransferase 1 is essential
for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem
Cell. 2009;5(4):442-449.

96

66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.

Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH.
Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through
derepression of bivalent chromatin domains. Genes Dev. 2012;26(4):344-349.
Broske AM, Vockentanz L, Kharazi S, et al. DNA methylation protects
hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet.
2009;41(11):1207-1215.
Austin TW, Solar GP, Ziegler FC, Liem L, Matthews W. A role for the Wnt gene
family in hematopoiesis: expansion of multilineage progenitor cells. Blood.
1997;89(10):3624-3635.
Brandon C, Eisenberg LM, Eisenberg CA. WNT signaling modulates the
diversification of hematopoietic cells. Blood. 2000;96(13):4132-4141.
Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of
haematopoietic stem cells. Nature. 2003;423(6938):409-414.
Chung EJ, Hwang SG, Nguyen P, et al. Regulation of leukemic cell adhesion,
proliferation, and survival by beta-catenin. Blood. 2002;100(3):982-990.
Xue Y, Gao X, Lindsell CE, et al. Embryonic lethality and vascular defects in
mice lacking the Notch ligand Jagged1. Hum Mol Genet. 1999;8(5):723-730.
Walker L, Lynch M, Silverman S, et al. The Notch/Jagged pathway inhibits
proliferation of human hematopoietic progenitors in vitro. Stem Cells.
1999;17(3):162-171.
Ohishi K, Varnum-Finney B, Bernstein ID. Delta-1 enhances marrow and thymus
repopulating ability of human CD34(+)CD38(-) cord blood cells. J Clin Invest.
2002;110(8):1165-1174.
Varnum-Finney B, Xu L, Brashem-Stein C, et al. Pluripotent, cytokinedependent, hematopoietic stem cells are immortalized by constitutive Notch1
signaling. Nat Med. 2000;6(11):1278-1281.
Groszer M, Erickson R, Scripture-Adams DD, et al. Negative regulation of neural
stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo.
Science. 2001;294(5549):2186-2189.
Groszer M, Erickson R, Scripture-Adams DD, et al. PTEN negatively regulates
neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl
Acad Sci U S A. 2006;103(1):111-116.
Gregorian C, Nakashima J, Le Belle J, et al. Pten deletion in adult neural
stem/progenitor cells enhances constitutive neurogenesis. J Neurosci.
2009;29(6):1874-1886.
Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes
haematopoietic stem cells from leukaemia-initiating cells. Nature.
2006;441(7092):475-482.
Zhang J, Grindley JC, Yin T, et al. PTEN maintains haematopoietic stem cells
and acts in lineage choice and leukaemia prevention. Nature.
2006;441(7092):518-522.
Winnier G, Blessing M, Labosky PA, Hogan BL. Bone morphogenetic protein-4
is required for mesoderm formation and patterning in the mouse. Genes Dev.
1995;9(17):2105-2116.

97

82.
83.
84.

85.
86.
87.
88.
89.
90.
91.
92.
93.

94.
95.
96.
97.

Bhatia M, Bonnet D, Wu D, et al. Bone morphogenetic proteins regulate the
developmental program of human hematopoietic stem cells. J Exp Med.
1999;189(7):1139-1148.
Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation
of primitive human hematopoietic cells via BMP regulation. Nat Immunol.
2001;2(2):172-180.
Goey H, Keller JR, Back T, Longo DL, Ruscetti FW, Wiltrout RH. Inhibition of
early murine hemopoietic progenitor cell proliferation after in vivo locoregional
administration of transforming growth factor-beta 1. J Immunol. 1989;143(3):877880.
Blank U, Karlsson G, Moody JL, et al. Smad7 promotes self-renewal of
hematopoietic stem cells. Blood. 2006;108(13):4246-4254.
Guo S, Lu J, Schlanger R, et al. MicroRNA miR-125a controls hematopoietic
stem cell number. Proc Natl Acad Sci U S A. 2010;107(32):14229-14234.
Georgantas RW, 3rd, Hildreth R, Morisot S, et al. CD34+ hematopoietic stemprogenitor cell microRNA expression and function: a circuit diagram of
differentiation control. Proc Natl Acad Sci U S A. 2007;104(8):2750-2755.
Petriv OI, Kuchenbauer F, Delaney AD, et al. Comprehensive microRNA
expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci U S A.
2010;107(35):15443-15448.
O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D.
MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term
hematopoietic output. Proc Natl Acad Sci U S A. 2010;107(32):14235-14240.
Gentner B, Visigalli I, Hiramatsu H, et al. Identification of hematopoietic stem
cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy. Sci
Transl Med. 2010;2(58):58ra84.
Bousquet M, Quelen C, Rosati R, et al. Myeloid cell differentiation arrest by miR125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the
t(2;11)(p21;q23) translocation. J Exp Med. 2008;205(11):2499-2506.
Chapiro E, Russell LJ, Struski S, et al. A new recurrent translocation
t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute
lymphoblastic leukemia. Leukemia. 2010;24(7):1362-1364.
Sonoki T, Iwanaga E, Mitsuya H, Asou N. Insertion of microRNA-125b-1, a
human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene
locus in a patient with precursor B-cell acute lymphoblastic leukemia. Leukemia.
2005;19(11):2009-2010.
Calin GA, Croce CM. Chronic lymphocytic leukemia: interplay between
noncoding RNAs and protein-coding genes. Blood. 2009;114(23):4761-4770.
O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of
microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder.
J Exp Med. 2008;205(3):585-594.
Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response
by microRNA-155. Science. 2007;316(5824):604-608.
Fazi F, Rosa A, Fatica A, et al. A minicircuitry comprised of microRNA-223 and
transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis.
Cell. 2005;123(5):819-831.

98

98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.

Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell
proliferation and granulocyte function by microRNA-223. Nature.
2008;451(7182):1125-1129.
Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic
lineage differentiation. Science. 2004;303(5654):83-86.
Xiao C, Calado DP, Galler G, et al. MiR-150 controls B cell differentiation by
targeting the transcription factor c-Myb. Cell. 2007;131(1):146-159.
Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and
autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat
Immunol. 2008;9(4):405-414.
Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA
expressed in mature B and T cells, blocks early B cell development when
expressed prematurely. Proc Natl Acad Sci U S A. 2007;104(17):7080-7085.
Akam M. Hox and HOM: homologous gene clusters in insects and vertebrates.
Cell. 1989;57(3):347-349.
Kaufman TC, Seeger MA, Olsen G. Molecular and genetic organization of the
antennapedia gene complex of Drosophila melanogaster. Adv Genet.
1990;27:309-362.
Duncan I. The bithorax complex. Annu Rev Genet. 1987;21:285-319.
Mazo AM, Huang DH, Mozer BA, Dawid IB. The trithorax gene, a trans-acting
regulator of the bithorax complex in Drosophila, encodes a protein with zincbinding domains. Proc Natl Acad Sci U S A. 1990;87(6):2112-2116.
Alharbi RA, Pettengell R, Pandha HS, Morgan R. The role of HOX genes in
normal hematopoiesis and acute leukemia. Leukemia. 2013;27(5):1000-1008.
Kaneko Y, Shikano T, Maseki N, et al. Clinical characteristics of infant acute
leukemia with or without 11q23 translocations. Leukemia. 1988;2(10):672-676.
Hunger SP, Tkachuk DC, Amylon MD, et al. HRX involvement in de novo and
secondary leukemias with diverse chromosome 11q23 abnormalities. Blood.
1993;81(12):3197-3203.
Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression
and segmental identity in Mll-mutant mice. Nature. 1995;378(6556):505-508.
Yagi H, Deguchi K, Aono A, Tani Y, Kishimoto T, Komori T. Growth
disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood.
1998;92(1):108-117.
Lessard J, Baban S, Sauvageau G. Stage-specific expression of polycomb group
genes in human bone marrow cells. Blood. 1998;91(4):1216-1224.
Moens CB, Selleri L. Hox cofactors in vertebrate development. Dev Biol.
2006;291(2):193-206.
Mann RS, Lelli KM, Joshi R. Hox specificity unique roles for cofactors and
collaborators. Curr Top Dev Biol. 2009;88:63-101.
Mann RS. The specificity of homeotic gene function. Bioessays.
1995;17(10):855-863.
Shen WF, Montgomery JC, Rozenfeld S, et al. AbdB-like Hox proteins stabilize
DNA binding by the Meis1 homeodomain proteins. Mol Cell Biol.
1997;17(11):6448-6458.

99

117.
118.
119.
120.
121.
122.
123.
124.
125.

126.
127.
128.
129.
130.
131.

Chang CP, Brocchieri L, Shen WF, Largman C, Cleary ML. Pbx modulation of
Hox homeodomain amino-terminal arms establishes different DNA-binding
specificities across the Hox locus. Mol Cell Biol. 1996;16(4):1734-1745.
Neuteboom ST, Peltenburg LT, van Dijk MA, Murre C. The hexapeptide
LFPWMR in Hoxb-8 is required for cooperative DNA binding with Pbx1 and
Pbx2 proteins. Proc Natl Acad Sci U S A. 1995;92(20):9166-9170.
Phelan ML, Rambaldi I, Featherstone MS. Cooperative interactions between
HOX and PBX proteins mediated by a conserved peptide motif. Mol Cell Biol.
1995;15(8):3989-3997.
Lu Q, Kamps MP. Selective repression of transcriptional activators by Pbx1 does
not require the homeodomain. Proc Natl Acad Sci U S A. 1996;93(1):470-474.
Shen WF, Chang CP, Rozenfeld S, et al. Hox homeodomain proteins exhibit
selective complex stabilities with Pbx and DNA. Nucleic Acids Res.
1996;24(5):898-906.
Shen WF, Rozenfeld S, Lawrence HJ, Largman C. The Abd-B-like Hox
homeodomain proteins can be subdivided by the ability to form complexes with
Pbx1a on a novel DNA target. J Biol Chem. 1997;272(13):8198-8206.
Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM. Meis1, a PBX1related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell
Biol. 1995;15(10):5434-5443.
Chang CP, Jacobs Y, Nakamura T, Jenkins NA, Copeland NG, Cleary ML. Meis
proteins are major in vivo DNA binding partners for wild-type but not chimeric
Pbx proteins. Mol Cell Biol. 1997;17(10):5679-5687.
Knoepfler PS, Kamps MP. The highest affinity DNA element bound by Pbx
complexes in t(1;19) leukemic cells fails to mediate cooperative DNA-binding or
cooperative transactivation by E2a-Pbx1 and class I Hox proteins - evidence for
selective targetting of E2a-Pbx1 to a subset of Pbx-recognition elements.
Oncogene. 1997;14(21):2521-2531.
Nakamura T, Jenkins NA, Copeland NG. Identification of a new family of Pbxrelated homeobox genes. Oncogene. 1996;13(10):2235-2242.
Steelman S, Moskow JJ, Muzynski K, et al. Identification of a conserved family
of Meis1-related homeobox genes. Genome Res. 1997;7(2):142-156.
Berthelsen J, Zappavigna V, Mavilio F, Blasi F. Prep1, a novel functional partner
of Pbx proteins. EMBO J. 1998;17(5):1423-1433.
Berthelsen J, Zappavigna V, Ferretti E, Mavilio F, Blasi F. The novel
homeoprotein Prep1 modulates Pbx-Hox protein cooperativity. EMBO J.
1998;17(5):1434-1445.
Shen WF, Rozenfeld S, Kwong A, Kom ves LG, Lawrence HJ, Largman C.
HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol
Cell Biol. 1999;19(4):3051-3061.
Giampaolo A, Sterpetti P, Bulgarini D, et al. Key functional role and lineagespecific expression of selected HOXB genes in purified hematopoietic progenitor
differentiation. Blood. 1994;84(11):3637-3647.

100

132.

133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.

Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE. Expression of
HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined
subpopulations of leukemic and normal human hematopoietic cells. Leukemia.
1999;13(5):687-698.
Pineault N, Helgason CD, Lawrence HJ, Humphries RK. Differential expression
of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine
hematopoietic ontogeny. Exp Hematol. 2002;30(1):49-57.
Sauvageau G, Lansdorp PM, Eaves CJ, et al. Differential expression of homeobox
genes in functionally distinct CD34+ subpopulations of human bone marrow
cells. Proc Natl Acad Sci U S A. 1994;91(25):12223-12227.
Crooks GM, Fuller J, Petersen D, et al. Constitutive HOXA5 expression inhibits
erythropoiesis and increases myelopoiesis from human hematopoietic progenitors.
Blood. 1999;94(2):519-528.
Fuller JF, McAdara J, Yaron Y, Sakaguchi M, Fraser JK, Gasson JC.
Characterization of HOX gene expression during myelopoiesis: role of HOX A5
in lineage commitment and maturation. Blood. 1999;93(10):3391-3400.
So CW, Karsunky H, Wong P, Weissman IL, Cleary ML. Leukemic
transformation of hematopoietic progenitors by MLL-GAS7 in the absence of
Hoxa7 or Hoxa9. Blood. 2004;103(8):3192-3199.
Thorsteinsdottir U, Mamo A, Kroon E, et al. Overexpression of the myeloid
leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell
expansion. Blood. 2002;99(1):121-129.
Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G.
Hoxa9 transforms primary bone marrow cells through specific collaboration with
Meis1a but not Pbx1b. EMBO J. 1998;17(13):3714-3725.
Buske C, Feuring-Buske M, Antonchuk J, et al. Overexpression of HOXA10
perturbs human lymphomyelopoiesis in vitro and in vivo. Blood.
2001;97(8):2286-2292.
Sauvageau G, Thorsteinsdottir U, Eaves CJ, et al. Overexpression of HOXB4 in
hematopoietic cells causes the selective expansion of more primitive populations
in vitro and in vivo. Genes Dev. 1995;9(14):1753-1765.
Bijl J, Thompson A, Ramirez-Solis R, et al. Analysis of HSC activity and
compensatory Hox gene expression profile in Hoxb cluster mutant fetal liver
cells. Blood. 2006;108(1):116-122.
Sauvageau G, Thorsteinsdottir U, Hough MR, et al. Overexpression of HOXB3 in
hematopoietic cells causes defective lymphoid development and progressive
myeloproliferation. Immunity. 1997;6(1):13-22.
Ko KH, Lam QL, Zhang M, et al. Hoxb3 deficiency impairs B lymphopoiesis in
mouse bone marrow. Exp Hematol. 2007;35(3):465-475.
Shimamoto T, Tang Y, Naot Y, et al. Hematopoietic progenitor cell abnormalities
in Hoxc-8 null mutant mice. J Exp Zool. 1999;283(2):186-193.
Kappen C. Disruption of the homeobox gene Hoxb-6 in mice results in increased
numbers of early erythrocyte progenitors. Am J Hematol. 2000;65(2):111-118.

101

147.

148.
149.
150.
151.
152.
153.
154.
155.
156.

157.
158.
159.
160.

Fischbach NA, Rozenfeld S, Shen W, et al. HOXB6 overexpression in murine
bone marrow immortalizes a myelomonocytic precursor in vitro and causes
hematopoietic stem cell expansion and acute myeloid leukemia in vivo. Blood.
2005;105(4):1456-1466.
Daga A, Podesta M, Capra MC, Piaggio G, Frassoni F, Corte G. The retroviral
transduction of HOXC4 into human CD34(+) cells induces an in vitro expansion
of clonogenic and early progenitors. Exp Hematol. 2000;28(5):569-574.
Takeshita K, Bollekens JA, Hijiya N, Ratajczak M, Ruddle FH, Gewirtz AM. A
homeobox gene of the Antennapedia class is required for human adult
erythropoiesis. Proc Natl Acad Sci U S A. 1993;90(8):3535-3538.
Magnusson M, Brun AC, Lawrence HJ, Karlsson S. Hoxa9/hoxb3/hoxb4
compound null mice display severe hematopoietic defects. Exp Hematol.
2007;35(9):1421-1428.
Amsellem S, Pflumio F, Bardinet D, et al. Ex vivo expansion of human
hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Nat
Med. 2003;9(11):1423-1427.
Brun AC, Bjornsson JM, Magnusson M, et al. Hoxb4-deficient mice undergo
normal hematopoietic development but exhibit a mild proliferation defect in
hematopoietic stem cells. Blood. 2004;103(11):4126-4133.
Bjornsson JM, Larsson N, Brun AC, et al. Reduced proliferative capacity of
hematopoietic stem cells deficient in Hoxb3 and Hoxb4. Mol Cell Biol.
2003;23(11):3872-3883.
Borrow J, Shearman AM, Stanton VP, Jr., et al. The t(7;11)(p15;p15)
translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98
and class I homeoprotein HOXA9. Nat Genet. 1996;12(2):159-167.
Nakamura T, Largaespada DA, Lee MP, et al. Fusion of the nucleoporin gene
NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human
myeloid leukaemia. Nat Genet. 1996;12(2):154-158.
Fujino T, Suzuki A, Ito Y, et al. Single-translocation and double-chimeric
transcripts: detection of NUP98-HOXA9 in myeloid leukemias with HOXA11 or
HOXA13 breaks of the chromosomal translocation t(7;11)(p15;p15). Blood.
2002;99(4):1428-1433.
Suzuki A, Ito Y, Sashida G, et al. t(7;11)(p15;p15) Chronic myeloid leukaemia
developed into blastic transformation showing a novel NUP98/HOXA11 fusion.
Br J Haematol. 2002;116(1):170-172.
Taketani T, Taki T, Shibuya N, et al. The HOXD11 gene is fused to the NUP98
gene in acute myeloid leukemia with t(2;11)(q31;p15). Cancer Res.
2002;62(1):33-37.
Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD.
NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia.
Cancer Res. 1998;58(19):4269-4273.
Taketani T, Taki T, Shibuya N, Kikuchi A, Hanada R, Hayashi Y. Novel NUP98HOXC11 fusion gene resulted from a chromosomal break within exon 1 of
HOXC11 in acute myeloid leukemia with t(11;12)(p15;q13). Cancer Res.
2002;62(16):4571-4574.

102

161.
162.
163.
164.
165.
166.
167.
168.
169.
170.

171.
172.

173.
174.
175.
176.

Slape C, Aplan PD. The role of NUP98 gene fusions in hematologic malignancy.
Leuk Lymphoma. 2004;45(7):1341-1350.
Pineault N, Buske C, Feuring-Buske M, et al. Induction of acute myeloid
leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13
in concert with Meis1. Blood. 2003;101(11):4529-4538.
Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. NUP98HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid
leukemias in mice. EMBO J. 2001;20(3):350-361.
Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis
induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad
Sci U S A. 2002;99(11):7622-7627.
Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain
methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10(5):11071117.
Slany RK. The molecular biology of mixed lineage leukemia. Haematologica.
2009;94(7):984-993.
Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL
oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17(18):22982307.
Wang J, Iwasaki H, Krivtsov A, et al. Conditional MLL-CBP targets GMP and
models therapy-related myeloproliferative disease. EMBO J. 2005;24(2):368-381.
Kumar AR, Hudson WA, Chen W, Nishiuchi R, Yao Q, Kersey JH. Hoxa9
influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia.
Blood. 2004;103(5):1823-1828.
Rawat VP, Thoene S, Naidu VM, et al. Overexpression of CDX2 perturbs HOX
gene expression in murine progenitors depending on its N-terminal domain and is
closely correlated with deregulated HOX gene expression in human acute myeloid
leukemia. Blood. 2008;111(1):309-319.
Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid
leukaemia with mutated NPM1: molecular basis and clinical implications.
Leukemia. 2009;23(10):1731-1743.
Mullighan CG, Kennedy A, Zhou X, et al. Pediatric acute myeloid leukemia with
NPM1 mutations is characterized by a gene expression profile with dysregulated
HOX gene expression distinct from MLL-rearranged leukemias. Leukemia.
2007;21(9):2000-2009.
Lawrence HJ, Largman C. Homeobox genes in normal hematopoiesis and
leukemia. Blood. 1992;80(10):2445-2453.
Hills D, Gribi R, Ure J, et al. Hoxb4-YFP reporter mouse model: a novel tool for
tracking HSC development and studying the role of Hoxb4 in hematopoiesis.
Blood. 2011;117(13):3521-3528.
Helgason CD, Sauvageau G, Lawrence HJ, Largman C, Humphries RK.
Overexpression of HOXB4 enhances the hematopoietic potential of embryonic
stem cells differentiated in vitro. Blood. 1996;87(7):2740-2749.
Kyba M, Perlingeiro RC, Daley GQ. HoxB4 confers definitive lymphoid-myeloid
engraftment potential on embryonic stem cell and yolk sac hematopoietic
progenitors. Cell. 2002;109(1):29-37.

103

177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.

Chan KM, Bonde S, Klump H, Zavazava N. Hematopoiesis and immunity of
HOXB4-transduced embryonic stem cell-derived hematopoietic progenitor cells.
Blood. 2008;111(6):2953-2961.
Bowles KM, Vallier L, Smith JR, Alexander MR, Pedersen RA. HOXB4
overexpression promotes hematopoietic development by human embryonic stem
cells. Stem Cells. 2006;24(5):1359-1369.
Lu SJ, Feng Q, Ivanova Y, et al. Recombinant HoxB4 fusion proteins enhance
hematopoietic differentiation of human embryonic stem cells. Stem Cells Dev.
2007;16(4):547-559.
Lee GS, Kim BS, Sheih JH, Moore M. Forced expression of HoxB4 enhances
hematopoietic differentiation by human embryonic stem cells. Mol Cells.
2008;25(4):487-493.
Thorsteinsdottir U, Sauvageau G, Humphries RK. Enhanced in vivo regenerative
potential of HOXB4-transduced hematopoietic stem cells with regulation of their
pool size. Blood. 1999;94(8):2605-2612.
Antonchuk J, Sauvageau G, Humphries RK. HOXB4 overexpression mediates
very rapid stem cell regeneration and competitive hematopoietic repopulation.
Exp Hematol. 2001;29(9):1125-1134.
Antonchuk J, Sauvageau G, Humphries RK. HOXB4-induced expansion of adult
hematopoietic stem cells ex vivo. Cell. 2002;109(1):39-45.
Buske C, Feuring-Buske M, Abramovich C, et al. Deregulated expression of
HOXB4 enhances the primitive growth activity of human hematopoietic cells.
Blood. 2002;100(3):862-868.
Zhang XB, Schwartz JL, Humphries RK, Kiem HP. Effects of HOXB4
overexpression on ex vivo expansion and immortalization of hematopoietic cells
from different species. Stem Cells. 2007;25(8):2074-2081.
Lee J, Shieh JH, Zhang J, et al. Improved ex vivo expansion of adult
hematopoietic stem cells by overcoming CUL4-mediated degradation of HOXB4.
Blood. 2013.
Zhang XB, Beard BC, Trobridge GD, et al. High incidence of leukemia in large
animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J
Clin Invest. 2008;118(4):1502-1510.
Fumasoni I, Meani N, Rambaldi D, Scafetta G, Alcalay M, Ciccarelli FD. Family
expansion and gene rearrangements contributed to the functional specialization of
PRDM genes in vertebrates. BMC Evol Biol. 2007;7:187.
Kinameri E, Inoue T, Aruga J, et al. Prdm proto-oncogene transcription factor
family expression and interaction with the Notch-Hes pathway in mouse
neurogenesis. PLoS One. 2008;3(12):e3859.
Derunes C, Briknarova K, Geng L, et al. Characterization of the PR domain of
RIZ1 histone methyltransferase. Biochem Biophys Res Commun.
2005;333(3):925-934.
Eom GH, Kim K, Kim SM, et al. Histone methyltransferase PRDM8 regulates
mouse testis steroidogenesis. Biochem Biophys Res Commun. 2009;388(1):131136.

104

192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.

204.
205.
206.
207.

Hayashi K, Yoshida K, Matsui Y. A histone H3 methyltransferase controls
epigenetic events required for meiotic prophase. Nature. 2005;438(7066):374378.
Fruhbeck G, Sesma P, Burrell MA. PRDM16: the interconvertible adipo-myocyte
switch. Trends Cell Biol. 2009;19(4):141-146.
Kim KC, Geng L, Huang S. Inactivation of a histone methyltransferase by
mutations in human cancers. Cancer Res. 2003;63(22):7619-7623.
Endo K, Karim MR, Taniguchi H, et al. Chromatin modification of Notch targets
in olfactory receptor neuron diversification. Nat Neurosci. 2012;15(2):224-233.
Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. The corepressor
CtBP interacts with Evi-1 to repress transforming growth factor beta signaling.
Blood. 2001;97(9):2815-2822.
Kajimura S, Seale P, Tomaru T, et al. Regulation of the brown and white fat gene
programs through a PRDM16/CtBP transcriptional complex. Genes Dev.
2008;22(10):1397-1409.
Nishikata I, Nakahata S, Saito Y, et al. Sumoylation of MEL1S at lysine 568 and
its interaction with CtBP facilitates its repressor activity and the blockade of GCSF-induced myeloid differentiation. Oncogene. 2011;30(40):4194-4207.
Palmer S, Brouillet JP, Kilbey A, et al. Evi-1 transforming and repressor activities
are mediated by CtBP co-repressor proteins. J Biol Chem. 2001;276(28):2583425840.
Quinlan KG, Nardini M, Verger A, et al. Specific recognition of ZNF217 and
other zinc finger proteins at a surface groove of C-terminal binding proteins. Mol
Cell Biol. 2006;26(21):8159-8172.
Van Campenhout C, Nichane M, Antoniou A, et al. Evi1 is specifically expressed
in the distal tubule and duct of the Xenopus pronephros and plays a role in its
formation. Dev Biol. 2006;294(1):203-219.
Kuo TC, Calame KL. B lymphocyte-induced maturation protein (Blimp)-1, IFN
regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites. J
Immunol. 2004;173(9):5556-5563.
Delwel R, Funabiki T, Kreider BL, Morishita K, Ihle JN. Four of the seven zinc
fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific
binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol. 1993;13(7):42914300.
Funabiki T, Kreider BL, Ihle JN. The carboxyl domain of zinc fingers of the Evi1 myeloid transforming gene binds a consensus sequence of GAAGATGAG.
Oncogene. 1994;9(6):1575-1581.
Brzezinski JAt, Lamba DA, Reh TA. Blimp1 controls photoreceptor versus
bipolar cell fate choice during retinal development. Development.
2010;137(4):619-629.
Katoh K, Omori Y, Onishi A, Sato S, Kondo M, Furukawa T. Blimp1 suppresses
Chx10 expression in differentiating retinal photoreceptor precursors to ensure
proper photoreceptor development. J Neurosci. 2010;30(19):6515-6526.
Wilm TP, Solnica-Krezel L. Essential roles of a zebrafish prdm1/blimp1 homolog
in embryo patterning and organogenesis. Development. 2005;132(2):393-404.

105

208.
209.
210.
211.
212.
213.
214.
215.
216.
217.
218.
219.

220.

221.
222.
223.

Harper J, Mould A, Andrews RM, Bikoff EK, Robertson EJ. The transcriptional
repressor Blimp1/Prdm1 regulates postnatal reprogramming of intestinal
enterocytes. Proc Natl Acad Sci U S A. 2011;108(26):10585-10590.
Muncan V, Heijmans J, Krasinski SD, et al. Blimp1 regulates the transition of
neonatal to adult intestinal epithelium. Nat Commun. 2011;2:452.
Shapiro-Shelef M, Lin KI, Savitsky D, Liao J, Calame K. Blimp-1 is required for
maintenance of long-lived plasma cells in the bone marrow. J Exp Med.
2005;202(11):1471-1476.
Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K. Transcriptional
repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase.
Mol Cell Biol. 2000;20(7):2592-2603.
Su ST, Ying HY, Chiu YK, Lin FR, Chen MY, Lin KI. Involvement of histone
demethylase LSD1 in Blimp-1-mediated gene repression during plasma cell
differentiation. Mol Cell Biol. 2009;29(6):1421-1431.
Seale P, Kajimura S, Yang W, et al. Transcriptional control of brown fat
determination by PRDM16. Cell Metab. 2007;6(1):38-54.
Seale P, Bjork B, Yang W, et al. PRDM16 controls a brown fat/skeletal muscle
switch. Nature. 2008;454(7207):961-967.
Chuikov S, Levi BP, Smith ML, Morrison SJ. Prdm16 promotes stem cell
maintenance in multiple tissues, partly by regulating oxidative stress. Nat Cell
Biol. 2010;12(10):999-1006.
Aguilo F, Avagyan S, Labar A, et al. Prdm16 is a physiologic regulator of
hematopoietic stem cells. Blood. 2011;117(19):5057-5066.
Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for
hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell.
2008;3(2):207-220.
Zhang Y, Stehling-Sun S, Lezon-Geyda K, et al. PR-domain-containing Mds1Evi1 is critical for long-term hematopoietic stem cell function. Blood.
2011;118(14):3853-3861.
Morishita K, Parganas E, William CL, et al. Activation of EVI1 gene expression
in human acute myelogenous leukemias by translocations spanning 300-400
kilobases on chromosome band 3q26. Proc Natl Acad Sci U S A.
1992;89(9):3937-3941.
Suzukawa K, Kodera T, Shimizu S, et al. Activation of EVI1 transcripts with
chromosomal translocation joining the TCRVbeta locus and the EVI1 gene in
human acute undifferentiated leukemia cell line (Kasumi-3) with a complex
translocation of der(3)t(3;7;8). Leukemia. 1999;13(9):1359-1366.
Yufu Y, Sadamura S, Ishikura H, et al. Expression of EVI1 and the
Retinoblastoma genes in acute myelogenous leukemia with t(3;13)(q26;q13-14).
Am J Hematol. 1996;53(1):30-34.
Storlazzi CT, Anelli L, Albano F, et al. A novel chromosomal translocation
t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1. Ann
Hematol. 2004;83(2):78-83.
Yoshida M, Nosaka K, Yasunaga J, Nishikata I, Morishita K, Matsuoka M.
Aberrant expression of the MEL1S gene identified in association with
hypomethylation in adult T-cell leukemia cells. Blood. 2004;103(7):2753-2760.

106

224.
225.

226.
227.
228.
229.
230.

231.
232.
233.
234.
235.
236.
237.

238.

Sakai I, Tamura T, Narumi H, et al. Novel RUNX1-PRDM16 fusion transcripts in
a patient with acute myeloid leukemia showing t(1;21)(p36;q22). Genes
Chromosomes Cancer. 2005;44(3):265-270.
Stevens-Kroef MJ, Schoenmakers EF, van Kraaij M, et al. Identification of
truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of
t(1;21)(p36;q22)-positive therapy-related AML. Leukemia. 2006;20(6):11871189.
Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic
granulomatous disease by gene therapy, augmented by insertional activation of
MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-409.
Du Y, Jenkins NA, Copeland NG. Insertional mutagenesis identifies genes that
promote the immortalization of primary bone marrow progenitor cells. Blood.
2005;106(12):3932-3939.
Ohinata Y, Ohta H, Shigeta M, Yamanaka K, Wakayama T, Saitou M. A
signaling principle for the specification of the germ cell lineage in mice. Cell.
2009;137(3):571-584.
Ohinata Y, Payer B, O'Carroll D, et al. Blimp1 is a critical determinant of the
germ cell lineage in mice. Nature. 2005;436(7048):207-213.
Vincent SD, Dunn NR, Sciammas R, et al. The zinc finger transcriptional
repressor Blimp1/Prdm1 is dispensable for early axis formation but is required for
specification of primordial germ cells in the mouse. Development.
2005;132(6):1315-1325.
Yamaji M, Seki Y, Kurimoto K, et al. Critical function of Prdm14 for the
establishment of the germ cell lineage in mice. Nat Genet. 2008;40(8):1016-1022.
Chia NY, Chan YS, Feng B, et al. A genome-wide RNAi screen reveals
determinants of human embryonic stem cell identity. Nature.
2010;468(7321):316-320.
Ma Z, Swigut T, Valouev A, Rada-Iglesias A, Wysocka J. Sequence-specific
regulator Prdm14 safeguards mouse ESCs from entering extraembryonic
endoderm fates. Nat Struct Mol Biol. 2011;18(2):120-127.
Tsuneyoshi N, Sumi T, Onda H, Nojima H, Nakatsuji N, Suemori H. PRDM14
suppresses expression of differentiation marker genes in human embryonic stem
cells. Biochem Biophys Res Commun. 2008;367(4):899-905.
Nishikawa N, Toyota M, Suzuki H, et al. Gene amplification and overexpression
of PRDM14 in breast cancers. Cancer Res. 2007;67(20):9649-9657.
Dettman EJ, Simko SJ, Ayanga B, et al. Prdm14 initiates lymphoblastic leukemia
after expanding a population of cells resembling common lymphoid progenitors.
Oncogene. 2011;30(25):2859-2873.
Mochizuki N, Shimizu S, Nagasawa T, et al. A novel gene, MEL1, mapped to
1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally
activated in t(1;3)(p36;q21)-positive leukemia cells. Blood. 2000;96(9):32093214.
Nishikata I, Sasaki H, Iga M, et al. A novel EVI1 gene family, MEL1, lacking a
PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and
blocks G-CSF-induced myeloid differentiation. Blood. 2003;102(9):3323-3332.

107

239.
240.
241.
242.
243.
244.
245.
246.
247.

248.
249.
250.
251.
252.
253.
254.
255.

Xiao Z, Zhang M, Liu X, Zhang Y, Yang L, Hao Y. MEL1S, not MEL1, is
overexpressed in myelodysplastic syndromes patients with t(1;3)(p36;q21). Leuk
Res. 2006;30(3):332-334.
Modlich U, Schambach A, Brugman MH, et al. Leukemia induction after a single
retroviral vector insertion in Evi1 or Prdm16. Leukemia. 2008;22(8):1519-1528.
Horn KH, Warner DR, Pisano M, Greene RM. PRDM16 expression in the
developing mouse embryo. Acta Histochem. 2011;113(2):150-155.
Warner DR, Horn KH, Mudd L, Webb CL, Greene RM, Pisano MM.
PRDM16/MEL1: a novel Smad binding protein expressed in murine embryonic
orofacial tissue. Biochim Biophys Acta. 2007;1773(6):814-820.
Kajimura S, Seale P, Kubota K, et al. Initiation of myoblast to brown fat switch
by a PRDM16-C/EBP-beta transcriptional complex. Nature.
2009;460(7259):1154-1158.
Ohno H, Shinoda K, Ohyama K, Sharp LZ, Kajimura S. EHMT1 controls brown
adipose cell fate and thermogenesis through the PRDM16 complex. Nature.
2013;504(7478):163-167.
Pinheiro I, Margueron R, Shukeir N, et al. Prdm3 and Prdm16 are H3K9me1
Methyltransferases Required for Mammalian Heterochromatin Integrity. Cell.
2012;150(5):948-960.
Deneault E, Cellot S, Faubert A, et al. A functional screen to identify novel
effectors of hematopoietic stem cell activity. Cell. 2009;137(2):369-379.
Hazourli S, Chagnon P, Sauvageau M, Fetni R, Busque L, Hebert J.
Overexpression of PRDM16 in the presence and absence of the
RUNX1/PRDM16 fusion gene in myeloid leukemias. Genes Chromosomes
Cancer. 2006;45(11):1072-1076.
Shing DC, Trubia M, Marchesi F, et al. Overexpression of sPRDM16 coupled
with loss of p53 induces myeloid leukemias in mice. J Clin Invest.
2007;117(12):3696-3707.
Satoh Y, Matsumura I, Tanaka H, et al. Roles for c-Myc in self-renewal of
hematopoietic stem cells. J Biol Chem. 2004;279(24):24986-24993.
Schiedlmeier B, Santos AC, Ribeiro A, et al. HOXB4's road map to stem cell
expansion. Proc Natl Acad Sci U S A. 2007;104(43):16952-16957.
Jiang J, Yu H, Shou Y, et al. Hemgn is a direct transcriptional target of HOXB4
and induces expansion of murine myeloid progenitor cells. Blood.
2010;116(5):711-719.
Lee HM, Zhang H, Schulz V, Tuck DP, Forget BG. Downstream targets of
HOXB4 in a cell line model of primitive hematopoietic progenitor cells. Blood.
2010;116(5):720-730.
Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and
Powerful Approach to Multiple Testing. J R Stat Soc B. 1995;57(1).
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expression profiles.
Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A
stem cell molecular signature. Science. 2002;298(5593):601-604.

108

256.
257.
258.
259.

260.

261.
262.

263.
264.
265.
266.
267.
268.
269.
270.

Oshima M, Endoh M, Endo TA, et al. Genome-wide analysis of target genes
regulated by HoxB4 in hematopoietic stem and progenitor cells developing from
embryonic stem cells. Blood. 2011;117(15):e142-150.
Fan R, Bonde S, Gao P, et al. Dynamic HoxB4-regulatory network during
embryonic stem cell differentiation to hematopoietic cells. Blood.
2012;119(19):e139-147.
Oguro H, Ding L, Morrison SJ. SLAM Family Markers Resolve Functionally
Distinct Subpopulations of Hematopoietic Stem Cells and Multipotent
Progenitors. Cell Stem Cell. 2013;13(1):102-116.
Deluche L, Joha S, Corm S, et al. Cryptic and partial deletions of PRDM16 and
RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of
progressive chronic myeloid leukemia: a complex chromosomal rearrangement of
underestimated frequency in disease progression? Genes Chromosomes Cancer.
2008;47(12):1110-1117.
Duhoux FP, Ameye G, Montano-Almendras CP, et al. PRDM16 (1p36)
translocations define a distinct entity of myeloid malignancies with poor
prognosis but may also occur in lymphoid malignancies. Br J Haematol.
2012;156(1):76-88.
Zhou S, Ma Z, Lu T, Janke L, Gray JT, Sorrentino BP. Mouse transplant models
for evaluating the oncogenic risk of a self-inactivating XSCID lentiviral vector.
PLoS One. 2013;8(4):e62333.
Bunting KD, Galipeau J, Topham D, Benaim E, Sorrentino BP. Effects of
retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal
and differentiation in culture. Ann N Y Acad Sci. 1999;872:125-140; discussion
140-121.
Zhang CC, Lodish HF. Murine hematopoietic stem cells change their surface
phenotype during ex vivo expansion. Blood. 2005;105(11):4314-4320.
Takiguchi M, Dow LE, Prier JE, et al. Variability of inducible expression across
the hematopoietic system of tetracycline transactivator transgenic mice. PLoS
One. 2013;8(1):e54009.
Groschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts
outcome in younger adult patients with acute myeloid leukemia and is associated
with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101-2107.
Buonamici S, Li D, Chi Y, et al. EVI1 induces myelodysplastic syndrome in
mice. J Clin Invest. 2004;114(5):713-719.
Eguchi-Ishimae M, Eguchi M, Ohyashiki K, Yamagata T, Mitani K. Enhanced
expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells. Int J
Hematol. 2009;89(2):253-256.
Kurokawa M, Mitani K, Yamagata T, et al. The evi-1 oncoprotein inhibits c-Jun
N-terminal kinase and prevents stress-induced cell death. EMBO J.
2000;19(12):2958-2968.
Buonamici S, Li D, Mikhail FM, et al. EVI1 abrogates interferon-alpha response
by selectively blocking PML induction. J Biol Chem. 2005;280(1):428-436.
Yoshimi A, Goyama S, Watanabe-Okochi N, et al. Evi1 represses PTEN
expression and activates PI3K/AKT/mTOR via interactions with polycomb
proteins. Blood. 2011;117(13):3617-3628.

109

271.
272.
273.
274.

275.

276.
277.
278.

Yoshimi A, Kurokawa M. Evi1 forms a bridge between the epigenetic machinery
and signaling pathways. Oncotarget. 2011;2(7):575-586.
Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute
myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254266.
Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid
cancers. N Engl J Med. 2009;360(22):2289-2301.
Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem
duplication in patients with acute myeloid leukemia (AML) adds important
prognostic information to cytogenetic risk group and response to the first cycle of
chemotherapy: analysis of 854 patients from the United Kingdom Medical
Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-1759.
Hemmat M, Chen W, Anguiano A, et al. Submicroscopic deletion of 5q involving
tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of
heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with
normal chromosome and FISH results. Mol Cytogenet. 2014;7:35.
Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2
mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood.
2009;113(25):6403-6410.
Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo
AML with noncomplex karyotype and confer an unfavorable prognosis. Blood.
2011;117(8):2348-2357.
Holme H, Hossain U, Kirwan M, Walne A, Vulliamy T, Dokal I. Marked genetic
heterogeneity in familial myelodysplasia/acute myeloid leukaemia. Br J
Haematol. 2012;158(2):242-248.

110

VITA
Hui Yu was born in Nantong, Jiangsu Province in P.R.China in 1981. In 2000 she
was enrolled in China Medical University. After receiving her Bachelor’s Degree of
Medicine in Nursing in 2000, she joined Master’s Program in Otolaryngology in Fudan
University in China and finished her study in 2008. In the same year she was admitted to
Integrated Program in Biomedical Sciences at the University of Tennessee Health
Science Center to pursue her PhD degree. In 2009 she joined Dr. Brian P. Sorrentino’s
lab at St. Jude Children’s Research Hospital and conducted research of hematopoietic
stem cell self-renewal and differentiation. Her study aimed to uncover the mechanism of
HOXB4-induced hematopoietic stem cell expansion and Prdm16’s role in HSC selfrenewal and leukemogenesis under the HOXB4 overexpression context in vivo. She is
expected to finish her work and graduate in December 2014.

111

